ID	Year of ICI treatment start	Age at ICI start	Sex	Cancer type	NLR	MSI type	TMB (Mutations/Mb)	IMPACT version	ICI drug class	Best Response	Response to ICI	Clinical Benefit with ICI	Progression	Progression-Free Survival (Months)	Vital status	Overall Survival (Months)	Stage at ICI start	ICI line of treatment	ECOG PS	MMR_canon	ARID1A_mut
8213	2017	61 - 65	Female	Colorectal	7.6		4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	5.62	IV	Subsequent-line	0	no	no
8214	2018	66 - 70	Female	Endometrial	1.19	Unstable	32.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.64	Alive	15.74	IV	Subsequent-line	1	mut-MMRd	yes
8215	2018	61 - 65	Female	SCLC	1.38	Stable	19.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	3.45	Alive	9.59	IV	Subsequent-line	0	no	no
8216	2015	56 - 60	Female	Melanoma	2.69	Stable	1	IMPACT-410	Combo	PD	No	No	Yes	0.56	Alive	50.14	IV	First-line	0	no	no
8217	2018	51 - 55	Female	NSCLC	2.54	Stable	10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.67	Alive	9.99	IV	Subsequent-line	0	no	no
8218	2017	66 - 70	Female	Hepatobiliary	3.32		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.91	Dead	6.05	IV	Subsequent-line	0	no	no
8219	2017	51 - 55	Male	Gastric	5.21	Stable	0	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	8.61	Dead	18.83	IV	First-line	0	no	no
8220	2015	61 - 65	Female	NSCLC	3.89	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	1.64	IV	Subsequent-line		no	no
8221	2016	61 - 65	Female	Pancreatic	2.18	Indeterminate	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	2.33	IV	Subsequent-line	1	no	no
8222	2017	51 - 55	Male	Renal	4.62	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.97	Dead	3.12	IV	Subsequent-line	1	no	no
8223	2017	66 - 70	Female	Colorectal	2.56	Indeterminate	41.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	7.13	Dead	7.13	IV	Subsequent-line	0	no	no
8224	2017	76 - 80	Female	Hepatobiliary	3.16		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	3.81	IV	Subsequent-line	1	no	no
8225	2017	66 - 70	Male	Bladder	1.88		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	2.37	IV	First-line	0	no	no
8226	2018	61 - 65	Male	SCLC	4.89	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	1.35	Alive	3.22	IV	Subsequent-line	1	no	no
8227	2017	61 - 65	Female	Sarcoma	4.63	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	18.23	IV	Subsequent-line	1	no	no
8228	2017	66 - 70	Female	SCLC	4.88		7	IMPACT-468	Combo	PD	No	No	Yes	1.08	Dead	9.33	IV	Subsequent-line	1	no	no
8229	2015	51 - 55	Female	NSCLC	2.92	Stable	19.7	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	45.96	Alive	48.82	IV	Subsequent-line	1	no	yes
8230	2017	66 - 70	Male	Bladder	4.25	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	6.77	IV	Subsequent-line	1	no	no
8231	2018	91 - 95	Female	Endometrial	4	Unstable	32.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	14.26	Alive	15.05	IV	First-line	0	other-MMRd	yes
8232	2018	61 - 65	Female	NSCLC	8.5	Stable	14	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.32	Dead	5.52	IV	First-line	1	no	no
8233	2018	76 - 80	Female	SCLC	5.4	Indeterminate	15.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	14.26	Alive	16.1	IV	Subsequent-line	0	no	no
8235	2016	51 - 55	Female	Bladder	2.56		1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.53	Dead	2.92	IV	Subsequent-line	2	no	no
8236	2017	61 - 65	Female	Endometrial	3.4	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	13.67	Alive	19.94	IV	Subsequent-line	0	no	no
8237	2017	76 - 80	Female	NSCLC	5.45		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	1.94	IV	Subsequent-line	1	no	no
8238	2017	76 - 80	Male	NSCLC	5.75	Stable	14.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.26	Alive	9.33	IV	Subsequent-line	1	no	no
8239	2017	81 - 85	Female	Esophageal	1	Unstable	24.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	7.89	IV	Subsequent-line	2	other-MMRd	no
8241	2018	61 - 65	Male	NSCLC	4.43	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.59	Dead	6.01	IV	First-line	1	no	no
8242	2018	56 - 60	Female	Renal	3	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.93	Alive	10.18	IV	Subsequent-line	0	no	no
8243	2018	66 - 70	Female	NSCLC	6.56	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	0.92	Dead	4.5	IV	Subsequent-line	1	no	no
8244	2018	71 - 75	Male	Gastric	6.14	Stable	11.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Alive	12.29	IV	Subsequent-line	1	no	no
8245	2018	81 - 85	Female	NSCLC	8.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	8.08	Alive	13.54	IV	Subsequent-line	1	no	no
8246	2017	61 - 65	Female	NSCLC	2.72	Stable	9.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.11	Alive	27.27	IV	First-line		no	no
8247	2016	71 - 75	Male	NSCLC	3.23		7	IMPACT-468	Combo	SD	No	No	Yes	2.46	Dead	13.9	IV	First-line	0	no	no
8248	2015	61 - 65	Male	Bladder	5.64	Stable	12.8	IMPACT-410	Combo	CR	Yes	Yes	No	38.41	Alive	38.64	IV	First-line	1	no	no
8251	2016	86 - 90	Female	NSCLC	2.33		3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	12.88	Dead	25.49	IV	First-line	0	no	no
8252	2017	56 - 60	Male	Colorectal	2.63	Unstable	50.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	11.17	Alive	17.38	IV	Subsequent-line	0	mut-MMRd	yes
8253	2016	61 - 65	Female	Endometrial	7.4	Stable	0	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	3.68	Dead	13.83	IV	Subsequent-line	1	no	no
8254	2017	51 - 55	Female	Colorectal	7	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.02	Dead	2.17	IV	Subsequent-line	1	no	no
8256	2017	61 - 65	Female	Melanoma	6.02	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.14	Dead	18.6	IV	First-line	0	no	no
8257	2016	66 - 70	Male	Melanoma	1.9	Stable	7.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.73	Alive	36.4		First-line	1	no	no
8258	2016	76 - 80	Male	NSCLC	13.2	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	2.69	IV	Subsequent-line	1	no	no
8259	2016	46 - 50	Female	Renal	7.5	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.71	Dead	4.63	IV	Subsequent-line	1	no	no
8260	2018	46 - 50	Male	Pancreatic	6.67	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	2.89	IV	Subsequent-line	1	no	no
8261	2017	66 - 70	Female	Head & Neck	4.46	Stable	17.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.98	Alive	10.15	IV	Subsequent-line	1	no	no
8262	2018	61 - 65	Male	Esophageal	9.09	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.13	Dead	0.13	IV	Subsequent-line	1	no	no
8263	2017	51 - 55	Female	NSCLC	10.14	Stable	7.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.52	Dead	16.13	IV	Subsequent-line	1	no	no
8264	2018	61 - 65	Female	Gastric	6	Stable	5.3	IMPACT-468	Combo	PD	No	No	Yes	0.95	Dead	0.95	IV	Subsequent-line	1	no	no
8265	2018	81 - 85	Male	NSCLC	1.81	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.61	Alive	10.91	IV	Subsequent-line		no	no
8266	2017	56 - 60	Female	SCLC	2.32	Stable	10.5	IMPACT-468	Combo	CR	Yes	Yes	No	27.37	Alive	30.13	IV	Subsequent-line	0	no	no
8267	2016	66 - 70	Female	NSCLC	3.27	Stable	12.8	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	0.85	Dead	0.85	IV	First-line	0	no	no
8268	2017	51 - 55	Female	NSCLC	1.32		2	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	20.73	Alive	20.73	IV	First-line		no	no
8270	2017	66 - 70	Female	Ovarian	2.25		1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.53	Dead	7.06	IV	Subsequent-line	0	no	no
8272	2018	66 - 70	Female	NSCLC	23	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.39	Dead	0.39	IV	Subsequent-line	1	no	no
8273	2018	76 - 80	Female	Endometrial	0.92	Unstable	29.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.76	Dead	11.27	IV	Subsequent-line	0	other-MMRd	yes
8274	2017	61 - 65	Male	Bladder	11.5	Stable	13.2	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.06	Alive	24.77	IV	First-line	2	no	yes
8275	2018	76 - 80	Female	NSCLC	2	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.43	Dead	8.25	IV	Subsequent-line	1	no	no
8276	2017	56 - 60	Male	Renal	3.28	Stable	0	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	11.24	Alive	19.38	IV	Subsequent-line	1	no	no
8277	2018	61 - 65	Male	Gastric	5.2	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.32	Dead	4.21	IV	Subsequent-line	2	no	no
8278	2016	71 - 75	Male	Melanoma	5.88		36	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	38.51	Alive	38.51	IV	First-line	0	no	no
8279	2018	81 - 85	Male	NSCLC	14.4	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Alive	5.26	IV	Subsequent-line	2	no	yes
8280	2017	51 - 55	Female	NSCLC	3.38		8.9	IMPACT-410	Combo	PR	Yes	Yes	Yes	5.68	Alive	9.56	IV	Subsequent-line	1	no	no
8281	2017	86 - 90	Male	Bladder	3.56	Indeterminate	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.07	Dead	12.12	IV	First-line	1	no	no
8283	2017	76 - 80	Male	Melanoma	1.91		36	IMPACT-468	Combo	SD	No	No	Yes	2.3	Alive	28.68	IV	First-line		no	no
8284	2018	71 - 75	Female	NSCLC	33.75	Stable	11.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	6.6	IV	First-line	1	no	no
8285	2016	71 - 75	Male	Pancreatic	3.79	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	4.63	IV	Subsequent-line	0	no	no
8286	2017	86 - 90	Male	NSCLC	2.6	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	24.8	Alive	25	IV	First-line	1	no	no
8287	2017	46 - 50	Female	Breast	1.77	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.29	Dead	20.07	III	Subsequent-line		no	no
8288	2018	46 - 50	Female	Renal	4.9	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	9.66	Alive	9.69	IV	Subsequent-line	0	no	no
8289	2018	71 - 75	Female	SCLC	5.2	Stable	10.5	IMPACT-468	Combo	SD	No	No	Yes	4.9	Dead	7.79	IV	Subsequent-line	1	no	no
8290	2017	61 - 65	Male	Hepatobiliary	4	Stable	3.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	14.55	Alive	26.84	IV	Subsequent-line	1	no	no
8291	2015	51 - 55	Male	Renal	2.57	Stable	8.9	IMPACT-410	Combo	PR	Yes	Yes	No	46.46	Alive	46.92	IV	First-line	0	no	no
8292	2016	46 - 50	Male	Renal	4.55	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	13.21	IV	Subsequent-line	0	no	no
8293	2016	36 - 40	Male	Pancreatic	6.25	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	14.16	IV	Subsequent-line	0	no	no
8294	2017	76 - 80	Male	Bladder	1.1		9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.23	Dead	12.06	IV	Subsequent-line	0	no	yes
8295	2016	71 - 75	Female	NSCLC	3.67	Stable	30.5	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	14.36	Alive	39.56	IV	Subsequent-line	0	no	no
8296	2016	46 - 50	Female	NSCLC	1.44		7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.1	Dead	10.05	IV	Subsequent-line		no	no
8297	2015	66 - 70	Male	NSCLC	6.08	Stable	39.4	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	20.93	IV	Subsequent-line	1	no	no
8298	2015	51 - 55	Male	Melanoma	3.83	Stable	49.2	IMPACT-410	Combo	CR	Yes	Yes	No	52.44	Alive	52.44	IV	First-line	0	no	yes
8299	2017	46 - 50	Female	NSCLC	2.95	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.28	Alive	20.44	IV	Subsequent-line	1	no	no
8300	2017	41 - 45	Male	Hepatobiliary	21.8	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.3	Dead	0.33	IV	Subsequent-line	2	no	no
8301	2017	61 - 65	Female	Sarcoma	4.6	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	1.54	Alive	21.78	IV	Subsequent-line	0	no	no
8303	2015	61 - 65	Male	NSCLC	14.8	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.03	Dead	0.03	IV	Subsequent-line		no	no
8304	2017	51 - 55	Male	NSCLC	13.9	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	12.12	IV	Subsequent-line	0	no	no
8306	2015	51 - 55	Male	Melanoma	20.75	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	35.75	IV	First-line	0	no	no
8307	2015	41 - 45	Female	Renal	3.29	Stable	6.9	IMPACT-410	Combo	CR	Yes	Yes	No	51.75	Alive	51.75	IV	First-line	0	no	yes
8308	2016	56 - 60	Male	NSCLC	5.33	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	7.62	IV	Subsequent-line	0	no	no
8309	2017	66 - 70	Female	NSCLC	6.29	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	3.35	IV	Subsequent-line	2	no	no
8310	2015	56 - 60	Female	NSCLC	3.25	Stable	5.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	50.23	Alive	52.04	IV	Subsequent-line	0	no	no
8311	2015	81 - 85	Male	Melanoma	7.88	Indeterminate	102.3	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	6.44	Dead	27.47	IV	First-line	0	no	yes
8312	2015	76 - 80	Female	Head & Neck	34.5	Stable	3.9	IMPACT-410	CTLA-4	PD	No	No	Yes	0.43	Dead	1.54	IV	Subsequent-line	1	no	no
8313	2015	56 - 60	Female	NSCLC	2.25	Stable	4.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	8.51	Dead	31.47	IV	Subsequent-line	0	no	no
8314	2016	46 - 50	Female	NSCLC	1.5	Stable	4.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	24.31	Alive	32.85	IV	Subsequent-line	1	no	no
8315	2018	36 - 40	Female	NSCLC	1.38	Stable	3	IMPACT-410	PD-1/PD-L1	SD	No	No	No	7.13	Alive	12.52	IV	Subsequent-line	0	no	no
8316	2015	56 - 60	Female	Melanoma	2.3	Stable	3	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	10.41	Alive	11.07	IV	First-line	0	no	no
8317	2015	76 - 80	Male	Melanoma	4.67	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	3.25	IV	First-line	1	no	no
8318	2015	56 - 60	Female	NSCLC	9.43	Stable	4.9	IMPACT-410	Combo	SD	No	No	Yes	5.06	Dead	27.96	IV	First-line	1	no	no
8319	2015	21 - 25	Male	Melanoma	5.82	Stable	9.8	IMPACT-410	Combo	PR	Yes	Yes	Yes	13.31	Alive	49.91	III	First-line	0	no	no
8320	2015	61 - 65	Male	NSCLC	28.2	Stable	13.8	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.12	Dead	3.68	IV	Subsequent-line	1	no	no
8321	2017	51 - 55	Male	Head & Neck	7.17	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.76	Alive	21.32	IV	Subsequent-line	1	no	no
8322	2015	61 - 65	Female	Sarcoma	1.72	Stable	0	IMPACT-410	Combo	PD	No	No	Yes	1.74	Dead	11.33	IV	Subsequent-line	1	no	no
8324	2016	76 - 80	Female	Endometrial	1.42	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.69	Dead	24.9	IV	Subsequent-line	0	no	no
8325	2017	51 - 55	Female	Melanoma	1.46	Stable	14.9	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	26.61	Alive	26.61	III	First-line	0	no	no
8326	2018	56 - 60	Female	Melanoma	1.68	Stable	13.2	IMPACT-468	Combo	SD	No	No	Yes	2.83	Dead	12.81	IV	First-line	0	no	no
8327	2016	56 - 60	Female	NSCLC	1.11	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	9.53	IV	Subsequent-line	0	no	no
8328	2016	66 - 70	Male	NSCLC	4.71	Stable	8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.59	Dead	1.02	IV	Subsequent-line	1	no	no
8330	2015	81 - 85	Female	Melanoma	3.19	Stable	39.4	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	9.59	Dead	10.55	IV	First-line	0	no	no
8331	2017	41 - 45	Male	Head & Neck	58		0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	3.15	IV	Subsequent-line	2	no	no
8332	2016	66 - 70	Male	SCLC	9	Indeterminate	8.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	1.64	Dead	1.64	IV	Subsequent-line	1	no	no
8333	2015	56 - 60	Female	NSCLC	5	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.45	Alive	13.47	IV	Subsequent-line	1	no	no
8334	2017	71 - 75	Female	Ovarian	7	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.39	Dead	9.69	IV	Subsequent-line	0	no	no
8335	2017	61 - 65	Female	NSCLC	2.5	Stable	6.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	29.24	Alive	29.7	IV	Subsequent-line		no	no
8336	2016	61 - 65	Female	Colorectal	5.4	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	3.88	IV	Subsequent-line	1	no	no
8337	2015	71 - 75	Female	NSCLC	3.83	Stable	1	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	11.53	Alive	41.13	IV	Subsequent-line	1	no	no
8339	2017	56 - 60	Male	Esophageal	2.63	Stable	2	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.13	Dead	5.13	IV	Subsequent-line	1	no	no
8340	2016	56 - 60	Female	Esophageal	8.71	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	2.76	IV	Subsequent-line	1	no	no
8341	2016	71 - 75	Male	NSCLC	2.7	Stable	59	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	35.88	Alive	35.88	III	Subsequent-line		no	no
8342	2017	56 - 60	Female	Colorectal	3.73	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.71	Dead	20.21	III	Subsequent-line	1	no	no
8343	2018	51 - 55	Female	NSCLC	2.23	Stable	12.8	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	8.84	Alive	14.29	IV	Subsequent-line		no	no
8344	2015	71 - 75	Female	NSCLC	4	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	1.74	IV	Subsequent-line	1	no	no
8345	2017	51 - 55	Female	Endometrial	3.78	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.71	Dead	12.32	IV	Subsequent-line	1	no	no
8346	2015	76 - 80	Male	NSCLC	9.22	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	10.28	Dead	13.67	IV	Subsequent-line		no	no
8347	2015	71 - 75	Female	NSCLC	9	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	1.74	IV	Subsequent-line	1	no	no
8348	2017	61 - 65	Male	SCLC	3.69	Stable	14.8	IMPACT-410	Combo	PR	Yes	Yes	Yes	2.66	Dead	11.53	IV	Subsequent-line	0	no	no
8349	2016	51 - 55	Female	Renal	1.57	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.6	Dead	11.3	IV	Subsequent-line	0	no	no
8350	2017	41 - 45	Male	Esophageal	2.44	Stable	5.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.2	Dead	10.91	IV	Subsequent-line	1	no	no
8351	2016	56 - 60	Male	Esophageal	1.12		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Dead	15.7	IV	Subsequent-line	1	no	yes
8352	2015	61 - 65	Male	NSCLC	1.48		4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	16.49	Dead	47.31	IV	Subsequent-line	0	no	no
8353	2015	71 - 75	Male	NSCLC	2.88	Stable	5.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.06	Dead	23.79	IV	Subsequent-line	4	no	yes
8354	2018	31 - 35	Male	Sarcoma	1.14	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	5.85	IV	Subsequent-line	0	no	no
8355	2016	51 - 55	Male	Esophageal	4.92		3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	23.52	Dead	23.52	IV	Subsequent-line	1	no	no
8356	2018	66 - 70	Female	NSCLC	2.95	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.99	Alive	12.22	IV	Subsequent-line	1	no	no
8357	2017	51 - 55	Male	Renal	2	Stable	3	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.03	Alive	20.21	IV	Subsequent-line	0	no	no
8358	2015	51 - 55	Male	Renal	3.31	Stable	3	IMPACT-410	Combo	PD	No	No	Yes	2.53	Dead	39.39	IV	First-line	0	no	yes
8359	2018	66 - 70	Male	Melanoma	3.18	Stable	51.2	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	10.28	Alive	10.28	III	First-line	0	no	no
8360	2017	51 - 55	Male	Sarcoma	2.91		7	IMPACT-468	Combo	PD	No	No	Yes	2	Alive	22.08		First-line		no	no
8361	2016	66 - 70	Female	NSCLC	3.45	Stable	11.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	20.67	IV	Subsequent-line	1	no	no
8362	2017	56 - 60	Male	Head & Neck	27.6	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	10.55	IV	Subsequent-line	1	no	no
8363	2015	56 - 60	Female	NSCLC	7.5	Stable	0	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	11.14	Alive	48.03	IV	Subsequent-line	1	no	no
8364	2018	36 - 40	Female	Breast	1.76	Indeterminate	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	17.64	IV	Subsequent-line	0	no	no
8367	2015	36 - 40	Male	NSCLC	11.67	Stable	8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	7.95	IV	Subsequent-line	1	no	no
8368	2016	71 - 75	Male	NSCLC	16.4		7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	38.41	Alive	38.41	IV	Subsequent-line	1	no	no
8369	2015	71 - 75	Male	Renal	3.56	Stable	9.8	IMPACT-410	Combo	PR	Yes	Yes	No	49.97	Alive	49.97	IV	First-line	1	no	no
8371	2015	51 - 55	Male	Melanoma	6.17	Stable	36.4	IMPACT-410	Combo	CR	Yes	Yes	No	46.88	Alive	50.07	IV	First-line	0	no	no
8372	2017	56 - 60	Female	Endometrial	1.79	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	11.07	IV	Subsequent-line	1	no	yes
8373	2018	36 - 40	Female	Gastric	4.5	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.26	Dead	2.43	IV	Subsequent-line	0	no	no
8374	2016	76 - 80	Male	Melanoma	2.41	Stable	12.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	Yes	6.08	Alive	37.78	III	Subsequent-line	0	no	no
8375	2017	66 - 70	Male	NSCLC	2.08	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.08	Dead	12.94	IV	First-line	1	no	no
8376	2016	71 - 75	Male	NSCLC	12	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.97	Dead	4.21	IV	Subsequent-line	1	no	no
8377	2015	66 - 70	Male	NSCLC	13.43	Stable	12.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	6.05	IV	Subsequent-line	0	no	no
8379	2016	66 - 70	Female	NSCLC	10.56	Stable	1	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.3	Dead	8.8	IV	Subsequent-line		no	no
8381	2015	61 - 65	Male	Bladder	3	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Alive	46	IV	Subsequent-line	1	no	no
8382	2017	71 - 75	Female	Ovarian	2.25		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Alive	19.35	IV	Subsequent-line	0	no	no
8384	2015	66 - 70	Male	Bladder	5.27	Stable	27.5	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	6.8	Dead	31.54	IV	Subsequent-line	1	no	no
8385	2018	66 - 70	Male	Esophageal	3.67	Stable	3.9	IMPACT-410	PD-1/PD-L1	SD	No	No	No	5.26	Alive	7.43	IV	Subsequent-line	0	no	no
8386	2015	61 - 65	Male	SCLC	3.13	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	2.04	IV	Subsequent-line	0	no	no
8387	2018	71 - 75	Female	Sarcoma	2.67	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	12.65	Alive	12.75	IV	First-line	0	no	no
8388	2018	66 - 70	Male	Gastric	9.5	Stable	6.9	IMPACT-410	Combo	SD	No	No	Yes	3.38	Dead	15.64	IV	Subsequent-line	1	no	no
8389	2016	61 - 65	Male	Esophageal	2.56		8.8	IMPACT-468	Combo	PD	No	No	Yes	1.74	Dead	6.08	IV	First-line	1	no	no
8390	2016	66 - 70	Female	NSCLC	12.14	Stable	9.7	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	13.96	Alive	35.35	IV	Subsequent-line	1	no	no
8391	2016	51 - 55	Female	Colorectal	3.06	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.59	Dead	12.12	IV	Subsequent-line	0	no	no
8392	2016	56 - 60	Male	NSCLC	7.63	Stable	19.7	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.93	Dead	4.93	III	Subsequent-line	0	no	no
8393	2018	61 - 65	Female	Bladder	2.8	Stable	12.3	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	9.66	Alive	11.99	IV	Subsequent-line	0	no	no
8394	2016	76 - 80	Female	NSCLC	3.27	Stable	12.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.14	Dead	2.14	IV	Subsequent-line		no	no
8395	2017	61 - 65	Female	Melanoma	2.63	Stable	2	IMPACT-410	Combo	PR	Yes	Yes	No	19.78	Alive	19.78	IV	First-line	0	no	no
8396	2018	56 - 60	Male	Head & Neck	10	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	17.02	IV	Subsequent-line	1	no	no
8397	2017	61 - 65	Male	Bladder	4.16	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2	Dead	18.53	IV	Subsequent-line	0	no	no
8398	2016	66 - 70	Male	SCLC	10.75	Indeterminate	14.8	IMPACT-410	Combo	PD	No	No	Yes	1.18	Dead	1.18	IV	Subsequent-line	1	no	no
8399	2016	71 - 75	Female	NSCLC	4.36	Stable	7.9	IMPACT-410	Combo	SD	No	No	Yes	3.98	Alive	38.93	IV	Subsequent-line	1	no	no
8400	2015	61 - 65	Male	Melanoma	2.25	Stable	4.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	45.54	Alive	45.54	IV	First-line	1	no	no
8401	2016	51 - 55	Male	NSCLC	4.58	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	22.11	IV	Subsequent-line	1	no	no
8402	2015	56 - 60	Male	Melanoma	3.64	Stable	17.7	IMPACT-410	Combo	CR	Yes	Yes	No	17.91	Alive	29.11	IV	First-line	0	no	no
8403	2017	66 - 70	Female	Hepatobiliary	4.64		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	5.55	IV	Subsequent-line	1	no	no
8404	2016	86 - 90	Male	Melanoma	4.55		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.06	Alive	31.01	III	First-line	0	no	no
8405	2017	51 - 55	Female	Colorectal	1.86		5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.23	Dead	2.86	IV	Subsequent-line	1	no	no
8407	2015	61 - 65	Male	NSCLC	0.79	Stable	3.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	6.93	Dead	20.11	IV	Subsequent-line	0	no	no
8408	2016	61 - 65	Female	Breast	6	Stable	27.5	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	7.06	Dead	24.97	IV	Subsequent-line	0	no	no
8409	2018	26 - 30	Male	Sarcoma	2.33	Stable	1	IMPACT-410	Combo	PD	No	No	Yes	1.15	Alive	17.81	IV	Subsequent-line	1	no	no
8410	2016	61 - 65	Male	NSCLC	5	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.71	Dead	20.57	IV	Subsequent-line	0	no	no
8411	2017	36 - 40	Male	Hepatobiliary	3.19	Indeterminate	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.14	Dead	5.06	IV	Subsequent-line	1	no	yes
8412	2016	66 - 70	Female	NSCLC	17.91	Stable	7.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.71	Dead	3.71	IV	Subsequent-line	1	no	no
8414	2018	66 - 70	Male	Gastric	3.5	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.1	Dead	3.48	IV	Subsequent-line	1	no	no
8415	2018	26 - 30	Male	Colorectal	3.5	Stable	3.9	IMPACT-410	Combo	PD	No	No	Yes	1.58	Dead	4.14	IV	Subsequent-line	0	no	no
8416	2018	61 - 65	Male	Esophageal	8	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.53	Dead	6.21	IV	Subsequent-line	1	no	no
8417	2016	51 - 55	Male	Renal	2.92	Stable	3.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	8.31	Alive	42.64	IV	Subsequent-line	0	no	no
8418	2015	66 - 70	Female	NSCLC	2.25	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	3.22	IV	Subsequent-line		no	no
8419	2015	71 - 75	Female	NSCLC	2.94	Stable	2	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.29	Dead	36.96	II	Subsequent-line	0	no	no
8420	2018	66 - 70	Female	Hepatobiliary	12	Stable	3.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.76	Dead	2.76	IV	Subsequent-line	1	no	yes
8421	2015	41 - 45	Male	Gastric	4.33	Stable	2	IMPACT-410	Combo	PD	No	No	Yes	1.61	Dead	1.61	IV	Subsequent-line	1	no	no
8422	2016	51 - 55	Female	NSCLC	3.58	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	7.1	IV	Subsequent-line		no	no
8423	2016	56 - 60	Female	Pancreatic	3.75	Stable	3	IMPACT-410	Combo	PD	No	No	Yes	1.38	Dead	6.31	IV	Subsequent-line	1	no	no
8424	2016	66 - 70	Female	SCLC	8.4	Stable	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	1.87	IV	Subsequent-line	1	no	no
8425	2016	46 - 50	Male	NSCLC	2.15	Stable	7.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	6.47	Dead	16.69	IV	Subsequent-line	1	no	no
8427	2017	46 - 50	Male	Melanoma	2.99		7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.83	Alive	26.15	III	First-line	0	no	no
8428	2017	71 - 75	Male	Bladder	9	Indeterminate	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	4.76	IV	Subsequent-line	0	no	no
8429	2017	36 - 40	Male	Esophageal	11.33	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.59	Dead	0.59	IV	Subsequent-line	1	no	no
8430	2017	46 - 50	Female	Ovarian	3.57	Stable	1	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.36	Dead	9.99	IV	Subsequent-line	0	no	no
8431	2016	81 - 85	Female	NSCLC	9.78	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.71	Dead	5.39	IV	Subsequent-line		no	no
8432	2018	11 - 15	Female	Sarcoma	5.81	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.49	Dead	0.49	IV	Subsequent-line		no	no
8434	2016	71 - 75	Female	Melanoma	2.09	Stable	37.4	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	32.66	Alive	32.66	III	First-line	0	no	no
8435	2016	71 - 75	Female	Melanoma	2.8	Stable	51.2	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	20.73	Dead	25.76	IV	First-line	0	no	no
8436	2016	66 - 70	Male	SCLC	2.88	Stable	12.3	IMPACT-468	Combo	PR	Yes	Yes	Yes	2.6	Dead	13.83	IV	Subsequent-line	1	no	no
8437	2015	61 - 65	Male	Colorectal	2.63	Unstable	89.5	IMPACT-410	PD-1/PD-L1	SD	No	Yes	No	44.35	Alive	44.35	IV	First-line	0	mut-MMRd	yes
8438	2015	66 - 70	Male	Bladder	12.25		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	3.52	IV	Subsequent-line	2	no	no
8439	2016	61 - 65	Male	Pancreatic	8.33	Stable	3	IMPACT-410	Combo	PD	No	No	Yes	1.08	Dead	2.73	IV	Subsequent-line	1	no	no
8440	2016	56 - 60	Female	Renal	1.5	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.3	Dead	3.88	IV	Subsequent-line	1	no	no
8441	2016	51 - 55	Male	NSCLC	2.33	Stable	34.4	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	34.96	Alive	37.42	IV	Subsequent-line		no	no
8442	2016	46 - 50	Male	Head & Neck	12.43	Indeterminate	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.22	Dead	6.93	IV	Subsequent-line	1	no	no
8443	2016	66 - 70	Male	Head & Neck	4.33	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	13.9	IV	Subsequent-line	0	no	no
8444	2015	56 - 60	Female	NSCLC	49.71	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	1.38	IV	Subsequent-line	1	no	no
8445	2015	56 - 60	Female	NSCLC	4.67	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	10.28	IV	Subsequent-line	0	no	no
8446	2016	56 - 60	Male	Gastric	6.14	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	1.74	IV	Subsequent-line	1	no	no
8447	2016	36 - 40	Male	Head & Neck	10.67	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.56	Dead	3.42	IV	Subsequent-line	1	no	no
8449	2016	61 - 65	Male	Renal	6.53	Stable	3.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	32.66	Alive	34.63	IV	Subsequent-line	1	no	no
8451	2016	56 - 60	Female	Breast	10.57	Stable	5.9	IMPACT-410	CTLA-4	PD	No	No	Yes	2.3	Dead	3.09	IV	Subsequent-line	1	no	no
8452	2016	66 - 70	Male	Gastric	1.92	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.2	Alive	12.25	IV	Subsequent-line	2	no	no
8453	2017	66 - 70	Female	Ovarian	1.31	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.48	Alive	29.57	IV	Subsequent-line	0	no	no
8454	2017	41 - 45	Female	Breast	0.74	Stable	4.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	8.31	Alive	29.24	IV	Subsequent-line	0	no	no
8456	2017	46 - 50	Female	NSCLC	1.5	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	12.09	IV	Subsequent-line		no	no
8458	2018	36 - 40	Female	Renal	5.33	Stable	4.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.36	Alive	9.53	IV	Subsequent-line	1	no	no
8459	2016	56 - 60	Female	Hepatobiliary	1.92	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	9.3	IV	Subsequent-line	1	no	no
8460	2016	51 - 55	Female	NSCLC	1.68	Indeterminate	17.7	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	4.67	Dead	21.82	IV	Subsequent-line	1	no	no
8461	2016	71 - 75	Female	Bladder	7.6	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.12	Dead	9.07	IV	Subsequent-line	0	no	no
8462	2017	66 - 70	Male	SCLC	7.64	Stable	4.9	IMPACT-410	Combo	PD	No	No	Yes	1.18	Dead	1.51	IV	Subsequent-line	1	no	no
8464	2017	66 - 70	Male	Head & Neck	8.43	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	14.13	IV	Subsequent-line	0	no	no
8465	2016	71 - 75	Male	NSCLC	6.14		0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	9.13	IV	Subsequent-line	1	no	no
8467	2016	81 - 85	Male	NSCLC	9.5	Stable	20.7	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	33.91	Alive	39.39	IV	Subsequent-line	0	no	yes
8468	2016	56 - 60	Male	NSCLC	7.29	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	1.91	IV	Subsequent-line	1	no	no
8469	2015	51 - 55	Male	Renal	1.33	Stable	3.9	IMPACT-410	Combo	SD	No	No	Yes	4.14	Dead	31.84	IV	First-line	0	no	no
8470	2015	51 - 55	Male	Renal	9.27	Stable	1	IMPACT-410	Combo	PR	Yes	Yes	No	46.69	Alive	47.47	IV	First-line	1	no	no
8471	2017	36 - 40	Male	Sarcoma	6.13	Stable	3.9	IMPACT-410	Combo	PR	Yes	Yes	No	21.65	Alive	24.61	IV	Subsequent-line		no	no
8473	2015	61 - 65	Male	Melanoma	10.25	Stable	43.3	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.17	Dead	7.82	IV	Subsequent-line	1	no	yes
8474	2015	56 - 60	Male	NSCLC	4.2	Indeterminate	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.12	Dead	14.78	IV	Subsequent-line	1	no	no
8475	2018	66 - 70	Male	Melanoma	4.18	Stable	16.7	IMPACT-468	Combo	SD	No	No	Yes	3.78	Dead	5.72	IV	First-line	0	no	no
8476	2016	76 - 80	Female	Esophageal	2.27	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	1.38	IV	Subsequent-line	1	no	no
8477	2017	61 - 65	Female	Endometrial	18.6	Indeterminate	1	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	7.33	Dead	17.71	IV	Subsequent-line	1	no	no
8480	2016	71 - 75	Male	NSCLC	11.08	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	0.92	IV	Subsequent-line	1	no	no
8481	2017	71 - 75	Female	NSCLC	6.21		14.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.65	Dead	3.75	IV	Subsequent-line	1	no	no
8482	2016	46 - 50	Male	Renal	5.18	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	35.35	III	Subsequent-line	0	no	no
8483	2016	66 - 70	Male	NSCLC	4.11		12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	16.23	IV	Subsequent-line	1	no	no
8484	2016	66 - 70	Female	Esophageal	3.4	Stable	6.9	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	35.94	Alive	36.7	IV	Subsequent-line	1	no	no
8485	2018	76 - 80	Male	NSCLC	10	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.51	Dead	6.51	IV	Subsequent-line	1	no	no
8486	2015	71 - 75	Female	NSCLC	11.2	Unstable	13.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	2.69	IV	Subsequent-line	1	other-MMRd	no
8487	2018	46 - 50	Male	Sarcoma	12.5	Stable	0	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.68	Dead	6.34	IV	Subsequent-line	1	no	no
8488	2017	51 - 55	Female	Colorectal	1.29	Stable	4.9	IMPACT-410	Combo	PD	No	No	Yes	1.64	Dead	14.19	IV	Subsequent-line	0	no	no
8489	2017	61 - 65	Female	NSCLC	5.27	Stable	18.7	IMPACT-410	PD-1/PD-L1	SD	No	Yes	No	31.51	Alive	31.51	IV	Subsequent-line	0	no	no
8490	2016	21 - 25	Female	Sarcoma	1.67	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.41	Alive	32.43	IV	Subsequent-line	0	no	no
8491	2015	66 - 70	Female	Melanoma	1.4	Stable	19.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	13.31	III	First-line	0	no	no
8492	2016	61 - 65	Female	NSCLC	9.1	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	14.98	IV	Subsequent-line		no	no
8493	2017	76 - 80	Female	Hepatobiliary	1.35	Unstable	49.2	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	28.29	Alive	28.29	IV	Subsequent-line	1	mut-MMRd	yes
8494	2016	61 - 65	Male	NSCLC	0.71	Stable	22.6	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	39.79	Alive	40.71	IV	Subsequent-line	1	no	yes
8495	2017	51 - 55	Male	Colorectal	5.45	Stable	10.8	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.68	Dead	10.61	IV	Subsequent-line	0	no	no
8496	2016	86 - 90	Male	NSCLC	5.13	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.79	Dead	3.84	IV	Subsequent-line	1	no	yes
8497	2016	71 - 75	Male	Gastric	3.19	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2	Dead	3.65	IV	Subsequent-line	3	no	yes
8498	2016	21 - 25	Female	Gastric	43.5	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.23	Dead	0.23	IV	Subsequent-line	2	no	no
8499	2018	56 - 60	Male	Pancreatic	3.82	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	8.48	IV	Subsequent-line	0	no	no
8500	2016	46 - 50	Female	NSCLC	5.59	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	10.64	IV	Subsequent-line	1	no	no
8501	2015	66 - 70	Male	NSCLC	8.5	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	6.08	IV	Subsequent-line	0	no	yes
8502	2016	51 - 55	Female	Sarcoma	1.86	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.56	Dead	9.69		Subsequent-line	1	no	no
8503	2016	11 - 15	Male	Hepatobiliary	1.37	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	12.16	IV	Subsequent-line		no	no
8504	2015	11 - 15	Female	Renal	1.82	Stable	0	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	7.23	Dead	7.23	IV	Subsequent-line	1	no	no
8506	2017	61 - 65	Male	Hepatobiliary	2.73	Stable	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	2.2	IV	Subsequent-line	1	no	no
8507	2016	61 - 65	Male	NSCLC	2.81	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	12.16	IV	Subsequent-line	0	no	no
8508	2016	71 - 75	Male	NSCLC	3.6	Stable	0	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	15.74	Dead	27.07	IV	Subsequent-line		no	no
8509	2017	81 - 85	Female	NSCLC	2.73		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	1.61	IV	Subsequent-line	1	no	no
8510	2015	61 - 65	Male	Renal	2.68	Stable	3	IMPACT-410	Combo	PR	Yes	Yes	No	44.81	Alive	46.78	IV	First-line	0	no	no
8511	2016	66 - 70	Female	Hepatobiliary	1.75		2	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	37.95	Alive	37.95	IV	First-line	1	no	no
8512	2017	51 - 55	Female	Colorectal	4.6	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Dead	8.21	IV	Subsequent-line	1	no	no
8513	2016	46 - 50	Female	NSCLC	2.83	Stable	2	IMPACT-410	Combo	PR	Yes	Yes	Yes	16.46	Alive	41.53	IV	Subsequent-line	1	no	no
8514	2016	61 - 65	Male	Colorectal	7.69	Stable	153.5	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	1.68	IV	Subsequent-line	1	no	yes
8515	2016	56 - 60	Female	Ovarian	5.64		8.8	IMPACT-468	Combo	PD	No	No	Yes	1.74	Dead	14.75	IV	Subsequent-line	0	no	no
8516	2018	76 - 80	Male	Esophageal	13.5	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.43	Dead	0.46	IV	Subsequent-line	2	no	no
8517	2015	51 - 55	Female	Melanoma	2	Stable	15.7	IMPACT-410	Combo	CR	Yes	Yes	No	46.36	Alive	46.36	IV	First-line	0	no	no
8518	2017	31 - 35	Male	Pancreatic	5.8	Stable	3.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.66	Alive	4.96	IV	Subsequent-line	1	no	no
8519	2015	61 - 65	Male	NSCLC	3.63	Stable	5.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.27	Dead	8.57	IV	Subsequent-line	1	no	no
8520	2018	46 - 50	Male	Sarcoma	4	Stable	0	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	6.14	Dead	10.78	IV	Subsequent-line	0	no	no
8522	2016	61 - 65	Male	Head & Neck	22.67		10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	33.64	Alive	33.64	IV	Subsequent-line	0	no	no
8523	2017	91 - 95	Male	Sarcoma	2.33	Stable	35.4	IMPACT-410	Combo	CR	Yes	Yes	Yes	2.66	Dead	2.66		Subsequent-line		no	no
8524	2018	61 - 65	Male	Pancreatic	52	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	0.99	IV	Subsequent-line	1	no	no
8525	2015	46 - 50	Female	NSCLC	2.22	Stable	6.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	17.94	Dead	36.76	IV	First-line	0	no	yes
8526	2016	46 - 50	Female	NSCLC	1.96	Stable	23.6	IMPACT-410	PD-1/PD-L1	SD	No	Yes	No	35.06	Alive	35.06	IV	Subsequent-line	1	no	yes
8528	2016	56 - 60	Female	Renal	1.48	Stable	5.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	37.88	Alive	37.88	IV	Subsequent-line	0	no	no
8529	2016	51 - 55	Female	Head & Neck	9.88	Stable	3.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	36.11	Alive	37.55	IV	Subsequent-line	1	no	no
8530	2016	71 - 75	Female	Gastric	6.75	Unstable	47.2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	4.93	IV	Subsequent-line	0	other-MMRd	yes
8531	2015	51 - 55	Female	Renal	3.57	Stable	3	IMPACT-410	Combo	PD	No	No	Yes	2.46	Dead	18.4	IV	Subsequent-line	1	no	no
8532	2017	61 - 65	Female	Breast	7.43	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.02	Dead	3.02	IV	Subsequent-line	3	no	no
8534	2016	66 - 70	Female	NSCLC	12.38	Stable	20.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.66	Dead	14.13	IV	Subsequent-line		no	no
8535	2016	56 - 60	Female	NSCLC	20.25	Stable	7.9	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	20.5	Alive	38.9	IV	Subsequent-line	0	no	no
8537	2017	56 - 60	Male	Head & Neck	4.71		3.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	Yes	8.25	Dead	8.25	IV	Subsequent-line	1	no	no
8539	2015	61 - 65	Female	Renal	2.47	Stable	3	IMPACT-410	Combo	SD	No	No	Yes	5.29	Alive	25.03	IV	First-line	0	no	no
8540	2016	41 - 45	Male	Gastric	9.1	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.02	Dead	1.02	IV	Subsequent-line	1	no	no
8541	2016	56 - 60	Male	Bladder	1.71	Stable	7.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.88	Dead	24.64	IV	Subsequent-line	1	no	no
8544	2016	56 - 60	Male	Melanoma	3.23	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.66	Dead	18.5	III	First-line	0	no	no
8545	2017	66 - 70	Female	Melanoma	2.79	Stable	2	IMPACT-410	Combo	SD	No	No	Yes	3.88	Dead	6.21	IV	First-line	0	no	no
8547	2017	71 - 75	Female	Endometrial	3.14	Stable	3	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.91	Dead	13.17	IV	Subsequent-line	1	no	no
8548	2016	31 - 35	Male	Head & Neck	29	Unstable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	2.99	IV	Subsequent-line	0	other-MMRd	no
8549	2017	56 - 60	Female	Renal	3.17	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	7.95	IV	Subsequent-line	0	no	no
8550	2017	71 - 75	Male	Esophageal	3.71	Stable	6.1	IMPACT-468	Combo	PD	No	No	Yes	1.64	Dead	1.64	IV	Subsequent-line	0	no	no
8551	2017	61 - 65	Male	NSCLC	2.75	Stable	9.8	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	10.84	Dead	13.44	IV	Subsequent-line		no	no
8552	2016	51 - 55	Male	NSCLC	1.8	Stable	1	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	22.8	Alive	40.94	III	Subsequent-line	0	no	no
8553	2016	36 - 40	Male	Colorectal	2.38	Stable	3.9	IMPACT-410	Combo	PD	No	No	Yes	1.74	Dead	12.02	IV	Subsequent-line	1	no	no
8554	2016	61 - 65	Male	NSCLC	10.33	Stable	8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	5.88	III	Subsequent-line	1	no	no
8555	2018	56 - 60	Female	Sarcoma	8.83	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.59	Alive	0.92	IV	Subsequent-line	1	no	no
8557	2015	66 - 70	Female	NSCLC	4.33	Stable	16.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.99	Dead	6.74	IV	Subsequent-line	1	no	no
8558	2017	61 - 65	Female	Endometrial	6.26	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.43	Dead	0.43	IV	Subsequent-line	2	no	yes
8559	2016	46 - 50	Female	NSCLC	5.57	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.46	Dead	5.75	IV	Subsequent-line	1	no	no
8560	2018	51 - 55	Male	Renal	3.55	Stable	2	IMPACT-410	Combo	PR	Yes	Yes	No	14.26	Alive	14.26	IV	Subsequent-line	0	no	no
8561	2016	61 - 65	Female	Renal	2.79	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.6	Alive	37.95	IV	Subsequent-line	1	no	no
8562	2015	56 - 60	Female	NSCLC	2.5	Stable	4.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.6	Dead	21.49	IV	Subsequent-line	0	no	no
8563	2015	71 - 75	Male	NSCLC	5.5	Stable	13.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.5	Dead	2.5	IV	Subsequent-line	1	no	no
8564	2016	61 - 65	Female	NSCLC	5.22	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	11.33	IV	Subsequent-line	1	no	no
8566	2017	36 - 40	Male	Gastric	7.8	Stable	3.9	IMPACT-410	Combo	PD	No	No	Yes	0.59	Dead	0.89	IV	Subsequent-line	1	no	no
8567	2018	61 - 65	Male	Sarcoma	5.44	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	7.1	IV	Subsequent-line	1	no	no
8568	2016	76 - 80	Male	NSCLC	20.67	Stable	11.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	6.28	IV	Subsequent-line		no	no
8569	2015	61 - 65	Male	Renal	4.8	Stable	7.9	IMPACT-410	Combo	PR	Yes	Yes	No	44.65	Alive	44.81	IV	First-line	1	no	no
8570	2017	76 - 80	Male	Sarcoma	3.4	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	4.63	IV	Subsequent-line	1	no	no
8571	2017	71 - 75	Male	NSCLC	4.57	Stable	18.7	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.09	Alive	20.5	IV	Subsequent-line	1	no	no
8572	2017	56 - 60	Male	Renal	5.6	Stable	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	24.51	IV	Subsequent-line	0	no	no
8573	2015	71 - 75	Male	NSCLC	11.57	Stable	8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	0.69	IV	Subsequent-line	1	no	no
8574	2016	71 - 75	Male	Melanoma	3.69	Stable	7.9	IMPACT-410	Combo	PD	No	No	Yes	2.73	Dead	4.3	IV	First-line	1	no	no
8576	2017	41 - 45	Male	Hepatobiliary	6.81	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	0.95	IV	Subsequent-line	2	no	no
8577	2016	41 - 45	Female	Pancreatic	1.25	Stable	2	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	6.08	Alive	31.64	IV	Subsequent-line	0	no	no
8578	2015	36 - 40	Female	NSCLC	1.1	Stable	8.9	IMPACT-410	Combo	SD	No	Yes	Yes	9.2	Alive	35.94	IV	Subsequent-line	1	no	no
8579	2016	81 - 85	Male	Melanoma	2.15	Stable	15.7	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.59	Dead	10.41	III	First-line	0	no	no
8580	2016	56 - 60	Female	Ovarian	2.48	Stable	0	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	24.31	Alive	35.45	IV	Subsequent-line	0	no	no
8581	2016	61 - 65	Female	Endometrial	3.27	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	4.93	IV	Subsequent-line	1	no	no
8582	2017	71 - 75	Female	Endometrial	6.67	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	7.59	IV	Subsequent-line	1	no	no
8583	2018	36 - 40	Female	Breast	7	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	0.72	IV	Subsequent-line	1	no	no
8584	2015	76 - 80	Female	NSCLC	7.71	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	0.85	IV	Subsequent-line	1	no	yes
8585	2016	46 - 50	Male	Melanoma	5.21	Stable	6.9	IMPACT-410	Combo	PD	No	No	Yes	3.45	Alive	34.1	IV	Subsequent-line	0	no	no
8586	2017	66 - 70	Female	Renal	2.12	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.17	Alive	24.18	IV	First-line	0	no	no
8587	2017	66 - 70	Female	Melanoma	3.4	Stable	5.3	IMPACT-468	CTLA-4	SD	No	No	Yes	5.36	Dead	13.57		Subsequent-line	0	no	no
8588	2016	66 - 70	Male	Bladder	19.29	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.69	Dead	7.2	IV	Subsequent-line	1	no	no
8590	2016	66 - 70	Male	Renal	16.8	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	2.92	IV	Subsequent-line	1	no	no
8591	2017	51 - 55	Female	NSCLC	3.31	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	7.43	IV	Subsequent-line	1	no	no
8592	2016	31 - 35	Female	Breast	9.29	Stable	4.9	IMPACT-410	CTLA-4	SD	No	No	Yes	5.26	Dead	13.83	IV	Subsequent-line	1	no	yes
8595	2018	71 - 75	Female	Sarcoma	3.06		9.7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.47	Dead	4.47	IV	Subsequent-line	1	no	no
8597	2017	61 - 65	Male	NSCLC	1.86	Stable	18.7	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	16.39	Alive	27.66	IV	Subsequent-line	1	no	no
8598	2017	41 - 45	Female	NSCLC	1.23	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.91	Alive	4.44	IV	Subsequent-line		no	no
8599	2017	51 - 55	Female	Head & Neck	17.33		3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	16.26	Alive	29.67	IV	Subsequent-line	1	no	no
8600	2016	56 - 60	Female	NSCLC	5.53	Stable	16.7	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	39.2	Alive	39.39	IV	Subsequent-line	0	no	no
8601	2017	56 - 60	Male	Gastric	7.6		5.3	IMPACT-468	Combo	PD	No	No	Yes	0.85	Alive	1.94	IV	Subsequent-line	0	no	no
8602	2016	56 - 60	Male	NSCLC	5	Stable	11.8	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	6.44	Alive	20.99	IV	Subsequent-line	0	no	no
8603	2016	76 - 80	Male	NSCLC	4	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	6.05	IV	Subsequent-line	1	no	no
8605	2015	51 - 55	Female	NSCLC	2.17	Stable	3	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	43.24	Alive	44.88	IV	First-line	0	no	no
8606	2017	71 - 75	Female	Head & Neck	7.2		7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	28.39	Alive	28.39	IV	Subsequent-line	1	no	no
8607	2016	51 - 55	Female	SCLC	87	Stable	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	2.27	IV	Subsequent-line	2	no	yes
8608	2016	61 - 65	Female	Melanoma	7	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.2	Dead	0.2	IV	First-line	3	no	no
8609	2017	66 - 70	Male	Gastric	2.95	Indeterminate	5.9	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	8.87	Dead	24.57	IV	Subsequent-line	0	no	no
8610	2017	61 - 65	Male	Hepatobiliary	1.62	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.98	Dead	12.91	IV	Subsequent-line	1	no	no
8612	2016	76 - 80	Male	NSCLC	7.5		0.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.71	Dead	37.29	IV	Subsequent-line	1	no	no
8613	2017	66 - 70	Female	Colorectal	5.36	Unstable	48.2	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	25.99	Alive	27.17	IV	Subsequent-line		other-MMRd	yes
8615	2017	61 - 65	Female	Endometrial	13.52	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	7.36	Alive	26.48	IV	Subsequent-line	1	no	no
8617	2017	76 - 80	Female	NSCLC	2.92	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.29	Dead	10.12	IV	Subsequent-line	0	no	no
8618	2015	71 - 75	Male	Renal	4.09	Stable	9.8	IMPACT-410	Combo	CR	Yes	Yes	No	41.66	Alive	44.06	IV	Subsequent-line	1	no	no
8619	2016	66 - 70	Male	Renal	12.8	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	14.88	Alive	33.97	IV	Subsequent-line	1	no	no
8620	2017	66 - 70	Male	Sarcoma	2.11	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Alive	18.04	IV	First-line	0	no	no
8621	2018	66 - 70	Male	NSCLC	3.46	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.27	Alive	18.83	IV	Subsequent-line	0	no	no
8622	2018	66 - 70	Female	Endometrial	3.67	Stable	3.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	19.35	Alive	19.35	IV	Subsequent-line	0	no	no
8623	2018	56 - 60	Male	Sarcoma	1.53	Stable	0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	9.63	Alive	9.72	III	Subsequent-line	0	no	no
8624	2017	76 - 80	Male	NSCLC	11.43	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	0.76	IV	Subsequent-line	1	no	no
8625	2016	71 - 75	Male	NSCLC	11	Stable	15.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	4.83	IV	Subsequent-line	0	no	no
8626	2017	76 - 80	Male	Bladder	7		10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	3.52	IV	Subsequent-line	1	no	no
8627	2017	51 - 55	Male	Head & Neck	6.43		0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.91	Dead	28.98	IV	Subsequent-line	0	no	no
8628	2018	66 - 70	Female	Melanoma	11.75	Stable	7	IMPACT-468	Combo	PD	No	No	Yes	1.38	Dead	2.4	IV	First-line	1	no	no
8629	2015	61 - 65	Male	Renal	29.58	Stable	7.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	13.8	Dead	23.49	IV	First-line	1	no	no
8630	2018	66 - 70	Female	Gastric	1.26	Unstable	51.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.66	Alive	15.18	IV	Subsequent-line	1	other-MMRd	yes
8631	2017	51 - 55	Male	Melanoma	1.46	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	13.73	IV	First-line		no	no
8632	2016	66 - 70	Male	Head & Neck	3.4		0	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	7.26	Dead	8.64	IV	Subsequent-line	0	no	no
8633	2017	61 - 65	Male	Head & Neck	13.2	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Dead	24.21	IV	Subsequent-line	1	no	no
8634	2018	61 - 65	Female	Sarcoma	4.5	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	1.58	Alive	11.14	IV	Subsequent-line	0	no	no
8635	2015	66 - 70	Male	Melanoma	5.67	Stable	43.3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.23	Alive	45.5	IV	First-line	3	no	yes
8636	2016	81 - 85	Male	Melanoma	25.86		28.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	3.15	IV	First-line	1	no	no
8637	2017	36 - 40	Female	Breast	3.67	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.08	Dead	5.19	IV	Subsequent-line	1	no	no
8638	2016	81 - 85	Male	NSCLC	4.83	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	20.63	IV	Subsequent-line	0	no	no
8639	2015	36 - 40	Male	Bladder	1.44	Stable	23.6	IMPACT-410	Combo	PD	No	No	Yes	1.22	Dead	12.48	IV	Subsequent-line	1	no	no
8641	2017	81 - 85	Female	NSCLC	21.25		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.08	Dead	1.08	IV	First-line	1	no	no
8642	2016	51 - 55	Female	Renal	6.3	Stable	1	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.42	Dead	11.1	IV	Subsequent-line	1	no	no
8643	2015	61 - 65	Male	NSCLC	5.36	Stable	3	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.73	Dead	7.13	IV	First-line	1	no	no
8645	2017	46 - 50	Male	NSCLC	1.37	Stable	23.6	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	27.6	Alive	27.6	IV	Subsequent-line	0	no	yes
8646	2016	41 - 45	Male	Sarcoma	3.29	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.07	Dead	9.56		Subsequent-line	0	no	no
8647	2016	51 - 55	Female	Endometrial	6.22	Unstable	31.5	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	26.41	Alive	39.1	IV	First-line	1	other-MMRd	yes
8649	2016	71 - 75	Female	NSCLC	5.86	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.09	Dead	3.09	IV	Subsequent-line	1	no	no
8651	2016	76 - 80	Female	Hepatobiliary	3.3	Stable	1	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	1.94	Dead	21.32	IV	Subsequent-line	1	no	no
8652	2017	61 - 65	Male	Head & Neck	3.25	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	6.7	IV	Subsequent-line	0	no	no
8653	2016	61 - 65	Male	NSCLC	1.94	Stable	6.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	37.45	Alive	38.18	IV	Subsequent-line	1	no	yes
8654	2016	66 - 70	Female	NSCLC	4.11	Stable	8.9	IMPACT-410	Combo	SD	No	No	Yes	5.36	Alive	37.95	IV	Subsequent-line	1	no	no
8656	2017	46 - 50	Male	Sarcoma	7	Stable	1	IMPACT-410	Combo	PD	No	No	Yes	0.26	Dead	0.26	IV	Subsequent-line		no	no
8657	2018	31 - 35	Female	Colorectal	4.56	Stable	7.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.48	Dead	11.17	IV	Subsequent-line	1	no	no
8658	2016	51 - 55	Male	Bladder	7.64	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	5.98	IV	Subsequent-line	1	no	no
8660	2018	41 - 45	Male	Colorectal	4	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Alive	15.41	IV	Subsequent-line	0	no	no
8661	2015	66 - 70	Male	NSCLC	2.8	Stable	4.9	IMPACT-410	Combo	PR	Yes	Yes	Yes	8.05	Dead	28.12	IV	First-line	0	no	no
8662	2017	71 - 75	Female	Pancreatic	8.29	Stable	3	IMPACT-410	Combo	SD	No	No	Yes	2.86	Dead	7.36	III	Subsequent-line	1	no	no
8663	2016	51 - 55	Female	NSCLC	1.06	Stable	32.5	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	10.25	Dead	35.58	IV	Subsequent-line	1	no	no
8664	2016	61 - 65	Male	NSCLC	3.55		1.8	IMPACT-468	Combo	SD	No	No	Yes	3.38	Dead	9.23	IV	Subsequent-line	0	no	no
8665	2016	31 - 35	Female	NSCLC	4.31	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.51	Alive	3.48	IV	Subsequent-line	1	no	no
8666	2016	46 - 50	Female	NSCLC	3.67		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.5	Dead	12.81	IV	Subsequent-line	0	no	no
8669	2015	66 - 70	Male	Renal	2.63	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	9.46	IV	First-line	1	no	no
8670	2016	56 - 60	Female	Bladder	12.5	Stable	16.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.3	Dead	0.3	IV	Subsequent-line	2	no	no
8671	2016	71 - 75	Male	Bladder	12.22	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	11.73	Alive	20.57	IV	Subsequent-line		no	no
8672	2017	56 - 60	Female	NSCLC	5.3	Stable	10.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	24.87	Alive	25.3	IV	Subsequent-line	1	no	yes
8673	2017	56 - 60	Female	NSCLC	4.05	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	4.34	IV	Subsequent-line	1	no	no
8675	2017	41 - 45	Male	Gastric	2.53	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	8.57	IV	Subsequent-line	1	no	no
8676	2018	76 - 80	Male	Head & Neck	4.92		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.71	Dead	15.74	IV	Subsequent-line	1	no	no
8677	2016	61 - 65	Female	Melanoma	2.62	Stable	15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.3	Alive	31.21	III	First-line	0	no	yes
8679	2017	46 - 50	Male	NSCLC	22.25	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	2.14	IV	Subsequent-line	1	no	no
8680	2016	56 - 60	Male	Head & Neck	9.5	Stable	25.6	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	18.07	Dead	18.07	IV	Subsequent-line	1	no	yes
8681	2016	66 - 70	Male	NSCLC	6.91		4.4	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	16.46	Dead	32.99	IV	Subsequent-line	1	no	no
8682	2016	26 - 30	Female	Colorectal	5.08	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	4.47	IV	Subsequent-line		no	no
8683	2017	66 - 70	Female	NSCLC	3.38	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	14.82	IV	Subsequent-line		no	no
8684	2016	71 - 75	Female	NSCLC	5.55	Stable	10.8	IMPACT-410	Combo	PR	Yes	Yes	Yes	14.39	Dead	21.75	IV	Subsequent-line	1	no	no
8685	2016	46 - 50	Female	NSCLC	5.27	Stable	11.8	IMPACT-410	Combo	PD	No	No	Yes	1.35	Dead	1.48	IV	Subsequent-line	0	no	no
8686	2017	81 - 85	Male	NSCLC	4	Indeterminate	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.89	Dead	7.95	IV	Subsequent-line	2	no	no
8687	2016	56 - 60	Male	Melanoma	2.24		26.3	IMPACT-468	Combo	SD	No	No	Yes	3.91	Alive	34.96	IV	First-line	0	no	no
8688	2017	51 - 55	Male	NSCLC	11	Stable	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	9.66	IV	Subsequent-line	1	no	no
8689	2016	46 - 50	Male	Sarcoma	3.67	Stable	2	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	24.15	Dead	29.73	IV	Subsequent-line	0	no	no
8691	2016	76 - 80	Male	NSCLC	4.94	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	5.36	IV	Subsequent-line	1	no	no
8692	2018	51 - 55	Male	Gastric	5.94	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2	Dead	6.47	IV	Subsequent-line	1	no	no
8693	2016	66 - 70	Male	NSCLC	6.9	Stable	11.8	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	33.45	Alive	33.81	IV	Subsequent-line	0	no	no
8694	2017	66 - 70	Male	Gastric	4.28	Stable	5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.32	Dead	4.63	IV	Subsequent-line	1	no	no
8695	2015	56 - 60	Male	NSCLC	2.87		1	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	9.17	Dead	22.7	IV	First-line	0	no	no
8696	2016	61 - 65	Male	NSCLC	13		14.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	17.05	Dead	18	IV	Subsequent-line	1	no	no
8697	2017	56 - 60	Female	NSCLC	10.36	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	4.24	IV	Subsequent-line	1	no	no
8698	2016	66 - 70	Female	SCLC	2		13.2	IMPACT-468	Combo	PR	Yes	Yes	Yes	14.95	Dead	14.95	III	Subsequent-line	1	no	no
8699	2017	71 - 75	Male	Melanoma	2.08	Stable	35.1	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	23.03	Alive	24.41	IV	First-line	1	no	no
8700	2016	61 - 65	Male	NSCLC	10.75	Stable	7.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.45	Dead	3.45	IV	Subsequent-line	0	no	no
8701	2016	51 - 55	Female	Breast	6.38		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.05	Dead	1.41	IV	Subsequent-line	1	no	no
8702	2015	86 - 90	Male	Melanoma	2.27	Stable	22.6	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	1.35	Dead	36.6	III	First-line	1	no	no
8703	2016	76 - 80	Male	NSCLC	8.29	Stable	3.9	IMPACT-410	Combo	PR	Yes	Yes	Yes	4.9	Dead	4.9	IV	First-line	1	no	no
8704	2016	71 - 75	Male	Pancreatic	13.9	Stable	3.9	IMPACT-410	Combo	PD	No	No	Yes	0.69	Dead	0.85	IV	Subsequent-line	1	no	no
8705	2016	56 - 60	Female	Sarcoma	13.29	Stable	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.49	Dead	4.73	IV	Subsequent-line	1	no	no
8706	2016	76 - 80	Male	Melanoma	1.63		25.6	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	8.44	Alive	9.26	III	First-line	1	no	no
8707	2016	56 - 60	Female	NSCLC	8	Stable	11.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.43	Dead	7.36	IV	Subsequent-line	1	no	no
8708	2017	56 - 60	Male	Hepatobiliary	2.29	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.87	Alive	3.48	IV	Subsequent-line	1	no	no
8709	2017	71 - 75	Male	Melanoma	3.3		70.2	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	26.38	Alive	26.38	III	First-line	0	no	no
8710	2016	21 - 25	Female	Sarcoma	3.4	Stable	1	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.4	Dead	29.08	IV	Subsequent-line		no	no
8711	2017	41 - 45	Female	Hepatobiliary	25	Stable	13.8	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	11.27	Alive	24.11	IV	Subsequent-line	1	no	yes
8713	2017	71 - 75	Female	NSCLC	2.33	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.87	Alive	27.7	IV	Subsequent-line		no	no
8714	2017	71 - 75	Female	NSCLC	5	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	3.32	IV	Subsequent-line		no	no
8715	2016	66 - 70	Male	Melanoma	2.42	Stable	40.3	IMPACT-410	Combo	CR	Yes	Yes	No	42.15	Alive	42.15	IV	First-line	1	no	no
8716	2016	71 - 75	Female	SCLC	4.6	Stable	16.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	0.72	IV	Subsequent-line	1	no	yes
8717	2018	51 - 55	Male	NSCLC	2.74	Stable	5.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.73	Alive	12.09	IV	Subsequent-line	0	no	no
8718	2017	46 - 50	Male	NSCLC	7.05	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.22	Dead	9.92	IV	Subsequent-line		no	no
8719	2017	51 - 55	Female	NSCLC	6.08	Stable	16.7	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	14.65	Alive	26.22	IV	Subsequent-line		no	no
8720	2016	66 - 70	Female	Colorectal	2	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.71	Alive	32.43	IV	Subsequent-line	1	no	no
8721	2016	71 - 75	Female	Sarcoma	6.08	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	1.54	IV	Subsequent-line	1	no	no
8723	2017	76 - 80	Male	Head & Neck	18.33		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.02	Dead	13.34	IV	Subsequent-line	2	no	no
8724	2017	56 - 60	Female	Sarcoma	5.65		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.13	Dead	1.68	IV	Subsequent-line	0	no	no
8725	2018	56 - 60	Female	Breast	1.25	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	7.75	IV	Subsequent-line	2	no	no
8726	2018	41 - 45	Male	Colorectal	7.45	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Alive	15.18	IV	First-line	0	no	no
8727	2017	41 - 45	Male	Gastric	2.38		17.6	IMPACT-468	Combo	PD	No	No	Yes	1.41	Dead	1.41	IV	Subsequent-line	1	no	no
8728	2016	61 - 65	Male	Bladder	14.29	Stable	47.2	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.91	Dead	10.71	IV	Subsequent-line	1	no	no
8729	2015	26 - 30	Female	Melanoma	4.64	Indeterminate	15.7	IMPACT-410	Combo	PD	No	No	Yes	0.2	Dead	1.02	IV	First-line	1	no	no
8732	2018	51 - 55	Female	Esophageal	3.44	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	3.91	IV	Subsequent-line	1	no	no
8733	2018	56 - 60	Male	Sarcoma	3.3	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	17.94	Alive	17.94	IV	Subsequent-line	0	no	no
8734	2016	56 - 60	Female	NSCLC	14	Stable	2	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	16.26	Dead	28.25	IV	Subsequent-line	1	no	no
8735	2016	81 - 85	Female	NSCLC	11.33	Stable	2	IMPACT-410	Combo	PR	Yes	Yes	Yes	7.95	Dead	7.95	IV	First-line	1	no	no
8736	2018	66 - 70	Female	Head & Neck	3.1	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Alive	14.95	IV	Subsequent-line	0	no	no
8737	2016	66 - 70	Male	SCLC	5.75	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	15.74	IV	Subsequent-line	1	no	no
8738	2016	76 - 80	Male	Bladder	12.33	Stable	12.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	0.79	IV	Subsequent-line	1	no	yes
8739	2016	51 - 55	Female	NSCLC	3.81		5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9	Dead	9	IV	Subsequent-line	1	no	no
8740	2016	61 - 65	Female	Bladder	6.27	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.18	Alive	34.27	IV	Subsequent-line	1	no	yes
8741	2016	81 - 85	Female	Colorectal	2.22	Unstable	43.3	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	31.05	Alive	31.05	IV	Subsequent-line	1	other-MMRd	yes
8742	2016	71 - 75	Male	Renal	14		5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.31	Dead	1.31	IV	Subsequent-line	1	no	no
8743	2017	71 - 75	Male	Melanoma	9		8.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	8.08	Alive	29.6	IV	First-line	0	no	no
8744	2016	76 - 80	Female	NSCLC	11.17	Indeterminate	3.9	IMPACT-410	Combo	PD	No	No	Yes	0.99	Dead	6.6	IV	Subsequent-line	1	no	no
8745	2017	56 - 60	Male	Melanoma	5.11	Stable	64.1	IMPACT-468	Combo	PD	No	No	Yes	1.35	Alive	25.43	IV	First-line	1	no	yes
8747	2017	61 - 65	Female	NSCLC	2	Stable	10.8	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	31.77	Alive	31.77	IV	Subsequent-line	0	no	no
8748	2018	36 - 40	Female	Melanoma	4.73	Stable	0.9	IMPACT-468	Combo	SD	No	Yes	No	15.01	Alive	16.13	IV	First-line	0	no	no
8749	2017	66 - 70	Female	Colorectal	2.86	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2	Dead	6.77	IV	Subsequent-line	1	no	no
8750	2016	46 - 50	Female	NSCLC	3.4	Stable	2	IMPACT-410	Combo	PD	No	No	Yes	1.54	Dead	3.88	IV	Subsequent-line	0	no	no
8751	2016	26 - 30	Female	Melanoma	1.35		0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Dead	20.93	III	First-line	0	no	no
8752	2016	81 - 85	Female	NSCLC	5	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	8.94	IV	Subsequent-line	1	no	no
8753	2016	56 - 60	Female	NSCLC	4.64	Stable	17.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.85	Dead	36.86	IV	Subsequent-line	1	no	no
8755	2016	66 - 70	Male	SCLC	4.7	Stable	8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	10.38	IV	First-line	1	no	no
8756	2017	71 - 75	Male	Head & Neck	8	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	23.59	IV	Subsequent-line	1	no	no
8758	2016	56 - 60	Male	Melanoma	1.06	Stable	25.6	IMPACT-410	Combo	CR	Yes	Yes	Yes	27.37	Alive	38.41	IV	First-line	0	no	no
8759	2016	81 - 85	Male	Melanoma	2.18		1.8	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	22.01	Alive	25.33	III	First-line	1	no	no
8761	2016	61 - 65	Female	NSCLC	5.75	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	0.99	IV	Subsequent-line	2	no	no
8762	2016	46 - 50	Female	Renal	6.14	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.63	Dead	5.39	IV	Subsequent-line	1	no	no
8763	2016	76 - 80	Male	NSCLC	2.23	Stable	17.7	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	27.66	Alive	32.26	IV	Subsequent-line	2	no	no
8764	2016	61 - 65	Male	Melanoma	1.93		14.9	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	30.59	Alive	30.59	IV	First-line	0	no	no
8765	2016	76 - 80	Male	Hepatobiliary	3.75	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	5.32	III	First-line	1	no	yes
8767	2017	51 - 55	Male	Renal	2.14		0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	5.52	Alive	23.62	IV	Subsequent-line	0	no	no
8768	2017	71 - 75	Female	SCLC	7.6	Stable	20.7	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.04	Dead	13.93	IV	Subsequent-line	0	no	no
8769	2017	61 - 65	Female	SCLC	7	Indeterminate	2	IMPACT-410	Combo	PD	No	No	Yes	2.37	Dead	23.26	IV	Subsequent-line	1	no	no
8770	2016	66 - 70	Male	NSCLC	2.69	Stable	8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.22	Dead	27.79	IV	First-line	1	no	yes
8772	2018	71 - 75	Female	Sarcoma	9.13		0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	2.86	IV	Subsequent-line	0	no	no
8773	2016	71 - 75	Male	Gastric	4.09	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	0.95	IV	Subsequent-line	1	no	no
8774	2016	46 - 50	Female	NSCLC	6.22	Stable	22.6	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	34.5	Alive	34.96	IV	Subsequent-line	1	no	no
8775	2016	66 - 70	Female	Hepatobiliary	12.5	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	2.04	IV	Subsequent-line	2	no	no
8776	2016	66 - 70	Male	NSCLC	7.4	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	12.32	IV	Subsequent-line	1	no	no
8777	2018	61 - 65	Female	Melanoma	2.33	Stable	3.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	7.2	Alive	18.4		First-line	0	no	no
8778	2017	51 - 55	Male	Bladder	1.31		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2	Dead	21.26	IV	Subsequent-line	1	no	no
8779	2016	66 - 70	Female	Bladder	4.31		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.53	Dead	1.61	IV	Subsequent-line	0	no	no
8780	2016	81 - 85	Female	NSCLC	23	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	3.55	IV	Subsequent-line	1	no	no
8781	2016	56 - 60	Male	Esophageal	12.13	Indeterminate	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	1.41	IV	Subsequent-line	1	no	no
8782	2017	66 - 70	Male	SCLC	3.13	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.63	Dead	8.41	IV	First-line		no	no
8783	2018	66 - 70	Male	NSCLC	4.76	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.07	Dead	12.85	IV	Subsequent-line	0	no	yes
8784	2018	51 - 55	Male	Melanoma	1.53	Stable	28.1	IMPACT-468	Combo	CR	Yes	Yes	No	10.38	Alive	11.07	IV	First-line	0	no	no
8785	2016	36 - 40	Male	NSCLC	4.21	Stable	2	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	9.2	Alive	14.03	IV	Subsequent-line	1	no	no
8786	2017	46 - 50	Male	Colorectal	25.63	Unstable	93	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	0.76	IV	Subsequent-line	2	mut-MMRd	yes
8787	2017	56 - 60	Female	NSCLC	2.08	Stable	16.7	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	13.37	Dead	21.19	IV	Subsequent-line	1	no	yes
8788	2018	61 - 65	Female	NSCLC	3.18	Stable	11.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.63	Dead	6.18	IV	Subsequent-line	1	no	no
8789	2016	66 - 70	Female	NSCLC	16.5	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	0.92	IV	Subsequent-line	1	no	no
8790	2016	76 - 80	Male	Bladder	7.4	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	3.32	IV	Subsequent-line	1	no	no
8791	2016	46 - 50	Male	Renal	2.81	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	8.25	Dead	28.52	IV	First-line	1	no	no
8793	2017	71 - 75	Male	Bladder	6.12	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.88	Dead	10.38	IV	Subsequent-line	2	no	no
8794	2017	16 - 20	Female	Sarcoma	1.17	Stable	2	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	8.74	Dead	20.4	IV	Subsequent-line	1	no	no
8795	2016	46 - 50	Male	Hepatobiliary	10.22		1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.83	Dead	10.68	IV	Subsequent-line	2	no	no
8797	2016	31 - 35	Male	Head & Neck	12.5		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Alive	6.21	IV	Subsequent-line	1	no	yes
8798	2017	46 - 50	Male	Head & Neck	7.57	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	9.23	IV	Subsequent-line	0	no	no
8799	2017	71 - 75	Male	NSCLC	2.47	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.63	Dead	19.38	IV	Subsequent-line	0	no	no
8800	2016	56 - 60	Male	Melanoma	5.56	Stable	69.8	IMPACT-410	Combo	CR	Yes	Yes	No	37.78	Alive	41.95	IV	First-line	2	no	no
8801	2016	71 - 75	Male	NSCLC	6.67	Stable	7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	16.07	IV	Subsequent-line	0	no	no
8802	2017	36 - 40	Male	Hepatobiliary	1	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	3.25	IV	Subsequent-line	0	no	yes
8803	2018	41 - 45	Female	Sarcoma	2.2		0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	3.55	IV	Subsequent-line	1	no	no
8804	2016	66 - 70	Male	NSCLC	5.9	Stable	3	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	5.78	Dead	12.85	IV	Subsequent-line	0	no	no
8805	2017	61 - 65	Male	NSCLC	5.42	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.1	Dead	12.91	IV	Subsequent-line	0	no	no
8806	2017	31 - 35	Female	Ovarian	18.33		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.59	Dead	0.59	IV	Subsequent-line	3	no	no
8807	2017	51 - 55	Male	Head & Neck	5.13		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	1.77	IV	Subsequent-line	1	no	no
8808	2016	66 - 70	Male	NSCLC	3	Stable	5.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	5.68	Dead	16.49	IV	Subsequent-line	1	no	no
8809	2017	71 - 75	Male	NSCLC	4.5		0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	21.16	Alive	29.67	III	Subsequent-line	1	no	no
8811	2018	71 - 75	Male	Pancreatic	14.75	Indeterminate	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.69	Alive	13.4	IV	Subsequent-line	1	no	no
8812	2017	26 - 30	Male	Pancreatic	1.99	Stable	12.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	1.54	IV	Subsequent-line	1	no	no
8813	2016	76 - 80	Female	NSCLC	18	Stable	3.9	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	9.2	Dead	31.47	IV	Subsequent-line	1	no	no
8815	2016	51 - 55	Female	NSCLC	4.33	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.39	Dead	0.39	IV	Subsequent-line	1	no	no
8816	2016	61 - 65	Male	Melanoma	2.62		10.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	29.63	Alive	29.63	IV	First-line	0	no	no
8817	2016	56 - 60	Female	NSCLC	5.59	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	1.84	Dead	1.84	IV	First-line	1	no	no
8818	2016	66 - 70	Male	NSCLC	3.71	Stable	5.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	1.91	Dead	1.91	IV	Subsequent-line	0	no	no
8819	2016	61 - 65	Female	Renal	2.12		1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.07	Alive	29.67	IV	Subsequent-line	0	no	no
8820	2018	56 - 60	Male	Head & Neck	1.88	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	9.69	Alive	9.69	IV	Subsequent-line	0	no	no
8821	2016	56 - 60	Female	NSCLC	3.67	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.2	Dead	2.66	IV	Subsequent-line	1	no	no
8822	2016	51 - 55	Male	Melanoma	2.95	Stable	1	IMPACT-410	Combo	CR	Yes	Yes	No	40.71	Alive	41.1	IV	First-line	1	no	no
8823	2016	56 - 60	Female	Colorectal	9.57		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.14	Dead	9.59	IV	Subsequent-line	1	no	no
8824	2016	61 - 65	Male	NSCLC	6.17		20.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.66	Dead	6.44	IV	Subsequent-line		no	yes
8825	2016	76 - 80	Male	NSCLC	7	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.9	Dead	12.81	IV	Subsequent-line	1	no	no
8826	2016	66 - 70	Male	Renal	2.69	Indeterminate	5.3	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	32.2	Alive	32.53	IV	First-line	0	no	no
8827	2017	66 - 70	Male	Melanoma	2.31	Stable	5.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	18.79	Alive	18.79	IV	First-line	0	no	yes
8829	2016	71 - 75	Male	Melanoma	2.14	Stable	11.8	IMPACT-410	Combo	PD	No	No	Yes	0.89	Alive	31.24	IV	Subsequent-line	1	no	no
8830	2016	71 - 75	Female	Bladder	10.7		14	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	6.67	Dead	14.32	IV	Subsequent-line	1	no	no
8831	2017	26 - 30	Female	Ovarian	1.43	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	4.44	Alive	18.17	IV	Subsequent-line	1	no	no
8832	2016	71 - 75	Male	NSCLC	1.8	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2	Dead	17.68	IV	Subsequent-line	0	no	no
8833	2017	56 - 60	Male	Sarcoma	24.57	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	0.89	IV	Subsequent-line	2	no	no
8835	2016	61 - 65	Male	Renal	2.5	Stable	5.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.94	Dead	26.61	IV	Subsequent-line		no	no
8836	2018	81 - 85	Female	NSCLC	1.69	Stable	2	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	7.2	Alive	20.01	IV	Subsequent-line		no	no
8837	2018	66 - 70	Male	Melanoma	3.78	Stable	93.5	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	15.01	Alive	15.18	IV	First-line	0	no	no
8838	2017	56 - 60	Female	NSCLC	1.3	Stable	2	IMPACT-410	Combo	SD	No	No	Yes	2.83	Dead	23.95	IV	Subsequent-line	1	no	no
8839	2016	56 - 60	Male	Melanoma	4.77	Stable	19.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.6	Alive	41.13	IV	First-line	0	no	no
8840	2016	66 - 70	Male	Bladder	6.91		15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	13.5	IV	Subsequent-line	1	no	no
8841	2016	76 - 80	Female	Melanoma	5.2	Stable	0	IMPACT-410	Combo	PD	No	No	Yes	0.72	Dead	2.3	IV	First-line	0	no	no
8842	2017	71 - 75	Male	Melanoma	4.43		88.6	IMPACT-468	Combo	CR	Yes	Yes	No	19.45	Alive	19.45	IV	First-line	0	no	no
8843	2016	51 - 55	Male	Melanoma	19.18	Stable	53.1	IMPACT-410	Combo	CR	Yes	Yes	No	39.33	Alive	41.17	IV	First-line	1	no	no
8846	2017	66 - 70	Male	Head & Neck	9.44	Stable	6.1	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	11.04	Alive	24.34	IV	First-line	0	no	no
8847	2018	71 - 75	Male	Bladder	6.89	Stable	6.1	IMPACT-468	Combo	SD	No	No	No	13.37	Alive	13.8	IV	Subsequent-line	0	no	no
8848	2016	66 - 70	Male	NSCLC	2.11	Indeterminate	50.2	IMPACT-410	Combo	PR	Yes	Yes	No	33.58	Alive	34	IV	Subsequent-line	1	no	no
8849	2018	66 - 70	Female	NSCLC	2.23	Stable	21.6	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	11.2	Alive	18.4	IV	Subsequent-line	1	no	no
8850	2016	71 - 75	Male	NSCLC	15.25	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.04	Dead	2.92	IV	Subsequent-line	1	no	no
8851	2017	61 - 65	Male	Renal	5.11	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	12.06	Alive	23.43	IV	Subsequent-line	1	no	no
8852	2016	71 - 75	Female	NSCLC	8.89	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.32	Dead	8.15	IV	Subsequent-line	1	no	no
8853	2017	66 - 70	Male	NSCLC	2	Stable	49.2	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.08	Dead	14.75	IV	Subsequent-line	0	no	yes
8854	2016	51 - 55	Female	NSCLC	8.22	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	2.33	IV	Subsequent-line	1	no	no
8855	2016	81 - 85	Male	NSCLC	3.15	Stable	3.9	IMPACT-410	Combo	SD	No	Yes	Yes	13.57	Dead	33.02	IV	First-line	1	no	yes
8856	2017	71 - 75	Female	NSCLC	4	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.69	Dead	7.16	IV	Subsequent-line		no	no
8857	2016	26 - 30	Male	Sarcoma	1.92	Stable	0	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.4	Dead	11.2	IV	First-line	0	no	no
8858	2016	31 - 35	Male	Melanoma	2.47		30.7	IMPACT-468	Combo	PD	No	No	Yes	0.46	Dead	17.81	III	First-line	0	no	no
8859	2016	41 - 45	Male	NSCLC	2.17	Stable	19.7	IMPACT-410	Combo	PD	No	No	Yes	1.35	Dead	12.52	IV	First-line	1	no	yes
8860	2018	56 - 60	Male	Renal	2.7	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.56	Alive	16.56	IV	Subsequent-line	0	no	no
8861	2017	56 - 60	Female	Bladder	4.5		0	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.24	Dead	22.28	IV	Subsequent-line		no	no
8862	2016	86 - 90	Male	NSCLC	6.56	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.36	Dead	0.36	IV	First-line	2	no	no
8863	2017	61 - 65	Female	NSCLC	8.92	Stable	15.7	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	8.02	Alive	25.13	IV	Subsequent-line		no	no
8864	2017	41 - 45	Female	Sarcoma	13.5		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	1.28	IV	Subsequent-line	0	no	no
8865	2017	36 - 40	Female	Renal	9.5	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.23	Dead	0.79	IV	Subsequent-line	1	no	no
8867	2018	71 - 75	Female	NSCLC	7.38	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	12.19	IV	Subsequent-line		no	no
8868	2017	66 - 70	Female	Renal	4.27	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	25.3	Alive	25.3	IV	Subsequent-line	0	no	no
8869	2017	61 - 65	Female	SCLC	4	Stable	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	4.17	IV	Subsequent-line	2	no	no
8870	2018	56 - 60	Male	NSCLC	2.36	Stable	3	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.32	Alive	19.06	IV	Subsequent-line		no	no
8871	2016	61 - 65	Male	NSCLC	10.33	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	0.89	IV	Subsequent-line	1	no	no
8872	2016	66 - 70	Male	NSCLC	5.64	Stable	1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	0.62	IV	First-line	1	no	no
8873	2016	41 - 45	Female	Renal	1.83	Stable	3	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	38.05	Alive	38.37	IV	Subsequent-line	0	no	no
8874	2017	31 - 35	Female	Colorectal	2.4	Unstable	61.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.49	Alive	18.76	IV	Subsequent-line	0	mut-MMRd	no
8875	2017	76 - 80	Male	Melanoma	3	Stable	3.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	26.09	Alive	26.09	III	First-line	2	no	no
8876	2017	71 - 75	Male	NSCLC	9.21	Stable	41.3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	5.06	IV	Subsequent-line		no	no
8877	2017	56 - 60	Male	Pancreatic	5.78	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	5.95	IV	Subsequent-line	1	no	no
8879	2017	66 - 70	Male	Pancreatic	4.17	Stable	3.9	IMPACT-410	Combo	SD	No	No	Yes	4.3	Dead	11.04	IV	Subsequent-line	1	no	no
8881	2016	56 - 60	Male	Renal	1.71		2.6	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	Yes	15.34	Dead	20.3	IV	First-line	0	no	yes
8882	2016	61 - 65	Female	NSCLC	2.33	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	11.4	IV	Subsequent-line	2	no	no
8883	2017	46 - 50	Male	Sarcoma	9.75		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.2	Alive	0.66	IV	Subsequent-line	1	no	no
8884	2017	56 - 60	Female	NSCLC	3.6	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.39	Dead	0.39	IV	Subsequent-line		no	no
8885	2018	56 - 60	Male	Esophageal	1.31		4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.6	Alive	16.33	IV	Subsequent-line	0	no	no
8886	2018	56 - 60	Male	Melanoma	1.57	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.86	Alive	9.66	IV	First-line	0	no	no
8887	2017	71 - 75	Female	NSCLC	11.08	Stable	4.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	28.29	Dead	28.78	IV	Subsequent-line		no	no
8888	2016	76 - 80	Male	SCLC	6	Stable	9.8	IMPACT-410	Combo	PR	Yes	Yes	Yes	9.79	Dead	19.09	IV	Subsequent-line	1	no	no
8889	2016	41 - 45	Female	NSCLC	6.57	Stable	1	IMPACT-410	Combo	PD	No	No	Yes	0.46	Dead	2.23	IV	Subsequent-line	0	no	no
8890	2017	61 - 65	Male	SCLC	3	Stable	5.9	IMPACT-410	Combo	PR	Yes	Yes	Yes	8.71	Dead	23.1	IV	Subsequent-line	0	no	no
8891	2016	61 - 65	Female	NSCLC	1.21	Indeterminate	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.81	Alive	3.22	IV	Subsequent-line	1	no	no
8892	2018	76 - 80	Female	NSCLC	15	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.56	Dead	2.56	IV	Subsequent-line	1	no	no
8893	2017	51 - 55	Male	NSCLC	20.25	Stable	2.6	IMPACT-468	Combo	SD	No	No	Yes	3.55	Dead	3.55	IV	Subsequent-line	0	no	no
8894	2017	61 - 65	Female	NSCLC	3	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.17	Dead	8.25	IV	Subsequent-line		no	yes
8895	2016	51 - 55	Male	NSCLC	5.57	Stable	11.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	4.21	IV	Subsequent-line	1	no	no
8896	2017	51 - 55	Female	Melanoma	2.89	Stable	17.7	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.29	Dead	6.87	IV	Subsequent-line	1	no	no
8897	2016	66 - 70	Female	NSCLC	6.5	Stable	7.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.65	Dead	6.44	IV	Subsequent-line	0	no	no
8898	2016	66 - 70	Female	NSCLC	8.17	Stable	0	IMPACT-410	Combo	PR	Yes	Yes	Yes	5.29	Dead	27.3	IV	First-line	0	no	no
8899	2017	56 - 60	Male	Head & Neck	3	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.05	Dead	12.71	IV	Subsequent-line	1	no	no
8900	2017	66 - 70	Male	NSCLC	6.5	Indeterminate	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.64	Alive	22.28	IV	Subsequent-line	0	no	no
8901	2016	71 - 75	Female	NSCLC	3.07	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	8.02	III	First-line	0	no	no
8902	2016	51 - 55	Male	NSCLC	3.67	Stable	11.4	IMPACT-468	Combo	SD	No	No	Yes	6.67	Dead	19.02	IV	Subsequent-line	1	no	no
8903	2017	61 - 65	Male	Bladder	3.13	Stable	14.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.81	Dead	27.53	IV	Subsequent-line	1	no	yes
8904	2016	71 - 75	Male	Renal	6		2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	28.98	Alive	29.57	IV	Subsequent-line	0	no	no
8905	2017	41 - 45	Female	Colorectal	5.6	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	4.83	IV	Subsequent-line	1	no	no
8906	2017	71 - 75	Male	Sarcoma	3		1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.36	Dead	19.91	IV	First-line	0	no	no
8907	2017	61 - 65	Male	NSCLC	5.75	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	3.61	IV	Subsequent-line	1	no	no
8908	2017	56 - 60	Female	NSCLC	4.6		7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.3	Dead	10.58	IV	Subsequent-line	1	no	no
8909	2016	81 - 85	Female	NSCLC	5.25	Stable	3.9	IMPACT-410	Combo	PR	Yes	Yes	No	1.38	Alive	1.84	IV	First-line	1	no	no
8910	2016	66 - 70	Male	NSCLC	25.8	Stable	8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	2.27	IV	Subsequent-line	2	no	no
8911	2016	51 - 55	Female	Melanoma	2.24	Stable	0	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	7.52	Dead	28.32	IV	First-line	0	no	no
8913	2016	61 - 65	Female	NSCLC	2.39		9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.76	Dead	7.52	IV	Subsequent-line	0	no	no
8914	2018	61 - 65	Female	Sarcoma	3	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	12.02	IV	First-line	0	no	no
8915	2016	76 - 80	Male	Melanoma	3.12	Stable	25.6	IMPACT-410	CTLA-4	PD	No	No	Yes	1.22	Dead	13.5	IV	First-line	1	no	no
8916	2016	56 - 60	Male	Melanoma	11.9	Stable	15.7	IMPACT-410	Combo	PR	Yes	Yes	No	37.62	Alive	37.62	IV	Subsequent-line	1	no	no
8917	2017	0 - 5	Male	Hepatobiliary	1.35	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	14.85	IV	Subsequent-line		no	no
8918	2017	76 - 80	Female	Sarcoma	3.45	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	1.87	Alive	5.52	IV	Subsequent-line	1	no	no
8919	2018	86 - 90	Female	Endometrial	3.75	Unstable	56.1	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	9.13	Alive	9.13	IV	Subsequent-line	1	mut-MMRd	yes
8920	2017	26 - 30	Male	Gastric	5.44		0	IMPACT-410	Combo	PD	No	No	Yes	0.26	Dead	2	IV	Subsequent-line	0	no	no
8921	2017	61 - 65	Female	Colorectal	3.82	Unstable	111.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	2.96	IV	Subsequent-line	2	mut-MMRd	yes
8922	2017	66 - 70	Female	Ovarian	2.67	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.17	Dead	4.37	IV	Subsequent-line	1	no	no
8923	2018	61 - 65	Female	Ovarian	9.75	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	1.97	IV	Subsequent-line	1	no	no
8924	2017	76 - 80	Male	Head & Neck	8.57	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	5.09	IV	Subsequent-line	1	no	no
8925	2016	76 - 80	Female	NSCLC	1.27		19.3	IMPACT-468	Combo	SD	No	Yes	Yes	8.05	Dead	23.2	IV	First-line	0	no	yes
8926	2017	41 - 45	Female	Hepatobiliary	5.92	Stable	2	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	2.69	Dead	5.16	IV	Subsequent-line	1	no	no
8927	2016	56 - 60	Male	Renal	17.33	Stable	4.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	No	34.04	Alive	34.04	IV	Subsequent-line	1	no	no
8928	2016	46 - 50	Male	Colorectal	3.25	Unstable	53.1	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	17.71	Alive	35.42	IV	Subsequent-line	2	mut-MMRd	yes
8929	2016	56 - 60	Female	NSCLC	9.22		22.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.04	Dead	9.2	IV	Subsequent-line	1	no	no
8930	2016	51 - 55	Male	Bladder	2.56		5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	23.16	Alive	25.2	IV	Subsequent-line	1	no	no
8931	2016	61 - 65	Male	NSCLC	5	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	0.66	IV	Subsequent-line	1	no	no
8932	2017	51 - 55	Male	Esophageal	3.32	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	12.25	Alive	25.46	IV	First-line	0	no	no
8933	2016	61 - 65	Female	NSCLC	2.8	Stable	1	IMPACT-410	Combo	SD	No	No	Yes	2.6	Alive	39.26	IV	First-line	0	no	no
8935	2017	56 - 60	Male	Colorectal	13.13		2.6	IMPACT-468	Combo	PD	No	No	Yes	0.53	Dead	0.53	IV	Subsequent-line	2	no	no
8936	2017	66 - 70	Male	NSCLC	23.58	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.23	Dead	4.57	IV	Subsequent-line	1	no	no
8937	2016	41 - 45	Male	SCLC	6.44	Stable	4.9	IMPACT-410	Combo	PD	No	No	Yes	1.31	Dead	2.69	IV	Subsequent-line	1	no	no
8938	2017	21 - 25	Male	Gastric	6.85	Stable	3	IMPACT-410	Combo	PD	No	No	Yes	0.69	Dead	0.69	IV	Subsequent-line	1	no	no
8940	2016	71 - 75	Male	Melanoma	2.36	Stable	11.8	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	35.42	Alive	35.48	IV	First-line	0	no	no
8941	2016	66 - 70	Female	NSCLC	5.63		4.9	IMPACT-410	Combo	SD	No	No	Yes	2.53	Dead	19.81	IV	First-line	1	no	no
8942	2017	46 - 50	Male	Melanoma	1.48	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.09	Alive	28.62	IV	Subsequent-line	1	no	no
8943	2017	51 - 55	Male	Gastric	6.5	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	1.28	Alive	23.43	IV	Subsequent-line	0	no	no
8944	2018	66 - 70	Female	Endometrial	12.67	Stable	3	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	15.34	Alive	15.8	IV	Subsequent-line	1	no	no
8945	2017	61 - 65	Male	Melanoma	4.06	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	27.37	Alive	27.6	III	First-line	0	no	no
8946	2017	61 - 65	Male	Gastric	51.75	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	2.6	IV	Subsequent-line	2	no	no
8947	2017	71 - 75	Male	Sarcoma	7.57		1.8	IMPACT-468	Combo	PD	No	No	Yes	2.37	Dead	17.48	IV	Subsequent-line		no	no
8949	2016	46 - 50	Male	Renal	5.4	Stable	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	6.18	IV	Subsequent-line	1	no	no
8950	2017	56 - 60	Male	Melanoma	2.27	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.99	Dead	23.92	IV	First-line	0	no	no
8951	2017	26 - 30	Male	Head & Neck	8	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	9.89	IV	Subsequent-line	0	no	no
8952	2016	56 - 60	Female	NSCLC	2.29	Stable	16.7	IMPACT-410	Combo	PD	No	No	Yes	0.46	Dead	9.13	IV	Subsequent-line	0	no	no
8953	2017	61 - 65	Female	NSCLC	2.33	Stable	1	IMPACT-410	Combo	PD	No	No	Yes	1.31	Dead	13.83	IV	Subsequent-line	0	no	no
8954	2016	61 - 65	Female	Melanoma	3.1	Stable	13.8	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	Yes	8.51	Dead	28.12	IV	Subsequent-line	1	no	no
8955	2017	66 - 70	Female	Head & Neck	13.53	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.56	Dead	1.58	IV	Subsequent-line		no	no
8956	2017	41 - 45	Male	Esophageal	2.33	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.1	Dead	15.24	IV	Subsequent-line	0	no	no
8957	2017	76 - 80	Female	NSCLC	21.71	Stable	5.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.68	Dead	5.68	IV	Subsequent-line	2	no	no
8958	2017	56 - 60	Female	Sarcoma	3.63	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.69	Dead	16.72		Subsequent-line	0	no	no
8959	2016	66 - 70	Male	Head & Neck	2.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	13.6	Dead	24.18	IV	Subsequent-line	1	no	no
8960	2018	71 - 75	Male	NSCLC	4.5	Stable	3	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	4.5	IV	Subsequent-line	1	no	no
8961	2016	66 - 70	Male	NSCLC	1.26	Stable	6.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	4.21	Dead	9.2	IV	Subsequent-line		no	no
8962	2017	71 - 75	Male	NSCLC	3.44	Stable	7.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	12.62	Dead	27.17	IV	Subsequent-line	1	no	no
8964	2016	71 - 75	Female	NSCLC	12.25	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.79	Dead	2.79	IV	Subsequent-line	1	no	yes
8965	2017	66 - 70	Female	NSCLC	4.19	Stable	4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	3.58	Dead	16.16	IV	Subsequent-line		no	no
8967	2016	56 - 60	Female	Melanoma	2.89	Stable	7.9	IMPACT-468	Combo	PR	Yes	Yes	Yes	8.57	Alive	37.82	IV	First-line	0	no	no
8968	2016	51 - 55	Female	NSCLC	2.7	Stable	3.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.73	Dead	4.73	IV	Subsequent-line	0	no	no
8970	2017	61 - 65	Female	Ovarian	3.64	Stable	0	IMPACT-468	Combo	PD	No	No	Yes	2.63	Dead	2.63	IV	Subsequent-line	1	no	no
8971	2016	71 - 75	Male	NSCLC	5.75	Stable	5.9	IMPACT-410	Combo	PD	No	No	Yes	0.49	Dead	0.49	IV	First-line	1	no	no
8972	2017	61 - 65	Female	Colorectal	4.63	Indeterminate	9.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	6.97	IV	Subsequent-line		no	no
8973	2016	46 - 50	Male	Bladder	7.4	Stable	6.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	1.84	IV	Subsequent-line	1	no	no
8975	2016	46 - 50	Male	Melanoma	1.68	Stable	11.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	3.55	IV	Subsequent-line	0	no	no
8976	2017	31 - 35	Female	Melanoma	2.31		9.7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	30.72	Alive	31.47	IV	First-line	0	no	no
8977	2017	41 - 45	Female	NSCLC	20.6	Stable	2.6	IMPACT-468	Combo	SD	No	No	Yes	1.74	Dead	2.63	IV	Subsequent-line	1	no	no
8979	2018	71 - 75	Male	Sarcoma	7.83	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.36	Alive	12.02	IV	Subsequent-line	0	no	no
8980	2017	61 - 65	Male	Hepatobiliary	5.43	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	8.97	IV	Subsequent-line	1	no	no
8981	2017	46 - 50	Male	NSCLC	6.64		41.3	IMPACT-468	Combo	PR	Yes	Yes	No	28.71	Alive	30.62	IV	Subsequent-line	1	no	yes
8982	2018	66 - 70	Female	Melanoma	16	Stable	33.4	IMPACT-468	Combo	PD	No	No	Yes	3.09	Dead	5.13	IV	First-line	0	no	no
8983	2016	61 - 65	Female	NSCLC	4.1	Stable	5.9	IMPACT-410	Combo	PD	No	No	Yes	1.31	Alive	4.01	IV	First-line	1	no	no
8985	2016	36 - 40	Female	Breast	2.56		0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.66	Dead	17.08	IV	Subsequent-line	1	no	no
8986	2017	56 - 60	Male	Esophageal	5.52	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	4.37	IV	Subsequent-line	1	no	no
8987	2017	61 - 65	Male	SCLC	2.61		8.9	IMPACT-410	Combo	PR	Yes	Yes	Yes	5.03	Alive	30.65	IV	Subsequent-line	1	no	no
8988	2017	31 - 35	Female	Ovarian	3.29	Stable	9.8	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	3.75	Dead	3.81	IV	Subsequent-line	1	no	no
8989	2017	66 - 70	Male	Esophageal	2.8	Indeterminate	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.27	Dead	2.76	IV	Subsequent-line	0	no	no
8990	2016	71 - 75	Male	NSCLC	3.41	Stable	8.9	IMPACT-410	Combo	SD	No	No	Yes	2.6	Dead	7.82	IV	First-line	1	no	no
8991	2016	86 - 90	Male	NSCLC	2.82	Stable	4.9	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.49	Dead	8.51	IV	Subsequent-line		no	no
8992	2018	11 - 15	Female	Sarcoma	1.75	Indeterminate	2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.61	Alive	13.11	IV	Subsequent-line	1	no	no
8993	2016	66 - 70	Male	NSCLC	5.36		2.6	IMPACT-468	Combo	SD	No	No	Yes	1.05	Dead	23.46	IV	First-line	1	no	no
8995	2016	16 - 20	Female	Hepatobiliary	2.07	Stable	0	IMPACT-410	PD-1/PD-L1	SD	No	Yes	Yes	22.31	Alive	31.21	IV	Subsequent-line	0	no	no
8996	2017	66 - 70	Female	NSCLC	6.88	Stable	0	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.4	Dead	2.4	IV	Subsequent-line		no	no
8997	2016	71 - 75	Male	NSCLC	2.88		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	5.95	IV	Subsequent-line	1	no	no
8999	2016	16 - 20	Male	NSCLC	6.25	Stable	2	IMPACT-410	Combo	PR	Yes	Yes	Yes	4.17	Alive	34.86	IV	Subsequent-line	0	no	no
9000	2018	61 - 65	Male	Sarcoma	3.13	Stable	0	IMPACT-410	PD-1/PD-L1	SD	No	No	Yes	5.09	Alive	8.48	IV	First-line	1	no	no
9004	2016	46 - 50	Female	NSCLC	4.89	Stable	9.8	IMPACT-410	Combo	PR	Yes	Yes	No	36.57	Alive	37.39	IV	First-line	1	no	no
9005	2016	61 - 65	Male	Head & Neck	7.75		0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	14.26	IV	Subsequent-line	0	no	no
9006	2017	71 - 75	Female	NSCLC	2.65	Stable	3.9	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	8.11	Alive	20.86	IV	Subsequent-line	0	no	no
9007	2017	56 - 60	Female	NSCLC	20.25		47.2	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	1.94	IV	Subsequent-line	1	no	no
9008	2016	56 - 60	Male	NSCLC	5.17	Stable	10.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	0.46	IV	Subsequent-line	1	no	no
9010	2016	76 - 80	Male	NSCLC	3.93		9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	4.3	III	Subsequent-line		no	no
9011	2016	81 - 85	Female	NSCLC	4.33		11.4	IMPACT-468	Combo	SD	No	No	Yes	4.14	Dead	4.14	IV	First-line	1	no	no
9013	2017	71 - 75	Male	Gastric	2	Stable	21.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.32	Dead	9.79	IV	Subsequent-line	1	no	no
9014	2017	66 - 70	Female	NSCLC	10.73		16.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	1.25	IV	Subsequent-line	2	no	yes
9015	2016	41 - 45	Female	Melanoma	1		3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.07	Alive	32.43	III	First-line	0	no	no
9016	2017	41 - 45	Female	Gastric	1.56	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	1.22	Dead	3.88	IV	Subsequent-line	2	no	no
9017	2016	81 - 85	Male	NSCLC	4.7		18.7	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	3.71	Dead	9.33	IV	First-line	2	no	no
9018	2016	61 - 65	Male	NSCLC	11.5		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.05	Dead	1.05	IV	Subsequent-line	1	no	no
9020	2017	61 - 65	Male	NSCLC	3.5	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.47	Alive	17.22	IV	Subsequent-line	1	no	no
9021	2017	36 - 40	Male	Sarcoma	1.89		0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	12.78	IV	Subsequent-line	1	no	no
9022	2017	61 - 65	Male	Renal	10.25	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.91	Dead	11.99	IV	Subsequent-line	1	no	no
9023	2016	31 - 35	Female	Melanoma	3.29	Stable	15.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.32	Alive	31.54	III	First-line	0	no	no
9026	2016	66 - 70	Male	Head & Neck	2.14		8.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	8.08	III	Subsequent-line	1	no	no
9027	2018	66 - 70	Male	NSCLC	8.14	Stable	16.7	IMPACT-410	PD-1/PD-L1	SD	No	Yes	No	13.57	Alive	13.77	IV	Subsequent-line	1	no	no
9028	2018	71 - 75	Female	Endometrial	4.71	Unstable	32.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.97	Dead	11.6	IV	Subsequent-line	1	other-MMRd	yes
9031	2016	66 - 70	Female	SCLC	3.58		10.5	IMPACT-468	Combo	PD	No	No	Yes	2.92	Dead	3.65	IV	Subsequent-line	0	no	no
9032	2016	76 - 80	Female	NSCLC	16.22		14	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	22.05	Dead	22.05	IV	Subsequent-line	1	no	no
9033	2018	56 - 60	Male	Bladder	3.67	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	2.5	IV	Subsequent-line	1	no	no
9034	2017	66 - 70	Male	Bladder	3.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Alive	20.37	IV	Subsequent-line	1	no	no
9035	2017	21 - 25	Female	Sarcoma	11.58	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.2	Dead	3.48	IV	Subsequent-line	2	no	no
9036	2018	66 - 70	Female	NSCLC	2.22	Stable	5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.17	Dead	17.87	IV	Subsequent-line	1	no	no
9037	2017	61 - 65	Male	Bladder	4.41		4.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	2.56	Dead	7.36	IV	Subsequent-line	0	no	no
9038	2017	66 - 70	Male	Renal	7.13	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.81	Dead	13.77	IV	Subsequent-line	1	no	no
9039	2016	46 - 50	Male	Melanoma	2.28		1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.42	Alive	30.95	IV	First-line	0	no	no
9040	2017	61 - 65	Female	Ovarian	2.44	Indeterminate	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.99	Dead	17.38	IV	Subsequent-line	0	no	no
9041	2016	61 - 65	Male	NSCLC	4.38	Stable	7	IMPACT-468	Combo	PD	No	No	Yes	1.15	Dead	10.09	IV	First-line	1	no	no
9042	2017	76 - 80	Female	Bladder	3.71	Stable	14	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	12.09	Alive	22.28	IV	First-line	3	no	no
9044	2018	61 - 65	Male	Bladder	5.18	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	3.81	IV	Subsequent-line	1	no	no
9045	2018	71 - 75	Female	Gastric	12.63	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.23	Dead	1.05	IV	Subsequent-line	1	no	no
9046	2017	81 - 85	Male	Esophageal	6		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.76	Dead	2.76	IV	Subsequent-line	2	no	no
9047	2017	61 - 65	Female	Melanoma	2.03		2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.17	Dead	7.62	IV	First-line	1	no	no
9049	2017	61 - 65	Female	NSCLC	4.77		15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.69	Dead	5.98	IV	Subsequent-line	0	no	no
9050	2016	56 - 60	Male	Bladder	2.22	Unstable	57.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	7.52	IV	Subsequent-line	1	mut-MMRd	yes
9051	2016	61 - 65	Male	Melanoma	4.63	Stable	7.9	IMPACT-410	Combo	CR	Yes	Yes	No	33.28	Alive	33.28	IV	First-line	0	no	no
9052	2018	66 - 70	Female	Renal	4.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	19.29	Alive	19.42	IV	Subsequent-line	0	no	no
9053	2017	56 - 60	Female	NSCLC	10	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	3.91	IV	Subsequent-line	1	no	no
9055	2018	51 - 55	Female	Ovarian	6.11	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.22	Dead	5.52	IV	Subsequent-line	1	no	no
9056	2016	56 - 60	Male	Melanoma	7.64	Stable	11.8	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.39	Dead	8.34	IV	First-line	2	no	no
9057	2018	46 - 50	Female	Colorectal	2.92	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	2.56	Alive	14.95	IV	Subsequent-line	0	no	no
9058	2017	76 - 80	Male	NSCLC	5.36		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	3.98	IV	Subsequent-line	1	no	no
9060	2018	86 - 90	Male	NSCLC	4.46		12.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	10.58	Alive	11.96	IV	Subsequent-line	1	no	no
9061	2018	71 - 75	Male	NSCLC	9.5	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Dead	17.45	III	Subsequent-line	0	no	yes
9062	2017	26 - 30	Female	Sarcoma	6.14		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2	Dead	4.01	IV	Subsequent-line	1	no	no
9064	2017	76 - 80	Male	Melanoma	4.07	Stable	32.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.66	Alive	29.86	III	First-line	0	no	yes
9065	2017	56 - 60	Female	Renal	2.07		2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.61	Alive	17.91	IV	Subsequent-line	0	no	no
9066	2017	71 - 75	Female	Melanoma	4.23		0.9	IMPACT-468	Combo	PR	Yes	Yes	Yes	10.87	Alive	28.25	IV	First-line	2	no	no
9067	2017	66 - 70	Male	NSCLC	8	Indeterminate	24.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.21	Dead	21.36	IV	Subsequent-line		no	no
9068	2017	56 - 60	Male	NSCLC	4.02		5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	27.14	Alive	27.14	IV	First-line	1	no	no
9069	2016	61 - 65	Male	NSCLC	10.33		10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	17.18	IV	Subsequent-line	1	no	no
9070	2018	66 - 70	Male	Melanoma	3	Stable	41.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	9.76	Alive	10.68	III	Subsequent-line	0	no	yes
9072	2017	46 - 50	Male	Head & Neck	13.75	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.22	Dead	1.51	IV	Subsequent-line	2	no	no
9073	2017	36 - 40	Male	Head & Neck	30.5		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	9.46	IV	Subsequent-line	2	no	no
9074	2016	61 - 65	Female	SCLC	2.2		11.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	5.85	IV	Subsequent-line	1	no	yes
9075	2017	51 - 55	Female	Melanoma	2.19		0	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	20.24	Alive	20.27	III	First-line	0	no	no
9076	2017	56 - 60	Male	NSCLC	10.89		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	2.14	IV	Subsequent-line	0	no	no
9077	2016	81 - 85	Female	NSCLC	7.69		7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.97	Dead	1.97	IV	Subsequent-line	1	no	no
9078	2018	31 - 35	Male	Colorectal	4	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.02	Dead	6.6	IV	Subsequent-line	1	no	no
9079	2017	61 - 65	Female	NSCLC	2.36	Stable	14	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.56	Alive	23.95	IV	Subsequent-line	0	no	no
9081	2017	56 - 60	Female	Colorectal	6.14	Unstable	91.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	7.75	Dead	7.75	IV	Subsequent-line	1	mut-MMRd	yes
9084	2017	56 - 60	Male	Bladder	4.23	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	14.26	IV	Subsequent-line	0	no	no
9085	2018	51 - 55	Male	Esophageal	1.89	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	9.69	Alive	10.09	III	First-line	0	no	no
9086	2017	36 - 40	Male	Renal	3.18		1.8	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	29.44	Alive	29.44	IV	Subsequent-line	0	no	no
9087	2018	76 - 80	Female	Endometrial	10.75	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.29	Alive	12.42	IV	First-line	0	no	yes
9088	2018	66 - 70	Female	Ovarian	7.75	Stable	5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.34	Dead	7.72	IV	Subsequent-line	0	no	no
9090	2016	51 - 55	Male	Melanoma	4.73		11.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	0.79	Alive	34.73	III	First-line	1	no	no
9091	2017	71 - 75	Male	Sarcoma	4.18		11.4	IMPACT-468	Combo	PR	Yes	Yes	Yes	4.11	Alive	7.29		Subsequent-line	1	no	no
9092	2016	76 - 80	Female	NSCLC	2.75	Stable	11.4	IMPACT-468	Combo	PR	Yes	Yes	Yes	16.76	Dead	26.32	IV	First-line	1	no	no
9093	2017	41 - 45	Female	Colorectal	5.58	Unstable	14	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.11	Dead	7.79	IV	Subsequent-line	1	other-MMRd	no
9094	2018	26 - 30	Male	Sarcoma	7.14		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Alive	2.76	IV	Subsequent-line	0	no	no
9095	2017	56 - 60	Male	Bladder	4.78	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.53	Dead	6.9	IV	Subsequent-line	1	no	no
9097	2016	66 - 70	Male	Melanoma	3.93		1.8	IMPACT-468	Combo	PD	No	No	Yes	1.28	Dead	10.97	IV	First-line	0	no	no
9098	2017	66 - 70	Female	NSCLC	52.5		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	1.48	IV	Subsequent-line	0	no	no
9099	2016	41 - 45	Female	NSCLC	3.08		6.1	IMPACT-468	Combo	PR	Yes	Yes	Yes	2.53	Dead	31.74	IV	First-line	0	no	no
9100	2017	51 - 55	Female	NSCLC	2.69		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.33	Dead	12.35	IV	Subsequent-line	1	no	no
9101	2016	66 - 70	Female	NSCLC	11.89		15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	14.13	IV	Subsequent-line	1	no	no
9102	2016	71 - 75	Male	Renal	4.23	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.34	Dead	32.92	IV	First-line	0	no	no
9103	2016	71 - 75	Male	NSCLC	4.25		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	9.1	IV	Subsequent-line	2	no	no
9106	2017	56 - 60	Female	Bladder	1.28		7.9	IMPACT-468	Combo	PR	Yes	Yes	No	20.6	Alive	20.73	IV	Subsequent-line	0	no	yes
9107	2016	76 - 80	Male	NSCLC	2.05		7	IMPACT-468	Combo	PR	Yes	Yes	Yes	12.71	Alive	33.81	IV	First-line	1	no	no
9108	2017	31 - 35	Female	Breast	6.88		1.8	IMPACT-468	Combo	PD	No	No	Yes	0.56	Dead	0.82	IV	Subsequent-line	4	no	no
9109	2016	56 - 60	Male	Melanoma	3.36		19.7	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	1.58	IV	Subsequent-line	1	no	no
9110	2017	56 - 60	Male	Colorectal	2.91	Unstable	30.7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	24.54	Alive	24.57	III	First-line	0	mut-MMRd	no
9111	2017	81 - 85	Male	SCLC	15		5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.49	Dead	1.28	IV	Subsequent-line	1	no	yes
9112	2017	71 - 75	Female	NSCLC	12.67		2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	4.34	IV	Subsequent-line	1	no	no
9113	2018	61 - 65	Male	Gastric	3.27	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	11.79	IV	Subsequent-line	1	no	no
9114	2017	31 - 35	Male	Melanoma	1.9		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	18.69		First-line	0	no	no
9115	2017	31 - 35	Female	Breast	0.3	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.97	Dead	3.35	IV	Subsequent-line	0	no	no
9116	2017	71 - 75	Male	NSCLC	2.38		7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.65	Alive	20.7	IV	Subsequent-line	1	no	no
9117	2017	61 - 65	Male	Hepatobiliary	5.67		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	1.84	IV	Subsequent-line	2	no	no
9118	2017	61 - 65	Female	Renal	2.95		0.9	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	22.57	Alive	23.03	IV	Subsequent-line		no	no
9119	2018	56 - 60	Female	Endometrial	3.55	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.84	Dead	7.49	IV	Subsequent-line	0	no	yes
9120	2016	61 - 65	Female	NSCLC	3.22		5.3	IMPACT-468	Combo	PD	No	No	Yes	0.49	Dead	0.79	IV	Subsequent-line	1	no	no
9122	2018	46 - 50	Male	Head & Neck	2.67	Stable	6.1	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	19.32	Alive	19.71	IV	Subsequent-line	0	no	no
9123	2017	26 - 30	Male	Melanoma	7.2		16.7	IMPACT-468	Combo	SD	No	No	Yes	2.04	Alive	30.65	IV	First-line	1	no	yes
9124	2017	46 - 50	Male	Gastric	14.67	Stable	8.8	IMPACT-468	Combo	PR	Yes	Yes	Yes	9.1	Dead	14.52	IV	Subsequent-line	1	no	no
9125	2017	66 - 70	Female	Hepatobiliary	1.52	Unstable	50.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	20.63	Alive	21.88	IV	Subsequent-line	0	mut-MMRd	yes
9126	2017	66 - 70	Female	Esophageal	2.71		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.33	Dead	0.33	IV	Subsequent-line	2	no	no
9127	2017	56 - 60	Male	Colorectal	7.38	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	6.67	IV	Subsequent-line	0	no	no
9128	2017	56 - 60	Male	Renal	3.9	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.35	Dead	1.35	IV	Subsequent-line	1	no	no
9129	2017	76 - 80	Female	Endometrial	6	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.46	Dead	18.07	IV	Subsequent-line	1	no	yes
9130	2016	66 - 70	Male	NSCLC	2.67		20.2	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	32.13	Alive	32.13	IV	First-line	1	no	no
9131	2018	71 - 75	Male	Esophageal	1.67	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	2.86	IV	Subsequent-line	1	no	yes
9132	2017	51 - 55	Male	Head & Neck	5.86		1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.55	Dead	9.89	IV	Subsequent-line	0	no	no
9133	2018	26 - 30	Female	Sarcoma	1.1	Stable	0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	12.62	Alive	14.26	IV	Subsequent-line	0	no	no
9134	2017	61 - 65	Female	NSCLC	6.41	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	18.46	IV	Subsequent-line	1	no	no
9135	2017	51 - 55	Female	NSCLC	3.4		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Alive	21.72	IV	Subsequent-line	1	no	no
9136	2017	16 - 20	Male	Melanoma	9	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.76	Alive	30.59	IV	First-line	0	no	no
9137	2017	66 - 70	Female	NSCLC	9.2	Stable	16.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.17	Dead	12.62	IV	Subsequent-line	1	no	no
9138	2018	46 - 50	Male	Colorectal	2.86	Stable	7.9	IMPACT-468	Combo	PD	No	No	Yes	4.8	Alive	9.59	IV	Subsequent-line	0	no	no
9139	2017	66 - 70	Male	Hepatobiliary	5.34	Stable	7.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.17	Dead	5.29	IV	Subsequent-line	2	no	no
9141	2016	66 - 70	Female	NSCLC	3.31		4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.56	Dead	26.05	IV	First-line	0	no	no
9142	2016	81 - 85	Male	Melanoma	5.2		100.1	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	31.05	Alive	31.8	IV	First-line	1	no	yes
9143	2016	61 - 65	Male	NSCLC	3.79		7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.33	Dead	0.33	IV	Subsequent-line	1	no	no
9144	2017	51 - 55	Female	NSCLC	3.41	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	3.94	IV	Subsequent-line	1	no	no
9145	2017	66 - 70	Female	Bladder	3.8	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	18.27	IV	Subsequent-line	0	no	no
9147	2018	66 - 70	Male	Melanoma	2.73	Stable	51.8	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	11.33	Alive	13.4	IV	First-line	0	no	yes
9149	2018	21 - 25	Female	Esophageal	1.64	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2	Alive	7.16	IV	Subsequent-line	1	no	no
9151	2018	76 - 80	Female	Endometrial	4.5	Stable	5.3	IMPACT-468	Combo	SD	No	No	Yes	3.71	Alive	13.37	IV	Subsequent-line	0	no	no
9152	2016	31 - 35	Female	Breast	2.29		0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Dead	9.95	IV	Subsequent-line	0	no	no
9153	2017	71 - 75	Male	NSCLC	4.75		13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	2.63	IV	Subsequent-line	1	no	no
9154	2018	61 - 65	Male	Hepatobiliary	3.38	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.17	Alive	14.32	IV	Subsequent-line	1	no	yes
9155	2017	46 - 50	Female	NSCLC	13.43		19.3	IMPACT-468	Combo	PD	No	No	Yes	0.95	Dead	5.88	IV	Subsequent-line	1	no	yes
9157	2016	71 - 75	Male	Melanoma	10.6		69.3	IMPACT-468	Combo	CR	Yes	Yes	No	34.6	Alive	34.73	IV	First-line	1	no	no
9158	2018	31 - 35	Female	Breast	2.67	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Alive	3.35	IV	Subsequent-line	0	no	no
9159	2017	71 - 75	Male	NSCLC	4		19.3	IMPACT-468	Combo	SD	No	Yes	Yes	9.89	Alive	21.62	IV	Subsequent-line	1	no	no
9161	2017	36 - 40	Female	Ovarian	1.86		1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	No	4.4	Alive	15.05	IV	Subsequent-line	1	no	no
9162	2016	56 - 60	Male	NSCLC	1.69		29.8	IMPACT-468	Combo	PR	Yes	Yes	No	34.04	Alive	34.04	IV	First-line	0	no	no
9163	2018	71 - 75	Female	NSCLC	2.29		10.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	14.92	Alive	19.65	IV	Subsequent-line	1	no	no
9166	2017	61 - 65	Male	NSCLC	3.22	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.51	Dead	8.54	IV	Subsequent-line	1	no	no
9167	2018	76 - 80	Male	Melanoma	18.33	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.49	Dead	0.49	IV	First-line	2	no	no
9168	2017	41 - 45	Female	Hepatobiliary	5.17	Stable	2.6	IMPACT-468	CTLA-4	SD	No	Yes	Yes	21.85	Alive	27.14	IV	First-line	0	no	no
9169	2017	76 - 80	Male	NSCLC	3.31	Stable	11.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.22	Dead	4.5	IV	Subsequent-line		no	no
9171	2017	46 - 50	Male	NSCLC	7.67		14.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.14	Dead	21.03	IV	Subsequent-line	0	no	yes
9173	2018	51 - 55	Male	Colorectal	1.9	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.18	Dead	10.05	IV	First-line	0	no	no
9174	2016	71 - 75	Female	Melanoma	2.29		10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	2.07	Alive	17.74	IV	First-line	2	no	no
9175	2017	61 - 65	Male	Bladder	3.92		16.7	IMPACT-468	Combo	PR	Yes	Yes	No	23	Alive	23.23	IV	Subsequent-line	0	no	no
9176	2018	41 - 45	Male	Gastric	10.75	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	2.2	IV	Subsequent-line	2	no	no
9177	2016	51 - 55	Female	NSCLC	3	Stable	0.9	IMPACT-468	Combo	SD	No	No	Yes	5.03	Alive	34.53	IV	First-line	0	no	no
9178	2016	71 - 75	Female	NSCLC	3.94		24.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.69	Dead	13.04	IV	Subsequent-line		no	no
9179	2016	61 - 65	Male	NSCLC	10.07		10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	31.9	Alive	33.38	IV	First-line	0	no	no
9180	2016	61 - 65	Male	Melanoma	9.25		79.9	IMPACT-468	Combo	SD	No	No	Yes	1.51	Dead	4.96	IV	First-line	3	no	no
9181	2017	36 - 40	Female	Ovarian	1.33	Unstable	33.4	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	21.91	Alive	21.91	IV	First-line	0	mut-MMRd	yes
9182	2018	31 - 35	Female	Breast	1.6	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Alive	9.86	IV	Subsequent-line	0	no	no
9183	2018	56 - 60	Female	NSCLC	1.1	Stable	10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	15.21	Alive	15.24	III	Subsequent-line	1	no	yes
9184	2017	66 - 70	Male	NSCLC	6.83		7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.3	Dead	2.3	IV	Subsequent-line	1	no	no
9185	2016	71 - 75	Female	NSCLC	4.07		7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.33	Dead	13.77	IV	First-line	2	no	no
9186	2016	71 - 75	Male	NSCLC	3.48		29.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	32.36	Alive	33.81	IV	First-line	1	no	no
9187	2016	56 - 60	Female	NSCLC	6.91		7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	4.17	IV	Subsequent-line	1	no	no
9188	2017	36 - 40	Male	Renal	2.91	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	24.61	IV	Subsequent-line	0	no	no
9189	2016	86 - 90	Female	NSCLC	7.17		5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	12.78	Alive	16.3	IV	First-line	1	no	no
9190	2017	66 - 70	Female	Bladder	6.67	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.23	Dead	3.71	IV	Subsequent-line	0	no	yes
9191	2017	61 - 65	Female	Melanoma	23.75		15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	7.43	III	First-line	1	no	no
9194	2016	81 - 85	Male	Melanoma	5.67		51.8	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	33.31	Alive	33.31	III	First-line	1	no	no
9195	2017	76 - 80	Male	Melanoma	7.13	Stable	131.7	IMPACT-468	Combo	PR	Yes	Yes	Yes	5.55	Alive	23.23	IV	First-line	1	no	yes
9196	2017	66 - 70	Male	Melanoma	5.05	Stable	36.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	27.89	Alive	27.89	IV	First-line	0	no	yes
9197	2018	66 - 70	Male	Hepatobiliary	2.8		4.4	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	10.25	Alive	18.43	IV	Subsequent-line	0	no	no
9198	2017	56 - 60	Female	Head & Neck	28		16.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.16	Dead	0.16	IV	Subsequent-line	3	no	no
9199	2017	71 - 75	Female	NSCLC	3.07		9.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	19.32	Alive	21.26	IV	Subsequent-line		no	no
9200	2017	71 - 75	Female	Melanoma	1.3		2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	4.86	IV	First-line	0	no	no
9201	2016	31 - 35	Male	Melanoma	4.6		13.2	IMPACT-468	Combo	PD	No	No	Yes	1.12	Alive	33.45	IV	First-line	1	no	no
9202	2017	41 - 45	Female	Pancreatic	63		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	3.38	IV	Subsequent-line	1	no	no
9203	2017	61 - 65	Male	Renal	13	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.2	Dead	4.53	IV	Subsequent-line	2	no	no
9205	2017	61 - 65	Female	Ovarian	14	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	0.72	IV	Subsequent-line	2	no	no
9206	2017	16 - 20	Female	Head & Neck	17.33		0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	8.97	IV	Subsequent-line	1	no	no
9207	2016	56 - 60	Male	NSCLC	2.58		4.4	IMPACT-468	Combo	PD	No	No	Yes	1.18	Alive	34.14	IV	First-line	1	no	no
9208	2017	61 - 65	Female	Melanoma	4.32	Stable	12.3	IMPACT-468	Combo	PR	Yes	Yes	No	20.93	Alive	26.91	IV	First-line	1	no	no
9209	2018	41 - 45	Male	Renal	3.56	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.55	Alive	18.3	IV	Subsequent-line	0	no	no
9210	2017	51 - 55	Male	NSCLC	2.55		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	29.9	III	Subsequent-line	0	no	no
9211	2017	56 - 60	Female	Hepatobiliary	3		4.4	IMPACT-468	Combo	PD	No	No	Yes	1.77	Alive	26.61	IV	Subsequent-line	1	no	yes
9212	2018	36 - 40	Male	Gastric	3.09	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.61	Alive	14.95	IV	Subsequent-line	0	no	no
9213	2016	61 - 65	Female	Renal	2.56	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.11	Alive	27.89	IV	First-line	0	no	no
9214	2017	61 - 65	Female	Hepatobiliary	3	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.4	Alive	5.09	III	Subsequent-line	1	no	no
9215	2016	71 - 75	Male	Melanoma	13.55		36.9	IMPACT-468	Combo	PD	No	No	Yes	1.05	Dead	1.84	IV	First-line	1	no	yes
9216	2017	66 - 70	Female	Melanoma	7.17		26.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.4	Dead	7.43	IV	First-line	0	no	no
9217	2017	66 - 70	Male	NSCLC	4.77		18.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.98	Alive	29.01	IV	Subsequent-line	1	no	no
9219	2016	76 - 80	Male	NSCLC	2.71		2.6	IMPACT-468	Combo	PD	No	No	Yes	1.08	Alive	1.54	IV	First-line	1	no	no
9220	2018	76 - 80	Male	NSCLC	5.75	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.78	Alive	15.28	IV	Subsequent-line	0	no	no
9221	2016	66 - 70	Male	NSCLC	5.21		8.9	IMPACT-410	Combo	PR	Yes	Yes	Yes	3.58	Dead	3.58	IV	First-line	0	no	no
9222	2017	91 - 95	Female	Melanoma	0.58		36.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	26.81	Alive	30.13	III	First-line	0	no	no
9223	2017	61 - 65	Male	Melanoma	26.47		14.9	IMPACT-468	Combo	PD	No	No	Yes	0.36	Dead	0.36	IV	Subsequent-line	3	no	no
9224	2017	66 - 70	Male	Bladder	8.14	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	2.07	IV	Subsequent-line	1	no	no
9226	2017	81 - 85	Female	NSCLC	5.11		11.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.1	Dead	6.18	IV	Subsequent-line	1	no	no
9227	2016	56 - 60	Male	NSCLC	5.94		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Dead	4.37	IV	First-line	1	no	no
9229	2017	51 - 55	Female	Endometrial	7.2	Stable	32.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	23.79	Alive	23.79	IV	Subsequent-line	0	no	yes
9230	2017	61 - 65	Male	Head & Neck	5.33	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	11.3	IV	Subsequent-line	1	no	no
9231	2017	41 - 45	Female	Melanoma	3.94	Stable	73.7	IMPACT-468	Combo	PR	Yes	Yes	No	20.3	Alive	20.3	IV	First-line	0	no	yes
9233	2017	66 - 70	Male	Bladder	3.64		7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	25.95	Alive	27.4	IV	Subsequent-line	1	no	no
9234	2017	76 - 80	Male	Bladder	2.06		8.8	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	22.11	Alive	22.11	IV	Subsequent-line	0	no	no
9235	2017	66 - 70	Male	NSCLC	7.33		14	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.14	Alive	3.12	IV	Subsequent-line	1	no	no
9236	2017	66 - 70	Female	Sarcoma	2.56	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	12.45	IV	Subsequent-line	0	no	no
9237	2017	51 - 55	Male	Renal	2	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	10.97	Alive	25.79	IV	First-line	0	no	yes
9238	2018	86 - 90	Male	NSCLC	9.83		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.4	Dead	2.4	IV	Subsequent-line		no	no
9239	2017	66 - 70	Female	Endometrial	3.78	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	14.69	IV	Subsequent-line	0	no	no
9240	2018	56 - 60	Male	Hepatobiliary	1.38	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.5	Dead	2.5	IV	Subsequent-line	1	no	no
9241	2018	81 - 85	Male	Head & Neck	3.89	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	16.69	Alive 	17.25	IV	Subsequent-line	0	no	no
9242	2017	71 - 75	Male	NSCLC	6.2		12.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.94	Dead	7.13	IV	Subsequent-line	1	no	no
9243	2018	56 - 60	Female	Esophageal	3.8	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.37	Dead	2.89	IV	Subsequent-line	1	no	no
9244	2017	51 - 55	Female	Bladder	2	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	7.59	IV	Subsequent-line	1	no	no
9245	2017	56 - 60	Female	Hepatobiliary	0.95	Stable	11.4	IMPACT-468	CTLA-4	PD	No	No	Yes	1.77	Dead	17.02	IV	First-line	0	no	yes
9246	2016	61 - 65	Female	Renal	1.94	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	27.33	Alive	27.33	III	First-line	0	no	no
9247	2017	61 - 65	Male	Gastric	2.53	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.1	Dead	18.04	IV	Subsequent-line	0	no	yes
9248	2016	41 - 45	Female	Melanoma	7		14	IMPACT-468	Combo	CR	Yes	Yes	No	23.03	Alive	25.79	III	First-line	0	no	no
9249	2017	61 - 65	Male	Melanoma	5.86	Stable	27.2	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	24.15	Alive	24.38	IV	First-line	0	no	no
9250	2018	61 - 65	Male	Renal	13.3	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.6	Dead	9.3	IV	Subsequent-line	1	no	no
9251	2017	71 - 75	Male	NSCLC	10		9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	7.13	IV	Subsequent-line		no	no
9253	2017	56 - 60	Male	Colorectal	6		5.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.26	Dead	0.66	IV	Subsequent-line	2	no	no
9254	2017	51 - 55	Female	NSCLC	3.03		7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	2.92	IV	Subsequent-line	1	no	no
9255	2018	61 - 65	Male	Head & Neck	6.44	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.9	Alive	15.18	IV	Subsequent-line	0	no	no
9256	2016	56 - 60	Female	NSCLC	3.47		21.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	3.71	IV	First-line	0	no	no
9257	2017	66 - 70	Female	NSCLC	4.38	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	8.38	Alive	23.72	IV	Subsequent-line	1	no	no
9259	2017	66 - 70	Female	NSCLC	3.5		2.6	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	13.34	Alive	15.38	IV	First-line	1	no	no
9260	2018	76 - 80	Male	Gastric	1.2	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	1.58	IV	Subsequent-line	2	no	no
9261	2016	61 - 65	Male	Bladder	4.67		11.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	28.75	Alive	28.91	IV	First-line	1	no	no
9262	2017	46 - 50	Male	Renal	9.67		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	7.1	IV	Subsequent-line	1	no	no
9263	2017	61 - 65	Female	NSCLC	71		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Alive	0.95	IV	Subsequent-line	1	no	no
9264	2017	66 - 70	Female	NSCLC	3.58	Stable	20.2	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	11.24	Alive	16	IV	Subsequent-line	1	no	no
9265	2016	51 - 55	Male	NSCLC	14.86	Stable	21.6	IMPACT-410	PD-1/PD-L1	CR	Yes	Yes	No	29.24	Alive	29.24	III	Subsequent-line	2	no	yes
9266	2016	56 - 60	Male	NSCLC	3.78	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	14.49	IV	First-line	1	no	no
9267	2017	46 - 50	Female	Renal	10.63		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.59	Alive	0.69	IV	Subsequent-line	0	no	no
9268	2017	61 - 65	Female	Endometrial	2.36	Unstable	24.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.45	Alive	27.6	IV	Subsequent-line	1	other-MMRd	yes
9269	2017	51 - 55	Male	Renal	16		2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	1.38	IV	Subsequent-line	1	no	yes
9270	2017	66 - 70	Female	NSCLC	6.4		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Alive	2.3	IV	Subsequent-line	1	no	no
9271	2017	56 - 60	Male	NSCLC	4.27		1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.75	Dead	8.08	IV	Subsequent-line		no	no
9272	2017	51 - 55	Male	NSCLC	6.79	Stable	6.1	IMPACT-468	Combo	PD	No	No	Yes	0.69	Dead	1.74	IV	Subsequent-line	1	no	no
9273	2018	61 - 65	Female	Gastric	1.53	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	8.71	Alive	11.01	IV	Subsequent-line	0	no	no
9274	2017	56 - 60	Male	Colorectal	2.63	Unstable	44.8	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	21.32	Alive	21.32	II	First-line	0	other-MMRd	yes
9276	2017	76 - 80	Female	Endometrial	5.14	Unstable	44.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.99	Dead	6.28	IV	Subsequent-line		mut-MMRd	yes
9277	2017	76 - 80	Male	Bladder	1.69		21.9	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	21.62	Alive	21.65	IV	Subsequent-line	1	no	no
9278	2017	66 - 70	Male	Melanoma	3.1	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.83	Alive	21.22	IV	First-line	1	no	no
9280	2018	76 - 80	Male	Colorectal	3.64	Stable	12.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.26	Alive	16.59	IV	Subsequent-line	1	no	no
9281	2017	66 - 70	Female	NSCLC	1.82	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.56	Dead	4.04	IV	Subsequent-line	0	no	no
9282	2018	76 - 80	Female	Endometrial	5	Unstable	20.2	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.27	Dead	9.89	III	Subsequent-line	0	other-MMRd	yes
9283	2018	51 - 55	Male	Sarcoma	7	Stable	5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.83	Dead	6.31		Subsequent-line	2	no	no
9284	2017	51 - 55	Female	NSCLC	11.8	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.94	Dead	2.69	IV	Subsequent-line	1	no	no
9285	2017	66 - 70	Male	NSCLC	8.5		10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.88	Dead	23.59	IV	Subsequent-line	1	no	no
9286	2018	66 - 70	Female	Endometrial	4.78	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.18	Alive	16.56	IV	Subsequent-line	0	no	no
9287	2017	26 - 30	Male	SCLC	24.8		5.3	IMPACT-468	Combo	PD	No	No	Yes	0.82	Dead	0.82	IV	Subsequent-line	1	no	no
9288	2016	61 - 65	Female	NSCLC	4.93		4.4	IMPACT-468	Combo	SD	No	No	Yes	2.66	Dead	7.85	IV	First-line	0	no	no
9290	2017	71 - 75	Male	NSCLC	9.4	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.56	Dead	3.94	IV	Subsequent-line	1	no	no
9291	2018	71 - 75	Female	NSCLC	3		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	5.22	Alive	17.12	IV	Subsequent-line	1	no	yes
9292	2017	61 - 65	Male	Bladder	4		8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	9.76	IV	Subsequent-line	1	no	no
9293	2018	71 - 75	Female	Endometrial	4.5	Stable	4.4	IMPACT-468	Combo	SD	No	No	Yes	4.83	Dead	11.76	IV	Subsequent-line	1	no	no
9294	2018	71 - 75	Male	NSCLC	2.88		14.9	IMPACT-468	Combo	PD	No	No	Yes	1.18	Dead	1.18	IV	Subsequent-line	2	no	yes
9295	2017	61 - 65	Female	NSCLC	9.75		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.39	Dead	0.39	IV	Subsequent-line	0	no	no
9296	2017	71 - 75	Male	NSCLC	0.42		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	6.37	IV	Subsequent-line	1	no	no
9297	2017	76 - 80	Male	NSCLC	1.5		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.02	Dead	1.51	IV	Subsequent-line	1	no	no
9298	2018	56 - 60	Male	Melanoma	4.4	Stable	21.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	16.1		First-line	0	no	yes
9299	2017	51 - 55	Male	NSCLC	3.43	Stable	14	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	16.89	III	Subsequent-line	0	no	yes
9300	2018	66 - 70	Male	Hepatobiliary	4.9	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.4	Alive	9.36	IV	Subsequent-line	1	no	no
9301	2017	41 - 45	Male	Head & Neck	4.2	Stable	1.8	IMPACT-468	Combo	PD	No	No	Yes	2.3	Alive	21.78	IV	First-line	0	no	no
9302	2017	26 - 30	Male	Colorectal	3.94	Unstable	37.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	24.11	Alive	24.61	IV	Subsequent-line	1	other-MMRd	yes
9303	2017	46 - 50	Male	Gastric	4.08	Stable	4.4	IMPACT-468	Combo	PR	Yes	Yes	Yes	5.49	Alive	19.25	IV	Subsequent-line	0	no	no
9306	2017	76 - 80	Female	NSCLC	8.12		7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	0.95	IV	Subsequent-line	1	no	no
9307	2017	66 - 70	Female	Head & Neck	19.8		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.51	Dead	1.51	IV	Subsequent-line	2	no	no
9308	2018	41 - 45	Female	Colorectal	27.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.59	Dead	0.59	IV	Subsequent-line	1	no	no
9309	2017	46 - 50	Female	Gastric	8.29	Stable	7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	3.32	Dead	24.25	IV	First-line	1	no	no
9310	2017	76 - 80	Female	NSCLC	6.23	Stable	9.7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	8.44	Dead	8.44	IV	Subsequent-line	2	no	no
9311	2017	66 - 70	Female	Gastric	1.73	Stable	7	IMPACT-468	Combo	PR	Yes	Yes	Yes	17.28	Dead	24.54	IV	First-line	0	no	no
9312	2017	41 - 45	Female	Melanoma	7.25		4.4	IMPACT-468	Combo	PD	No	No	Yes	1.15	Dead	1.15	IV	First-line	1	no	no
9313	2017	56 - 60	Female	Bladder	2.29	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	9.89	IV	Subsequent-line	0	no	yes
9315	2018	71 - 75	Female	Sarcoma	8.75	Stable	0.9	IMPACT-468	Combo	PD	No	No	Yes	0.46	Dead	4.5		Subsequent-line	1	no	no
9316	2017	66 - 70	Male	Esophageal	5		4.4	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	23.46	Alive	23.46	III	First-line	0	no	no
9317	2018	31 - 35	Female	NSCLC	2.3		3.5	IMPACT-468	Combo	SD	No	No	Yes	7.16	Alive	9.76	IV	Subsequent-line		no	no
9318	2017	41 - 45	Male	Colorectal	8.18	Stable	7.9	IMPACT-468	Combo	PD	No	No	Yes	1.35	Dead	1.35	IV	Subsequent-line	1	no	no
9320	2017	76 - 80	Male	NSCLC	5.43	Stable	12.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.9	Dead	13.86	IV	Subsequent-line	1	no	no
9321	2018	61 - 65	Female	NSCLC	2.58		1	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	2.66	IV	Subsequent-line	1	no	no
9322	2017	71 - 75	Male	Bladder	1.71	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.42	Alive	17.18	I	First-line	0	no	yes
9324	2017	56 - 60	Male	Hepatobiliary	9.64		2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.55	Dead	5.45	IV	Subsequent-line	1	no	no
9326	2017	66 - 70	Female	Endometrial	4.2	Unstable	29.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	23.46	Alive	24.84	IV	Subsequent-line	0	mut-MMRd	yes
9327	2017	51 - 55	Male	NSCLC	7.89		12.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.22	Dead	8.64	IV	Subsequent-line	1	no	no
9328	2017	66 - 70	Male	Gastric	6.11	Stable	14	IMPACT-468	Combo	SD	No	Yes	Yes	8.41	Dead	27.33	IV	First-line	0	no	yes
9329	2017	61 - 65	Female	NSCLC	2.4	Stable	9.7	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	14.42	Dead	28.29	IV	First-line		no	no
9330	2017	81 - 85	Male	Melanoma	2.79	Stable	21.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	20.01	Alive	20.01	IV	First-line	1	no	no
9331	2017	71 - 75	Male	NSCLC	3.71		7.9	IMPACT-410	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	11.07	IV	Subsequent-line	1	no	no
9332	2017	51 - 55	Female	NSCLC	10	Stable	31.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.51	Dead	5.82	IV	Subsequent-line	1	no	no
9333	2017	46 - 50	Female	NSCLC	3.64		0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.3	Alive	22.54	IV	Subsequent-line	1	no	no
9334	2017	56 - 60	Male	Melanoma	2.93	Stable	77.2	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	23.69	Alive	23.69	IV	First-line	0	no	yes
9335	2018	66 - 70	Female	NSCLC	3.17	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	8.11	IV	Subsequent-line	1	no	no
9336	2017	41 - 45	Male	Sarcoma	3.92	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	9	IV	Subsequent-line	0	no	no
9337	2018	51 - 55	Male	Hepatobiliary	2.31		0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	16.72	Alive	16.72		Subsequent-line	0	no	no
9338	2017	66 - 70	Female	NSCLC	4	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.35	Dead	3.35	IV	Subsequent-line	1	no	no
9339	2017	41 - 45	Male	Renal	8.93	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	0.62	IV	Subsequent-line	2	no	no
9340	2017	56 - 60	Female	Endometrial	1.43	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	17.25	IV	Subsequent-line	0	no	no
9341	2017	76 - 80	Male	Hepatobiliary	2.75	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.29	Alive	19.38	III	First-line	1	no	yes
9342	2017	66 - 70	Male	SCLC	12.5		10.5	IMPACT-468	Combo	PD	No	No	Yes	1.08	Dead	1.08	IV	Subsequent-line	1	no	no
9343	2017	56 - 60	Female	NSCLC	2.13	Stable	19.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	21.29	Alive	22.24	IV	Subsequent-line	0	no	yes
9344	2017	61 - 65	Male	Melanoma	4.92	Stable	30.7	IMPACT-468	Combo	PR	Yes	Yes	No	18.86	Alive	18.86	IV	First-line	1	no	no
9346	2018	76 - 80	Male	NSCLC	6.92	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.39	Alive	14.16	IV	Subsequent-line		no	no
9347	2017	71 - 75	Female	Esophageal	1.91	Stable	10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	16.43	Alive	29.21	IV	First-line	1	no	yes
9348	2018	56 - 60	Male	NSCLC	15.17	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.54	Dead	3.19	IV	Subsequent-line	1	no	yes
9349	2017	81 - 85	Female	NSCLC	13.36		9.8	IMPACT-410	PD-1/PD-L1	PR	Yes	Yes	Yes	16.62	Dead	16.62	IV	First-line	1	no	no
9350	2017	71 - 75	Male	NSCLC	49.25	Unstable	42.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.53	Dead	0.53	IV	Subsequent-line	1	mut-MMRd	no
9351	2017	76 - 80	Male	Sarcoma	2.68		0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	17.18	Alive	31.05	IV	First-line	0	no	no
9352	2017	61 - 65	Female	Sarcoma	6.46	Stable	15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	5.59		Subsequent-line	1	no	no
9353	2018	51 - 55	Male	Head & Neck	4.25	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	7.75	Dead	7.75	IV	Subsequent-line	1	no	no
9354	2018	41 - 45	Female	Bladder	18.67	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.53	Dead	0.53	IV	Subsequent-line	2	no	no
9355	2017	41 - 45	Female	NSCLC	4.89		2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	12.22	IV	Subsequent-line		no	no
9356	2017	71 - 75	Female	Ovarian	9.33		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	19.98	IV	Subsequent-line	1	no	no
9357	2017	56 - 60	Female	SCLC	1.28		16.7	IMPACT-468	Combo	PD	No	No	Yes	1.54	Dead	5.26	IV	Subsequent-line	1	no	no
9358	2017	56 - 60	Male	Head & Neck	4.83	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Alive	21.39	IV	Subsequent-line	0	no	no
9359	2017	71 - 75	Female	NSCLC	6.1		3.5	IMPACT-468	Combo	PD	No	No	Yes	1.28	Dead	19.75	IV	First-line	0	no	no
9360	2017	66 - 70	Female	NSCLC	2.5		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.12	Dead	6.37	IV	Subsequent-line	1	no	no
9361	2017	76 - 80	Male	NSCLC	3.47		5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	3.42	IV	First-line	1	no	no
9362	2017	36 - 40	Female	Endometrial	3.13	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.43	Alive	20.93	IV	Subsequent-line	0	no	yes
9363	2018	61 - 65	Male	Melanoma	5.3	Stable	2.6	IMPACT-468	Combo	PR	Yes	Yes	No	14.72	Alive	14.72	IV	First-line	0	no	no
9364	2017	61 - 65	Female	Gastric	2.14	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	14.49	Alive	29.01	IV	First-line	1	no	no
9365	2017	51 - 55	Female	Ovarian	2.4		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.71	Dead	4.8	IV	Subsequent-line	1	no	no
9366	2017	66 - 70	Female	NSCLC	5	Stable	8.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.73	Dead	2.73	IV	Subsequent-line	2	no	no
9367	2017	66 - 70	Male	NSCLC	5		48.3	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	10.55	Alive	21.65	IV	Subsequent-line	1	no	no
9368	2018	76 - 80	Female	Bladder	3.06	Stable	9.7	IMPACT-468	Combo	PD	No	No	Yes	0.85	Dead	2.07	IV	Subsequent-line	1	no	no
9369	2017	71 - 75	Male	NSCLC	2.5		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	1.71	IV	Subsequent-line		no	no
9370	2017	76 - 80	Female	Melanoma	2.27		17.6	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	28.75	Alive	28.75	IV	First-line	0	no	no
9371	2017	71 - 75	Female	NSCLC	2.89		10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	4.44	IV	First-line	0	no	no
9373	2017	61 - 65	Female	Gastric	9.33	Stable	6.1	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.95	Dead	13.57	IV	First-line	0	no	no
9374	2017	46 - 50	Male	Melanoma	1.49		10.5	IMPACT-468	Combo	PD	No	No	Yes	1.12	Dead	18.3	IV	First-line	0	no	no
9375	2017	51 - 55	Male	SCLC	17.2		9.7	IMPACT-468	Combo	SD	No	No	Yes	4.4	Alive	27.24	IV	Subsequent-line	1	no	no
9376	2018	61 - 65	Female	Ovarian	10.33	Stable	5.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	Yes	5.29	Dead	9.23	IV	Subsequent-line	0	no	no
9377	2018	76 - 80	Male	Head & Neck	7.17	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.11	Alive	15.11	IV	Subsequent-line	0	no	no
9378	2017	56 - 60	Female	NSCLC	6.72		7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.43	Dead	0.43	IV	First-line	1	no	no
9379	2018	86 - 90	Male	NSCLC	3.07	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.66	Alive	11.04	IV	Subsequent-line	1	no	no
9380	2017	61 - 65	Male	Melanoma	3.33		8.8	IMPACT-468	Combo	PR	Yes	Yes	No	28.98	Alive	28.98	IV	First-line	1	no	no
9381	2018	81 - 85	Female	NSCLC	5.5		14	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Alive	18.76	III	Subsequent-line		no	no
9382	2017	71 - 75	Female	Ovarian	7.17	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	0.92	IV	Subsequent-line	2	no	no
9383	2018	81 - 85	Male	NSCLC	4.5		0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	10.97	Alive	13.11	III	Subsequent-line		no	no
9384	2017	76 - 80	Female	Melanoma	4	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.07	Dead	3.55	III	First-line	1	no	no
9385	2018	56 - 60	Female	Breast	6.5		2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.44	Dead	6.44	IV	Subsequent-line	0	no	no
9386	2018	51 - 55	Male	NSCLC	7.75	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	3.15	IV	Subsequent-line	1	no	no
9387	2017	61 - 65	Male	Head & Neck	3.56	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Dead	3.45	IV	Subsequent-line	2	no	no
9388	2018	31 - 35	Female	Renal	3.15	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.88	Dead	14.42	IV	Subsequent-line	1	no	no
9389	2018	66 - 70	Male	Sarcoma	2.7	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	14.46	IV	Subsequent-line	0	no	no
9390	2017	26 - 30	Male	Colorectal	8.75	Stable	8.8	IMPACT-468	Combo	SD	No	No	No	2.76	Alive	14.52	IV	Subsequent-line	0	no	no
9391	2017	76 - 80	Male	Pancreatic	4	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Alive	3.45	IV	Subsequent-line	1	no	no
9392	2018	76 - 80	Female	Melanoma	3.29	Stable	17.6	IMPACT-468	PD-1/PD-L1	SD	No	No	No	4.6	Alive	5.29	IV	First-line	0	no	no
9393	2017	66 - 70	Male	NSCLC	43.67	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	0.79	IV	Subsequent-line	1	no	no
9395	2017	81 - 85	Male	NSCLC	6.13	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	17.28	Dead	17.28	IV	Subsequent-line		no	no
9396	2018	66 - 70	Female	Gastric	10.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	3.98	IV	Subsequent-line	1	no	no
9398	2018	61 - 65	Female	NSCLC	6.43	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	4.3	IV	Subsequent-line	1	no	no
9399	2017	71 - 75	Male	NSCLC	1.14	Stable	7	IMPACT-468	Combo	PD	No	No	Yes	2	Dead	7.39	IV	Subsequent-line	1	no	no
9400	2018	61 - 65	Female	Endometrial	1.66	Stable	6.1	IMPACT-468	Combo	PD	No	No	Yes	1.61	Alive	16.1	IV	Subsequent-line	0	no	yes
9401	2018	41 - 45	Male	Sarcoma	5.89	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	1.91	IV	Subsequent-line	1	no	no
9402	2018	56 - 60	Female	Renal	2.45	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Alive	12.16	IV	Subsequent-line	0	no	no
9403	2017	81 - 85	Male	Melanoma	2.77		22.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.69	Dead	3.58	IV	First-line	1	no	no
9404	2018	41 - 45	Female	Colorectal	3.47	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Alive	16	IV	Subsequent-line	1	no	no
9406	2018	36 - 40	Male	NSCLC	3.36	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	10.22	IV	Subsequent-line	0	no	no
9407	2018	71 - 75	Male	NSCLC	7	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.51	Alive	14.36	IV	Subsequent-line		no	no
9409	2017	56 - 60	Male	Renal	2.7	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	26.22	Alive	26.22	IV	First-line	0	no	no
9410	2017	66 - 70	Female	Sarcoma	2	Stable	6.1	IMPACT-468	Combo	SD	No	No	Yes	3.55	Alive	19.42	IV	Subsequent-line	0	no	no
9411	2017	56 - 60	Female	Renal	6	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	6.34	IV	Subsequent-line	1	no	no
9413	2017	66 - 70	Male	Head & Neck	40.6	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.57	Dead	5.82	IV	Subsequent-line	2	no	no
9414	2017	41 - 45	Female	NSCLC	3.5	Stable	19.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	18.89	Alive	21.65	IV	Subsequent-line		no	no
9415	2018	66 - 70	Male	NSCLC	2.83		0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	11.93	Alive	13.86	IV	Subsequent-line	1	no	no
9416	2017	56 - 60	Female	NSCLC	8.67	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	14.29	III	Subsequent-line	1	no	no
9417	2017	56 - 60	Male	NSCLC	2.11		4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	0.46	IV	First-line	1	no	no
9418	2018	41 - 45	Male	Pancreatic	2.83	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Alive	10.61	IV	Subsequent-line	0	no	no
9419	2018	66 - 70	Male	Pancreatic	0.83		1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	11.6	IV	Subsequent-line	1	no	no
9420	2017	56 - 60	Female	NSCLC	10.91		10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.59	Dead	1.54	IV	Subsequent-line	1	no	no
9422	2017	81 - 85	Female	Melanoma	2.89	Stable	178.2	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	26.91	Alive	26.91	IV	First-line	0	no	no
9424	2017	61 - 65	Male	Head & Neck	3.25	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	6.77	Dead	7.82	IV	Subsequent-line	1	no	no
9425	2017	81 - 85	Female	NSCLC	4.11	Stable	11.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.14	Dead	4.63	IV	First-line		no	no
9426	2017	71 - 75	Female	Endometrial	3.85	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.01	Dead	8.05	IV	Subsequent-line	0	no	no
9427	2017	51 - 55	Female	Bladder	3.58	Stable	16.7	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	11.5	Dead	15.57	IV	Subsequent-line	1	no	no
9428	2017	66 - 70	Male	NSCLC	2.5	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Alive	23.1	III	Subsequent-line	1	no	no
9429	2018	46 - 50	Female	Colorectal	12.25	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	1.28	IV	Subsequent-line	1	no	no
9430	2017	61 - 65	Female	Endometrial	6.8	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	7.36	Dead	16.33	IV	Subsequent-line	0	no	yes
9431	2017	56 - 60	Male	Gastric	5.9	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	27.63	Alive	27.63	IV	First-line	0	no	no
9432	2017	51 - 55	Male	Gastric	5.93	Stable	8.8	IMPACT-468	Combo	PD	No	No	Yes	1.81	Dead	14.49	IV	Subsequent-line	0	no	no
9433	2017	71 - 75	Male	Melanoma	14.25	Stable	55.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.74	Dead	11.7	IV	First-line	1	no	yes
9434	2017	66 - 70	Female	NSCLC	36	Stable	15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.05	Dead	1.58	IV	Subsequent-line	1	no	no
9435	2018	76 - 80	Female	Ovarian	5.33	Indeterminate	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.46	Dead	3.84	IV	Subsequent-line	1	no	no
9437	2017	46 - 50	Male	Melanoma	6.22	Stable	18.4	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	24.61	Alive	24.61	III	First-line	0	no	no
9438	2017	61 - 65	Male	Gastric	5.89	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	8.34	IV	Subsequent-line	0	no	no
9439	2017	61 - 65	Female	Melanoma	2.09	Stable	37.7	IMPACT-468	Combo	SD	No	No	Yes	3.12	Alive	28.48	II	First-line		no	yes
9440	2017	61 - 65	Male	Melanoma	2.41	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.27	Dead	9.86	IV	First-line	0	no	no
9441	2017	61 - 65	Male	NSCLC	4.91	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.85	Alive	5.36	IV	Subsequent-line		no	no
9442	2018	66 - 70	Male	SCLC	20.5	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.12	Dead	5.78	IV	Subsequent-line	1	no	no
9445	2017	66 - 70	Female	Endometrial	2.36	Stable	7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	27.47	Alive	29.08	IV	Subsequent-line	0	no	no
9446	2018	51 - 55	Male	NSCLC	5.43	Stable	0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	7.1	Alive	18.63	IV	Subsequent-line	0	no	no
9447	2018	51 - 55	Female	Pancreatic	5.8	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	7.66	IV	Subsequent-line	1	no	no
9448	2017	56 - 60	Male	Head & Neck	7.71	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	9.2	IV	Subsequent-line	1	no	no
9452	2018	71 - 75	Male	NSCLC	8.27		0	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	13.63	Alive	18.73	IV	Subsequent-line	1	no	no
9453	2017	46 - 50	Female	Melanoma	1.93	Stable	6.1	IMPACT-468	Combo	PR	Yes	Yes	Yes	6.41	Alive	28.48		First-line	0	no	no
9454	2018	46 - 50	Male	Head & Neck	1.27	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.94	Alive	18.76	IV	Subsequent-line	0	no	no
9456	2018	71 - 75	Female	Bladder	1.4	Stable	14	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	14.49	Alive	14.49	IV	Subsequent-line	0	no	no
9457	2018	56 - 60	Male	Head & Neck	9.2	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	1.94	IV	Subsequent-line	1	no	no
9459	2018	51 - 55	Female	NSCLC	12.83	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	3.61	IV	Subsequent-line	1	no	no
9460	2018	66 - 70	Male	Head & Neck	5.33	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.07	Alive	10.58	IV	Subsequent-line	1	no	no
9461	2017	66 - 70	Male	Bladder	4.69	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.09	Dead	6.77	IV	Subsequent-line	1	no	yes
9462	2017	66 - 70	Male	Renal	2.11	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.33	Dead	9	IV	Subsequent-line	0	no	no
9463	2017	66 - 70	Female	Melanoma	3.64	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	0.99	Dead	9.13	IV	First-line	1	no	no
9464	2018	66 - 70	Male	Head & Neck	3.5	Stable	23.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	13.8	IV	Subsequent-line	1	no	yes
9465	2017	21 - 25	Female	Renal	3.43	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	4.21	Dead	17.41	IV	Subsequent-line	1	no	no
9466	2017	31 - 35	Male	Esophageal	5.14	Stable	7	IMPACT-468	Combo	CR	Yes	Yes	No	21.39	Alive	22.11	IV	Subsequent-line	0	no	no
9467	2017	66 - 70	Female	SCLC	6.33	Stable	8.8	IMPACT-468	Combo	PD	No	No	Yes	0.26	Dead	0.66	IV	Subsequent-line	1	no	no
9468	2018	71 - 75	Female	Renal	4.92	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.2	Dead	5.68	IV	Subsequent-line	1	no	no
9469	2017	71 - 75	Female	NSCLC	6	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Dead	17.51	IV	Subsequent-line	0	no	no
9470	2017	76 - 80	Male	Hepatobiliary	3.17	Stable	3.5	IMPACT-468	Combo	PR	Yes	Yes	No	24.84	Alive	24.87	IV	First-line	1	no	no
9471	2017	61 - 65	Male	Gastric	4.4	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	14.55	Dead	27.14	IV	First-line	0	no	no
9472	2017	71 - 75	Male	Head & Neck	10.4	Stable	14	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.19	Dead	5.19	IV	Subsequent-line	1	no	yes
9473	2017	81 - 85	Female	NSCLC	8.15	Stable	0.9	IMPACT-468	Combo	PR	Yes	Yes	Yes	5.22	Dead	5.22	IV	First-line	1	no	no
9475	2017	36 - 40	Female	Hepatobiliary	9.47	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	1.94	IV	Subsequent-line	1	no	no
9476	2017	71 - 75	Female	NSCLC	5.1	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.61	Alive	29.47	IV	First-line	1	no	no
9477	2018	46 - 50	Female	Colorectal	14.4	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	No	No	6.67	Alive	8.9	III	Subsequent-line	0	no	no
9479	2017	51 - 55	Female	Endometrial	4.44	Stable	9.7	IMPACT-468	Combo	PD	No	No	Yes	0.92	Dead	4.4	IV	Subsequent-line	0	no	no
9480	2017	66 - 70	Male	NSCLC	2.04	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	10.12	Dead	20.37	IV	First-line	1	no	no
9481	2017	61 - 65	Male	SCLC	10.89	Stable	10.5	IMPACT-468	Combo	SD	No	No	Yes	5.42	Dead	22.87	IV	Subsequent-line	0	no	no
9482	2017	71 - 75	Male	Melanoma	2.5	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.08	Dead	1.08	IV	First-line	3	no	no
9483	2017	66 - 70	Male	Hepatobiliary	17.25	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.14	Dead	8.48	IV	First-line	1	no	no
9484	2018	46 - 50	Female	Colorectal	1.28	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	2.56	IV	Subsequent-line	1	no	yes
9485	2017	61 - 65	Female	Bladder	2.35	Stable	22.8	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	24.38	Alive	24.38	IV	First-line	1	no	no
9486	2017	66 - 70	Female	Pancreatic	31.5	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	0.92	IV	Subsequent-line	2	no	no
9487	2017	76 - 80	Female	NSCLC	9.17	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.66	Dead	10.58	IV	Subsequent-line	1	no	no
9488	2018	51 - 55	Male	Esophageal	6	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.82	Alive	13.01	IV	Subsequent-line	1	no	no
9489	2018	21 - 25	Male	Renal	5.14	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.77	Dead	5.75	IV	Subsequent-line	1	no	no
9491	2018	76 - 80	Female	NSCLC	5.47	Stable	11.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	9.49	Alive	9.66	IV	First-line		no	no
9492	2017	66 - 70	Male	NSCLC	5.86	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.02	Dead	8.02	IV	Subsequent-line	0	no	no
9493	2017	31 - 35	Female	Breast	1.47	Stable	5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.52	Alive	27.86	IV	Subsequent-line	0	no	no
9494	2018	66 - 70	Female	Breast	9.5	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.65	Alive	11.04	IV	Subsequent-line	0	no	no
9496	2017	56 - 60	Male	Bladder	11.08	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.27	Dead	6.47	IV	First-line	1	no	yes
9498	2018	66 - 70	Female	NSCLC	7.25	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.45	Alive	15.11	IV	Subsequent-line	1	no	no
9499	2017	61 - 65	Male	Melanoma	2	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Alive	21.65	IV	First-line	0	no	no
9501	2017	61 - 65	Male	NSCLC	7.71	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	12.45	IV	First-line	1	no	no
9503	2018	71 - 75	Male	NSCLC	4.08	Stable	12.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.86	Dead	10.97	IV	Subsequent-line	1	no	no
9505	2017	51 - 55	Female	NSCLC	0.77	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	7.03	IV	Subsequent-line	0	no	no
9506	2017	51 - 55	Male	Colorectal	7	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	7	IV	Subsequent-line	1	no	yes
9507	2017	56 - 60	Male	NSCLC	5.56	Indeterminate	21.9	IMPACT-468	Combo	PD	No	No	Yes	1.61	Dead	1.61	IV	Subsequent-line	1	no	no
9508	2017	71 - 75	Female	Gastric	1.69	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.66	Dead	15.34	IV	Subsequent-line	0	no	yes
9509	2017	46 - 50	Male	Esophageal	4.07	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	11.76	Dead	14.85	III	First-line	1	no	no
9510	2018	51 - 55	Female	Gastric	4.7	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.14	Dead	2.14	IV	Subsequent-line	2	no	no
9511	2018	21 - 25	Male	Sarcoma	2.25	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.68	Alive	15.87	IV	Subsequent-line	0	no	no
9512	2017	61 - 65	Female	NSCLC	13	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.22	Dead	1.22	IV	Subsequent-line	1	no	no
9513	2018	51 - 55	Female	Endometrial	2.86	Unstable	37.7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	13.86	Alive	13.86	IV	Subsequent-line	0	mut-MMRd	yes
9514	2017	51 - 55	Male	Renal	1.64	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	4.17	IV	Subsequent-line	1	no	no
9515	2018	56 - 60	Female	Endometrial	2.36		0	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.91	Dead	16.56	IV	Subsequent-line	0	no	no
9517	2018	51 - 55	Male	Colorectal	4.3	Stable	8.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.32	Alive	16.62	IV	Subsequent-line	0	no	yes
9518	2018	26 - 30	Male	Renal	8	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	0.89	IV	Subsequent-line	2	no	no
9519	2018	66 - 70	Male	NSCLC	7.75	Stable	8.8	IMPACT-468	Combo	PR	Yes	Yes	No	13.17	Alive	13.17	IV	First-line	1	no	no
9520	2017	71 - 75	Female	NSCLC	3.5	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.73	Alive	5.49	IV	Subsequent-line		no	no
9521	2017	61 - 65	Male	Head & Neck	2.96	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	13.63	Alive	27.83	IV	First-line	1	no	yes
9522	2017	71 - 75	Female	SCLC	5.09	Stable	12.3	IMPACT-468	Combo	PR	Yes	Yes	Yes	5.55	Dead	9.63	IV	Subsequent-line	1	no	no
9523	2017	66 - 70	Female	NSCLC	9	Stable	15.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.71	Alive	21.26	IV	Subsequent-line	1	no	no
9525	2017	76 - 80	Female	Bladder	3.06	Stable	16.7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	27.37	Alive	28.06	IV	Subsequent-line		no	yes
9526	2017	61 - 65	Male	Renal	3.73	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	14.65	Alive	22.8	IV	Subsequent-line	0	no	no
9527	2018	41 - 45	Female	Colorectal	5.71	Stable	5.3	IMPACT-468	Combo	SD	No	No	Yes	2.1	Dead	4.99	IV	Subsequent-line	1	no	no
9528	2018	51 - 55	Male	NSCLC	15.75	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	9.53	IV	Subsequent-line	0	no	no
9529	2018	31 - 35	Female	Sarcoma	5.9	Stable	4.4	IMPACT-468	Combo	PD	No	No	Yes	0.23	Dead	0.43	IV	Subsequent-line	2	no	no
9530	2017	36 - 40	Male	NSCLC	1.83	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	18.69	Alive	26.25	IV	First-line	1	no	no
9531	2017	51 - 55	Female	SCLC	3.11	Indeterminate	7.9	IMPACT-468	Combo	PD	No	No	Yes	4.86	Alive	19.38	III	Subsequent-line	0	no	no
9532	2017	56 - 60	Female	NSCLC	5.54	Stable	18.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.5	Alive	25.76	IV	First-line	1	no	no
9534	2017	66 - 70	Female	NSCLC	2.17	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	4.83	Dead	4.83	IV	First-line	1	no	yes
9535	2017	51 - 55	Male	NSCLC	6.2		0	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	27.1	Alive	28.16	IV	Subsequent-line	0	no	no
9536	2017	71 - 75	Male	Sarcoma	18	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.02	Dead	1.87	IV	Subsequent-line	1	no	no
9537	2017	56 - 60	Female	NSCLC	5.29	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.73	Alive	27.17	IV	First-line	2	no	no
9538	2018	56 - 60	Female	NSCLC	25.25	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.91	Alive	15.01	IV	Subsequent-line	0	no	no
9539	2018	66 - 70	Female	Breast	1	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	1.77	IV	Subsequent-line		no	yes
9540	2017	71 - 75	Male	Head & Neck	19	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Dead	10.87	IV	Subsequent-line	0	no	yes
9541	2018	31 - 35	Male	Esophageal	35.33	Unstable	43	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	0.82	IV	Subsequent-line	2	mut-MMRd	yes
9542	2017	76 - 80	Male	NSCLC	8.2	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	0.99	IV	First-line		no	no
9543	2018	26 - 30	Male	NSCLC	2.1	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.49	Alive	17.77	IV	Subsequent-line	0	no	no
9544	2017	56 - 60	Male	NSCLC	11.18	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.73	Dead	4.07	IV	First-line	1	no	no
9545	2018	51 - 55	Female	Ovarian	4	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	3.71	IV	Subsequent-line	1	no	yes
9546	2017	51 - 55	Female	NSCLC	4.83	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.55	Dead	9.03	IV	First-line	1	no	no
9547	2017	66 - 70	Female	NSCLC	15.57	Stable	17.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	9.1	IV	Subsequent-line	1	no	no
9548	2018	51 - 55	Female	Pancreatic	2	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	7.43	IV	Subsequent-line	0	no	no
9549	2017	61 - 65	Female	NSCLC	9.57	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	0.95	IV	Subsequent-line	2	no	no
9550	2017	71 - 75	Male	SCLC	4.13	Stable	9.7	IMPACT-468	Combo	PD	No	No	Yes	2.63	Dead	14.95	IV	Subsequent-line	1	no	no
9552	2018	66 - 70	Female	NSCLC	26.29	Stable	27.2	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	13.14	Alive	15.11	IV	Subsequent-line		no	no
9553	2018	61 - 65	Female	Endometrial	4.59	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.15	Dead	3.15	IV	Subsequent-line	1	no	no
9554	2017	26 - 30	Female	Ovarian	4.38	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	11.7	IV	Subsequent-line	1	no	no
9555	2017	91 - 95	Male	Melanoma	12.45	Stable	79.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.74	Dead	6.74	IV	First-line	0	no	no
9556	2017	61 - 65	Female	NSCLC	6.28	Stable	16.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	17.22	Alive	24.8	IV	Subsequent-line	1	no	no
9557	2017	61 - 65	Female	NSCLC	7.75	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	15.11	Dead	21.52	IV	Subsequent-line		no	no
9558	2018	36 - 40	Female	Colorectal	3.44	Stable	6.1	IMPACT-468	Combo	PD	No	No	Yes	0.46	Alive	14.36	IV	Subsequent-line	0	no	no
9559	2018	71 - 75	Male	NSCLC	2.82	Stable	6.1	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	14.59	Alive	14.59	IV	First-line	0	no	no
9560	2017	61 - 65	Female	Gastric	4.82	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.89	Dead	7.89	IV	First-line	0	no	no
9561	2018	46 - 50	Male	Breast	2.75	Stable	36	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	9.2	Alive	9.66	II	Subsequent-line		no	no
9562	2018	91 - 95	Male	Melanoma	3.8	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	3.68	IV	First-line	2	no	no
9563	2018	41 - 45	Female	Head & Neck	11	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	7.69	IV	Subsequent-line	1	no	no
9564	2017	81 - 85	Male	Melanoma	4.73	Stable	44.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.96	Dead	10.91	IV	First-line	1	no	no
9565	2017	71 - 75	Female	Endometrial	0.83	Stable	7.9	IMPACT-468	Combo	SD	No	No	Yes	3.45	Dead	12.75	IV	Subsequent-line	0	no	no
9566	2017	61 - 65	Female	Endometrial	1.79	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	10.28	IV	Subsequent-line	0	no	no
9567	2017	46 - 50	Female	NSCLC	0.65	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.12	Alive	27.37	IV	First-line	1	no	no
9568	2017	71 - 75	Male	SCLC	6.62	Stable	15.8	IMPACT-468	Combo	PD	No	No	Yes	0.36	Dead	0.36	IV	Subsequent-line	1	no	no
9569	2017	71 - 75	Male	Melanoma	3.2	Stable	17.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.31	Alive	18.92	III	First-line	0	no	yes
9570	2017	61 - 65	Male	Esophageal	5	Stable	11.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	10.94	Alive	18.17	IV	Subsequent-line	0	no	no
9571	2018	51 - 55	Female	Ovarian	6.2	Unstable	43.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.01	Dead	6.37	IV	Subsequent-line	1	mut-MMRd	yes
9572	2018	61 - 65	Female	Endometrial	7	Unstable	21.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.56	Alive	14.32	IV	Subsequent-line	0	other-MMRd	yes
9574	2017	66 - 70	Male	NSCLC	5.57	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	0.99	IV	Subsequent-line	1	no	yes
9575	2017	66 - 70	Male	Melanoma	4.24	Stable	17.6	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	23	Alive	23.72	III	First-line	0	no	no
9576	2017	71 - 75	Male	Melanoma	8.8	Stable	31.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.34	Alive	15.54	III	First-line	0	no	yes
9577	2018	76 - 80	Male	Melanoma	3.67	Stable	41.3	IMPACT-468	Combo	PR	Yes	Yes	No	12.09	Alive	13.11	IV	First-line	1	no	no
9578	2017	66 - 70	Male	Melanoma	0.98	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.51	Alive	11.76	IV	First-line	1	no	no
9579	2018	61 - 65	Female	Endometrial	3.33	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.99	Alive	13.86	IV	Subsequent-line	1	no	yes
9580	2018	51 - 55	Female	Melanoma	2	Stable	14.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	11.04	Alive	11.04		Subsequent-line	0	no	no
9581	2018	56 - 60	Female	Endometrial	3.21	Unstable	52.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	14.26	Alive	14.49	IV	Subsequent-line	0	mut-MMRd	no
9582	2017	76 - 80	Male	NSCLC	16.67	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	2.23	IV	Subsequent-line	1	no	no
9583	2017	51 - 55	Female	Esophageal	3.56	Unstable	43.9	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	19.78	Alive	19.78	IV	Subsequent-line	1	other-MMRd	yes
9585	2018	71 - 75	Male	NSCLC	4.63	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Alive	15.7	IV	Subsequent-line	1	no	no
9587	2018	66 - 70	Female	SCLC	16.38	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	1.81	IV	Subsequent-line	1	no	no
9588	2017	66 - 70	Female	Esophageal	14.57	Unstable	33.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	0.92	Alive	2.3	IV	Subsequent-line	2	other-MMRd	no
9589	2017	46 - 50	Female	Colorectal	2.78	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.23	Dead	9.59	IV	Subsequent-line	1	no	no
9590	2017	61 - 65	Male	Hepatobiliary	7	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	20.47	Alive	21.49	IV	Subsequent-line	1	no	no
9591	2018	56 - 60	Male	Pancreatic	4.3	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.27	Dead	14.42	IV	Subsequent-line	0	no	no
9592	2018	66 - 70	Male	NSCLC	4.06	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.6	Dead	16.16	IV	Subsequent-line	0	no	no
9594	2018	71 - 75	Female	Pancreatic	6.36	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	4.14	IV	Subsequent-line	1	no	yes
9595	2017	66 - 70	Male	Melanoma	2.27	Stable	5.3	IMPACT-468	Combo	PR	Yes	Yes	Yes	6.93	Alive	27.1	IV	First-line	1	no	no
9596	2017	86 - 90	Male	Melanoma	4.06	Stable	52.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	22.77	Alive	25.76	IV	First-line	1	no	no
9598	2018	61 - 65	Male	NSCLC	5.9	Stable	14.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	14.95	Alive	17.25	IV	Subsequent-line	0	no	no
9600	2017	66 - 70	Female	Melanoma	1.53	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	25.53	Alive	25.72	IV	First-line		no	no
9601	2017	56 - 60	Female	Colorectal	2.2	Indeterminate	6.1	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	11.73	Alive	19.19	IV	Subsequent-line	1	no	no
9602	2018	71 - 75	Female	Endometrial	4.16	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.53	Alive	9.76	IV	Subsequent-line	1	no	no
9603	2017	61 - 65	Male	NSCLC	5.18	Indeterminate	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	1.28	IV	First-line	2	no	no
9604	2018	56 - 60	Male	Head & Neck	27	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.72	Dead	3.55	IV	Subsequent-line	1	no	no
9605	2017	56 - 60	Female	Endometrial	3.42	Unstable	29.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	11.93	IV	Subsequent-line	0	other-MMRd	yes
9606	2018	66 - 70	Female	NSCLC	7.36	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	1.81	IV	Subsequent-line	1	no	no
9607	2018	36 - 40	Male	Sarcoma	7.11	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	6.87	IV	Subsequent-line	0	no	no
9609	2018	56 - 60	Female	NSCLC	2.56	Stable	7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	12.19	Alive	12.68	IV	Subsequent-line	0	no	no
9610	2017	76 - 80	Female	Bladder	2.13	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	24.71	IV	First-line	0	no	no
9611	2017	61 - 65	Male	Renal	3.31	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	3.81	Alive	17.68	IV	Subsequent-line	1	no	yes
9612	2017	46 - 50	Male	Gastric	3.25	Stable	4.4	IMPACT-468	Combo	PD	No	No	Yes	0.33	Dead	21.95	IV	First-line	0	no	no
9613	2018	71 - 75	Male	NSCLC	4.78	Stable	75.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	19.09	Alive	19.78	IV	Subsequent-line	1	no	no
9614	2017	76 - 80	Male	NSCLC	2.67	Stable	5.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	23.03	Alive	23.06	IV	Subsequent-line	0	no	no
9615	2018	31 - 35	Female	Head & Neck	5	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	4.04	IV	Subsequent-line	1	no	no
9616	2018	31 - 35	Male	Melanoma	1.6	Indeterminate	11.4	IMPACT-468	Combo	PD	No	No	Yes	1.71	Dead	6.57	IV	Subsequent-line	0	no	no
9617	2018	61 - 65	Male	Pancreatic	1.22	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	4.34	IV	Subsequent-line	1	no	no
9618	2017	76 - 80	Female	NSCLC	4.42	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.98	Dead	3.98	IV	Subsequent-line	1	no	no
9619	2017	61 - 65	Male	Renal	5.88	Stable	1.8	IMPACT-468	Combo	PD	No	No	Yes	1.58	Dead	6.21	IV	Subsequent-line	1	no	no
9620	2018	66 - 70	Male	Esophageal	5.42	Indeterminate	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	0.85	IV	Subsequent-line	2	no	no
9622	2018	76 - 80	Female	NSCLC	15.93	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	14.85	Alive	16.69	IV	First-line	1	no	no
9623	2018	71 - 75	Male	NSCLC	3.05	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Alive	15.9	IV	Subsequent-line		no	no
9624	2018	61 - 65	Male	NSCLC	3.36	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.32	Alive	13.31	IV	Subsequent-line	0	no	no
9626	2017	46 - 50	Female	Ovarian	3.21	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.64	Dead	10.87	IV	Subsequent-line	1	no	no
9627	2018	51 - 55	Male	Colorectal	3.88	Stable	8.8	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	Yes	13.63	Alive	15.9	IV	Subsequent-line	0	no	no
9628	2018	56 - 60	Female	NSCLC	3.08	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	4.24	IV	Subsequent-line	1	no	no
9629	2018	41 - 45	Female	NSCLC	6.13	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	10.22	IV	Subsequent-line	1	no	no
9631	2018	71 - 75	Female	NSCLC	11.33	Indeterminate	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	4.47	IV	Subsequent-line	2	no	no
9633	2018	46 - 50	Male	NSCLC	49.5	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.22	Dead	1.22	IV	Subsequent-line	1	no	no
9634	2017	76 - 80	Female	Gastric	3.25	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	10.97	Alive	23.89	IV	First-line	1	no	no
9635	2017	76 - 80	Male	NSCLC	8.13	Stable	18.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	3.88	IV	Subsequent-line	2	no	no
9636	2017	71 - 75	Male	Melanoma	2.24	Stable	48.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	19.55	Alive	19.55	IV	First-line	0	no	no
9637	2018	51 - 55	Female	NSCLC	4.36	Stable	23.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.79	Alive	17.48	IV	Subsequent-line	1	no	no
9638	2018	16 - 20	Male	Sarcoma	5.9	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.51	Dead	4.73	IV	Subsequent-line	1	no	no
9640	2017	36 - 40	Male	SCLC	4.29	Stable	12.3	IMPACT-468	Combo	PD	No	No	Yes	1.08	Dead	9.07	IV	Subsequent-line		no	no
9642	2017	46 - 50	Male	Bladder	6.25	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	1.58	IV	First-line	0	no	no
9643	2018	46 - 50	Male	Gastric	6.18	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	1.64	Alive	2.23	IV	Subsequent-line	0	no	no
9644	2017	66 - 70	Male	NSCLC	12.29	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.47	Alive	20.76	III	Subsequent-line	2	no	no
9645	2017	41 - 45	Male	Bladder	4.23	Stable	17.6	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	21.68	Alive	21.68	IV	First-line	1	no	no
9646	2017	51 - 55	Male	NSCLC	8.15	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Alive	5.72	IV	First-line	3	no	yes
9648	2018	66 - 70	Female	Sarcoma	4	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.21	Alive	14.06	IV	Subsequent-line	0	no	no
9649	2018	61 - 65	Male	SCLC	5.38	Stable	14	IMPACT-468	Combo	PD	No	No	Yes	0.85	Alive	17.25	IV	Subsequent-line	1	no	yes
9650	2018	71 - 75	Female	NSCLC	7	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.79	Dead	3.58	IV	Subsequent-line	1	no	no
9652	2017	66 - 70	Male	NSCLC	4.25	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.36	Dead	0.36	IV	First-line	0	no	no
9653	2018	71 - 75	Female	SCLC	0.47	Stable	4.4	IMPACT-468	Combo	PD	No	No	Yes	1.61	Dead	3.68	IV	Subsequent-line	1	no	no
9654	2018	61 - 65	Male	Head & Neck	8.17	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	2.53	IV	Subsequent-line	1	no	no
9655	2018	46 - 50	Male	Colorectal	4.08	Stable	4.4	IMPACT-468	Combo	PD	No	No	Yes	1.74	Alive	10.28	IV	Subsequent-line	0	no	no
9657	2018	56 - 60	Female	NSCLC	2.67	Stable	17.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	10.58	Alive	11.07	IV	Subsequent-line	1	no	no
9658	2018	66 - 70	Male	Sarcoma	4.36	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	4.99		Subsequent-line	0	no	no
9659	2018	51 - 55	Male	NSCLC	6.11	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	6.54	IV	Subsequent-line	0	no	no
9661	2018	66 - 70	Male	Esophageal	4.13	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.62	Dead	6.67	IV	Subsequent-line	2	no	no
9662	2017	61 - 65	Male	NSCLC	2.64	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	5.03	IV	Subsequent-line	0	no	no
9663	2017	61 - 65	Female	Melanoma	2.86	Stable	13.2	IMPACT-468	Combo	PR	Yes	Yes	No	24.15	Alive	24.15	IV	First-line	0	no	no
9664	2018	56 - 60	Male	SCLC	10.75	Stable	6.1	IMPACT-468	Combo	PD	No	No	Yes	0.89	Dead	1.22	IV	Subsequent-line	1	no	no
9665	2017	31 - 35	Female	Gastric	2.86	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	9.43	Alive	17.25	IV	First-line	0	no	no
9666	2017	46 - 50	Female	Melanoma	2	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	0.59	Dead	8.9		First-line	1	no	no
9667	2017	61 - 65	Male	Melanoma	4.8	Stable	36.9	IMPACT-468	Combo	PR	Yes	Yes	Yes	6.28	Dead	13.37	IV	First-line	1	no	no
9668	2017	66 - 70	Male	NSCLC	10.91	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	1.28	IV	Subsequent-line	1	no	no
9669	2017	56 - 60	Male	Gastric	3.91	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.87	Dead	17.61	IV	First-line	0	no	no
9670	2017	61 - 65	Female	NSCLC	2.2	Stable	18.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	22.51	Alive	23	IV	First-line	0	no	no
9671	2018	56 - 60	Male	NSCLC	23.33	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.9	Dead	10.35	IV	Subsequent-line	1	no	no
9672	2017	56 - 60	Male	NSCLC	3.59	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	20.4	Alive	23.85	IV	Subsequent-line	1	no	yes
9673	2018	51 - 55	Male	Sarcoma	16.5	Indeterminate	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.11	Alive	7.98	IV	Subsequent-line	1	no	no
9674	2018	61 - 65	Male	Gastric	2.22	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	3.19	IV	Subsequent-line	1	no	no
9675	2017	61 - 65	Male	Melanoma	2.87	Stable	47.4	IMPACT-468	Combo	CR	Yes	Yes	No	21.32	Alive	21.32	IV	First-line	0	no	no
9678	2018	61 - 65	Male	Pancreatic	4.75	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	5.52	IV	Subsequent-line	1	no	no
9681	2018	66 - 70	Male	SCLC	3.2	Stable	11.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	1.87	IV	Subsequent-line	2	no	no
9682	2018	46 - 50	Male	Melanoma	3.4	Stable	4.4	IMPACT-468	Combo	PD	No	No	Yes	2.5	Dead	14.29	IV	First-line	0	no	no
9683	2018	56 - 60	Female	Head & Neck	5	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Alive	14.62	IV	Subsequent-line	0	no	no
9684	2018	61 - 65	Male	NSCLC	4.22	Stable	5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	No	8.31	Alive	9.72	IV	Subsequent-line	0	no	no
9685	2018	66 - 70	Male	Colorectal	3.11	Indeterminate	22.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.39	Alive	12.98	IV	Subsequent-line	1	no	no
9686	2018	36 - 40	Male	Renal	2.69	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.36	Alive	18.23	IV	First-line	0	no	no
9687	2017	41 - 45	Male	Melanoma	3.25	Stable	14.9	IMPACT-468	Combo	PD	No	No	Yes	1.25	Alive	20.5	IV	First-line	0	no	no
9688	2017	61 - 65	Male	Head & Neck	9.86	Stable	9.7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	20.93	Alive	22.6	IV	Subsequent-line	1	no	no
9689	2018	51 - 55	Male	Melanoma	26	Stable	16.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.23	Dead	0.23	IV	Subsequent-line	4	no	no
9690	2017	56 - 60	Male	Gastric	5.11	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.57	Dead	6.51	IV	First-line	0	no	no
9691	2017	71 - 75	Male	Esophageal	4.27	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	10.97	Alive	21.85	IV	First-line	1	no	no
9693	2017	56 - 60	Female	Endometrial	5.35	Unstable	40.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.17	Alive	23.1	IV	Subsequent-line	1	other-MMRd	yes
9694	2018	66 - 70	Female	Breast	5.6	Indeterminate	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.38	Alive	15.38	IV	Subsequent-line	1	no	no
9695	2018	41 - 45	Female	Endometrial	3.4	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.53	Dead	9.03	IV	Subsequent-line	0	no	no
9696	2017	66 - 70	Female	NSCLC	2.95	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	7.33	IV	First-line	0	no	no
9697	2017	46 - 50	Male	Renal	3.36	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	22.08	Alive	22.08	IV	First-line	0	no	no
9698	2017	86 - 90	Male	Sarcoma	4.09	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.07	Alive	19.42	IV	Subsequent-line	1	no	no
9699	2017	46 - 50	Male	Renal	10.67	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	22.08	Alive	22.08	IV	Subsequent-line	0	no	no
9701	2018	56 - 60	Female	Endometrial	3.78	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	1.61	Dead	5.45	IV	Subsequent-line	1	no	no
9702	2018	81 - 85	Male	Melanoma	5.36	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.07	Dead	4.53	IV	First-line	2	no	no
9703	2017	76 - 80	Male	Bladder	1.59	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.12	Dead	2.92	IV	First-line	1	no	no
9707	2017	61 - 65	Female	Sarcoma	1.81	Stable	0	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	18.4	Dead	19.25	IV	Subsequent-line	1	no	no
9709	2017	66 - 70	Male	Melanoma	2.33	Stable	42.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.8	Alive	20.44	IV	First-line	0	no	no
9710	2017	86 - 90	Male	Bladder	4.33	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	4.07	IV	First-line	1	no	no
9711	2018	56 - 60	Female	Pancreatic	7.88	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	5.42	IV	Subsequent-line	1	no	no
9712	2017	56 - 60	Female	NSCLC	2.91	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.21	Alive	21.91	IV	First-line	1	no	no
9713	2018	66 - 70	Male	NSCLC	77.33	Stable	24.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	0.92	IV	Subsequent-line	1	no	no
9714	2018	31 - 35	Female	Hepatobiliary	2.78		7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	7.13	Alive	17.68	IV	Subsequent-line	0	no	no
9715	2018	66 - 70	Female	NSCLC	6.5	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.07	Alive	10.97	IV	Subsequent-line	1	no	no
9716	2017	61 - 65	Male	NSCLC	2.48		6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	2.46	IV	Subsequent-line	3	no	no
9717	2017	66 - 70	Female	NSCLC	6.5	Stable	14.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	3.61	Alive	21.29	IV	Subsequent-line	2	no	no
9721	2018	81 - 85	Male	NSCLC	7.83	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	2.69	IV	Subsequent-line	2	no	no
9723	2018	61 - 65	Female	NSCLC	10	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	3.68	IV	Subsequent-line	1	no	no
9725	2018	66 - 70	Female	Sarcoma	1.07	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	6.8	IV	Subsequent-line	0	no	no
9726	2018	66 - 70	Female	Endometrial	1.82	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	4.53	IV	Subsequent-line	0	no	no
9727	2017	56 - 60	Male	Gastric	8	Stable	0	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.97	Dead	12.32	IV	Subsequent-line	0	no	no
9728	2017	76 - 80	Female	NSCLC	4	Stable	19.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.96	Dead	18.37	IV	First-line	1	no	no
9729	2018	46 - 50	Male	NSCLC	10.38	Stable	15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.99	Dead	0.99	IV	Subsequent-line	1	no	no
9730	2017	31 - 35	Female	NSCLC	1.53	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	7.23	IV	First-line	0	no	no
9731	2018	66 - 70	Female	NSCLC	5.75	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	0.79	IV	Subsequent-line	1	no	no
9732	2018	61 - 65	Female	Endometrial	9	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.53	Dead	15.51	IV	Subsequent-line	1	no	yes
9733	2018	71 - 75	Male	NSCLC	3.29	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	2.4	IV	Subsequent-line	1	no	yes
9734	2018	71 - 75	Male	NSCLC	3.6	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Alive	14.13	IV	Subsequent-line	0	no	no
9735	2018	61 - 65	Male	Head & Neck	6.14	Stable	17.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.23	Dead	9.46	IV	Subsequent-line	1	no	no
9737	2018	61 - 65	Male	NSCLC	4	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	18.17	Alive	18.2	III	Subsequent-line	1	no	no
9738	2018	56 - 60	Female	NSCLC	2.42	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.17	Alive	13.8	IV	Subsequent-line	0	no	no
9739	2017	46 - 50	Male	Gastric	2.36	Stable	13.2	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	5.68	Alive	5.75	IV	First-line	0	no	no
9740	2018	56 - 60	Male	Hepatobiliary	14	Indeterminate	16.7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.22	Alive	16.39	IV	Subsequent-line	0	no	yes
9741	2018	71 - 75	Male	NSCLC	12.33	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.06	Dead	7.95	IV	First-line	1	no	no
9742	2017	56 - 60	Male	Sarcoma	2.21	Stable	16.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	22.08	Alive	22.77	IV	First-line	1	no	no
9743	2018	56 - 60	Female	Breast	4.75	Indeterminate	6.1	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	13.34	Alive	13.47	IV	Subsequent-line	0	no	no
9745	2018	66 - 70	Male	NSCLC	7.56	Stable	7.9	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	19.58	Alive	19.58	IV	Subsequent-line	0	no	no
9746	2018	61 - 65	Female	NSCLC	15.75	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.02	Dead	7.56	IV	Subsequent-line	1	no	yes
9747	2018	76 - 80	Male	Hepatobiliary	5.71	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.6	Alive	15.38	III	Subsequent-line	1	no	no
9748	2017	46 - 50	Female	NSCLC	5.42	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	8.02	Dead	11.6	IV	First-line	1	no	no
9749	2018	91 - 95	Male	NSCLC	1.4	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.56	Dead	0.56	IV	Subsequent-line	1	no	no
9750	2018	76 - 80	Female	NSCLC	2.22	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	7.13	Dead	7.98	IV	Subsequent-line		no	no
9751	2017	71 - 75	Male	Bladder	8.72	Stable	6.1	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.31	Dead	8.57	IV	First-line	2	no	no
9753	2017	26 - 30	Male	NSCLC	8.72	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Alive	19.88	IV	First-line	0	no	no
9754	2017	66 - 70	Female	NSCLC	3.56	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Dead	6.8	IV	Subsequent-line	1	no	no
9755	2017	56 - 60	Male	NSCLC	4.23	Stable	15.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	16.76	Dead	21.39	IV	First-line	0	no	yes
9756	2017	56 - 60	Male	Gastric	4.67	Stable	6.1	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.37	Dead	7.16	IV	First-line	0	no	no
9757	2017	56 - 60	Female	Bladder	2.06	Stable	19.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Alive	18.17	IV	First-line	0	no	yes
9758	2017	66 - 70	Male	NSCLC	2	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.51	Alive	22.28	IV	First-line	0	no	no
9759	2017	56 - 60	Male	NSCLC	4.5	Stable	12.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	16.13	Alive	23.06	IV	First-line	0	no	no
9760	2017	36 - 40	Male	Sarcoma	2.33	Stable	0.9	IMPACT-468	Combo	PD	No	No	Yes	2.07	Alive	21.42		First-line	0	no	no
9761	2018	61 - 65	Female	NSCLC	14.2		0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2	Dead	2.53	IV	Subsequent-line		no	no
9762	2018	71 - 75	Female	NSCLC	2.69	Stable	12.3	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	12.55	Alive	14.72	IV	Subsequent-line	1	no	no
9763	2018	56 - 60	Female	Pancreatic	3.35	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Alive	3.22	IV	Subsequent-line	1	no	no
9765	2018	81 - 85	Female	Gastric	3.31	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.8	Dead	5.55	IV	Subsequent-line	1	no	no
9766	2018	61 - 65	Female	Head & Neck	11.2	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	9.59	IV	Subsequent-line	1	no	no
9767	2018	66 - 70	Female	NSCLC	4.28	Stable	24.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.64	Alive	15.67	IV	First-line		no	no
9768	2017	71 - 75	Male	Melanoma	9.2	Stable	144.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.23	Dead	0.23	IV	First-line	3	no	yes
9769	2017	66 - 70	Male	Head & Neck	7.38	Stable	59.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	21.65	Alive	21.65	IV	Subsequent-line	1	no	no
9770	2018	51 - 55	Male	Renal	4	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.2	Dead	3.84	IV	Subsequent-line	0	no	no
9771	2018	51 - 55	Female	Hepatobiliary	6.14	Stable	10.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.3	Dead	3.09	IV	Subsequent-line	1	no	yes
9772	2017	41 - 45	Male	NSCLC	4.2	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Alive	22.67	IV	Subsequent-line		no	no
9773	2017	51 - 55	Male	Gastric	8.44	Unstable	47.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	20.01	Alive	20.01	IV	First-line	0	mut-MMRd	yes
9774	2017	66 - 70	Female	Melanoma	3.2	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.03	Alive	19.15	IV	First-line	0	no	no
9775	2018	66 - 70	Male	NSCLC	7	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	14.55	IV	Subsequent-line	1	no	no
9776	2018	41 - 45	Male	NSCLC	4.43	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	9	IV	Subsequent-line	1	no	no
9778	2017	36 - 40	Male	Melanoma	1.6	Stable	1.8	IMPACT-468	Combo	SD	No	No	Yes	4.6	Alive	20.37	IV	First-line	0	no	no
9780	2018	66 - 70	Female	NSCLC	6.53	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Dead	7.36	IV	Subsequent-line	1	no	no
9781	2018	31 - 35	Male	Colorectal	4.3	Unstable	368.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.95	Alive	16.95	III	First-line	1	mut-MMRd	yes
9783	2017	81 - 85	Male	Melanoma	1.58	Stable	4.4	IMPACT-468	Combo	SD	No	Yes	Yes	8.28	Dead	11.79	IV	First-line	1	no	no
9785	2018	56 - 60	Male	Renal	14.6	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	6.01	IV	Subsequent-line	1	no	no
9786	2018	61 - 65	Male	Sarcoma	4.53	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	8.9	IV	Subsequent-line	0	no	no
9789	2018	71 - 75	Female	Endometrial	7.67	Stable	4.4	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	12.42	Alive	12.42	IV	Subsequent-line	0	no	no
9790	2018	66 - 70	Male	Sarcoma	13.4	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	5.59	IV	Subsequent-line	0	no	no
9791	2017	51 - 55	Male	Sarcoma	4.35	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.49	Alive	10.81	IV	Subsequent-line	0	no	no
9792	2018	41 - 45	Male	NSCLC	9	Stable	11.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.86	Dead	15.67	IV	Subsequent-line	1	no	no
9793	2018	46 - 50	Female	Breast	9.33	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.85	Dead	0.99	IV	Subsequent-line	0	no	no
9794	2017	66 - 70	Male	Melanoma	1.32		3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	1.31	IV	Subsequent-line	3	no	no
9795	2017	76 - 80	Male	NSCLC	5.04	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	13.04	Dead	17.28	IV	First-line		no	no
9796	2017	71 - 75	Male	Melanoma	5.71	Stable	12.3	IMPACT-468	Combo	PR	Yes	Yes	Yes	13.8	Alive	21.26	IV	First-line	0	no	no
9798	2018	66 - 70	Female	Hepatobiliary	3.45	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	0.76	IV	Subsequent-line	0	no	no
9801	2018	56 - 60	Male	Bladder	1.6	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.63	Alive	8.05	IV	Subsequent-line	1	no	no
9802	2017	61 - 65	Male	NSCLC	6	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	14.95	IV	First-line	1	no	no
9803	2017	66 - 70	Male	NSCLC	14.7	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	8.08	IV	First-line	0	no	no
9804	2018	46 - 50	Male	Hepatobiliary	3.47	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.17	Alive	2.3	IV	Subsequent-line	1	no	no
9805	2017	61 - 65	Female	NSCLC	5.36	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.64	Alive	22.34	IV	First-line	1	no	yes
9806	2018	46 - 50	Female	Breast	0.8	Indeterminate	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Alive	11.73	IV	Subsequent-line	0	no	no
9808	2017	61 - 65	Female	NSCLC	2.6	Stable	20.2	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.38	Alive	21.82	IV	First-line	1	no	no
9809	2018	61 - 65	Female	Endometrial	1.29	Unstable	31.6	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	10.74	Alive	13.5	IV	Subsequent-line	1	mut-MMRd	yes
9810	2018	66 - 70	Female	SCLC	3.94	Stable	4.4	IMPACT-468	Combo	PR	Yes	Yes	No	4.86	Alive	5.85	IV	Subsequent-line		no	no
9811	2018	61 - 65	Male	Melanoma	3.53	Stable	51.8	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	16.1	Alive	16.23	IV	First-line	0	no	no
9812	2018	56 - 60	Male	NSCLC	4.78	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.3	Alive	13.57	IV	Subsequent-line	1	no	no
9813	2017	56 - 60	Male	Melanoma	5.33	Stable	19.3	IMPACT-468	Combo	PD	No	No	Yes	0.26	Dead	2.4	IV	First-line	2	no	no
9815	2018	46 - 50	Male	Renal	2.16	Stable	7	IMPACT-468	Combo	PR	Yes	Yes	No	10.12	Alive	12.06	IV	First-line	0	no	no
9816	2017	71 - 75	Male	NSCLC	10.8	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.22	Alive	21.91	IV	First-line	0	no	no
9817	2018	61 - 65	Female	Pancreatic	4.4	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.53	Dead	2	IV	Subsequent-line	1	no	no
9818	2018	51 - 55	Male	Bladder	4	Stable	13.2	IMPACT-468	Combo	PR	Yes	Yes	Yes	6.08	Alive	11.96	IV	Subsequent-line	0	no	no
9819	2017	56 - 60	Female	NSCLC	3.75	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	5.82	IV	First-line	0	no	no
9820	2017	71 - 75	Female	NSCLC	2.88	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.1	Dead	0.1	IV	First-line	3	no	no
9821	2018	71 - 75	Male	NSCLC	3.55	Stable	11.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	17.25	Alive	17.25	IV	First-line	1	no	no
9822	2018	61 - 65	Male	Melanoma	2.73	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.99	Dead	9.76	IV	First-line	1	no	no
9823	2017	71 - 75	Female	NSCLC	8	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	19.68	IV	First-line	1	no	no
9824	2017	71 - 75	Male	Gastric	4	Stable	6.1	IMPACT-468	Combo	PR	Yes	Yes	Yes	19.35	Alive	20.44	IV	First-line	0	no	no
9826	2018	46 - 50	Female	NSCLC	4.33	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	2.04	IV	Subsequent-line	3	no	no
9827	2018	26 - 30	Male	Head & Neck	32.17	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.3	Dead	0.62	IV	Subsequent-line	1	no	no
9829	2018	91 - 95	Male	Bladder	12.75	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	4.14	Dead	4.14	IV	Subsequent-line	1	no	no
9830	2017	46 - 50	Male	Melanoma	2.33	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.91	Alive	20.76	IV	First-line	0	no	no
9831	2018	71 - 75	Male	Pancreatic	1.81	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	1.91	IV	Subsequent-line	1	no	no
9833	2017	46 - 50	Male	Head & Neck	9.6	Stable	7.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.55	Alive	21.65	IV	First-line	0	no	no
9834	2018	51 - 55	Female	Colorectal	18.8	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.43	Dead	0.43	IV	Subsequent-line	2	no	no
9836	2018	46 - 50	Female	Breast	3	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.52	Dead	3.52	IV	Subsequent-line	1	no	no
9837	2017	71 - 75	Female	Esophageal	5.64	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.52	Alive	19.32	IV	First-line	0	no	no
9838	2017	56 - 60	Female	NSCLC	4.76	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	5.06	IV	First-line	1	no	no
9839	2017	76 - 80	Female	NSCLC	1.76	Stable	24.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.4	Dead	5.85	IV	Subsequent-line	2	no	no
9840	2017	61 - 65	Male	NSCLC	6.56	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	3.94	Dead	10.94	IV	First-line	1	no	no
9841	2018	61 - 65	Male	NSCLC	8.83	Stable	32.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.32	Dead	10.41	III	Subsequent-line	1	no	no
9842	2018	61 - 65	Male	Esophageal	13.25	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	0.82	IV	Subsequent-line	2	no	no
9843	2017	66 - 70	Female	Hepatobiliary	3.6	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	17.51	Alive	19.55	II	First-line	1	no	no
9845	2017	41 - 45	Female	Ovarian	2.44	Indeterminate	32.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	19.48	Alive	19.75	IV	Subsequent-line	0	no	yes
9846	2018	66 - 70	Male	Pancreatic	6.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.71	Alive	2.6	IV	Subsequent-line	1	no	no
9847	2018	51 - 55	Male	NSCLC	2.44	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	11.04	Alive	11.04	IV	Subsequent-line	1	no	no
9848	2017	71 - 75	Male	Melanoma	7.88	Stable	12.3	IMPACT-468	Combo	PR	Yes	Yes	Yes	14.16	Alive	21.45	IV	First-line	1	no	no
9849	2018	61 - 65	Female	NSCLC	23.57	Indeterminate	30.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.71	Dead	4.44	IV	Subsequent-line	2	no	no
9851	2018	66 - 70	Female	NSCLC	1.62	Stable	12.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.91	Alive	14.03	IV	Subsequent-line	0	no	no
9852	2018	76 - 80	Male	Esophageal	4.43	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	1.18	IV	Subsequent-line	1	no	no
9853	2018	71 - 75	Female	NSCLC	7.44	Stable	14	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.67	Alive	16.36	IV	Subsequent-line		no	no
9854	2017	56 - 60	Male	NSCLC	5.08	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Alive	21.03	IV	First-line	1	no	no
9855	2018	56 - 60	Female	SCLC	5.75	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.18	Dead	7.62	IV	Subsequent-line	1	no	no
9856	2018	61 - 65	Female	Sarcoma	8.08	Stable	0.9	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	12.42	Alive	12.45	IV	Subsequent-line	1	no	no
9857	2017	66 - 70	Male	NSCLC	3.6	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.52	Dead	8.28	IV	First-line	1	no	no
9858	2018	66 - 70	Male	Bladder	12.43	Stable	5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.61	Alive	2.07	IV	Subsequent-line	1	no	no
9859	2017	66 - 70	Male	NSCLC	4.64	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	1.22	Dead	11.27	IV	First-line	0	no	no
9860	2018	91 - 95	Male	NSCLC	2.43	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.13	Dead	0.13	IV	Subsequent-line	2	no	no
9861	2017	76 - 80	Male	Melanoma	14.44	Stable	59.7	IMPACT-468	Combo	PR	Yes	Yes	No	19.71	Alive	19.71	IV	First-line	0	no	no
9862	2018	81 - 85	Male	SCLC	3.88	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	2.14	IV	Subsequent-line	1	no	no
9863	2018	56 - 60	Female	Gastric	3.06	Stable	0	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	14.72	Alive	14.72	IV	Subsequent-line	1	no	no
9865	2018	36 - 40	Female	NSCLC	37.5	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.76	Dead	9.4	IV	First-line	1	no	no
9866	2018	71 - 75	Male	Gastric	1.48	Stable	0.9	IMPACT-468	Combo	PD	No	No	Yes	1.08	Dead	1.08	IV	Subsequent-line	1	no	no
9868	2018	56 - 60	Female	Endometrial	0.93	Unstable	31.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.29	Alive	12.52	IV	Subsequent-line	0	other-MMRd	yes
9869	2018	56 - 60	Female	SCLC	11.63	Indeterminate	5.3	IMPACT-468	Combo	PD	No	No	Yes	0.82	Dead	0.82	IV	Subsequent-line	2	no	no
9870	2018	56 - 60	Female	NSCLC	2.36	Stable	10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	18.4	Alive	20.3	IV	First-line	0	no	no
9871	2018	81 - 85	Male	NSCLC	2.04	Stable	23.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	11.73	IV	Subsequent-line	1	no	yes
9872	2017	36 - 40	Female	NSCLC	4.78	Stable	5.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	17.25	Alive	19.42	IV	First-line	0	no	no
9873	2017	61 - 65	Male	NSCLC	4.42	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	2.92	IV	Subsequent-line	1	no	no
9874	2018	56 - 60	Male	Hepatobiliary	28.33	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	0.66	IV	Subsequent-line	1	no	yes
9875	2017	76 - 80	Female	Ovarian	7.83	Stable	0	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	19.55	Alive	19.55	IV	First-line	1	no	no
9876	2017	56 - 60	Male	Bladder	4.71	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.31	Dead	12.94	IV	First-line	0	no	no
9877	2018	61 - 65	Female	Pancreatic	1.44	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	17.74	Alive	18.23	IV	First-line	1	no	no
9878	2018	56 - 60	Female	Sarcoma	3.19	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.48	Dead	3.68	IV	Subsequent-line	0	no	no
9879	2018	56 - 60	Female	NSCLC	3.32	Stable	12.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	1.94	IV	Subsequent-line	1	no	no
9880	2018	61 - 65	Female	Head & Neck	20.67	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.56	Alive	1.77	IV	Subsequent-line	1	no	no
9881	2018	61 - 65	Female	NSCLC	3.21	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	12.42	Alive	19.58	IV	First-line	2	no	no
9882	2018	21 - 25	Female	Sarcoma	88	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.91	Dead	1.91	IV	Subsequent-line	1	no	no
9883	2017	51 - 55	Male	Melanoma	2.74	Stable	19.3	IMPACT-468	Combo	PD	No	No	Yes	5.98	Dead	7.98	IV	First-line	0	no	no
9884	2018	56 - 60	Female	NSCLC	13	Stable	14.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.94	Dead	7.85	IV	Subsequent-line	1	no	no
9885	2018	61 - 65	Male	NSCLC	5.6	Indeterminate	15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.53	Dead	5.95	IV	Subsequent-line	1	no	no
9886	2018	61 - 65	Male	Hepatobiliary	4.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.87	Dead	3.22	IV	Subsequent-line	0	no	no
9887	2018	61 - 65	Male	NSCLC	9.89	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	2.96	IV	Subsequent-line	2	no	no
9888	2018	71 - 75	Male	Pancreatic	4.8	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Dead	9.49	IV	Subsequent-line	0	no	no
9889	2018	41 - 45	Female	NSCLC	2.35	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.98	Alive	15.34	IV	First-line	0	no	no
9890	2018	61 - 65	Male	SCLC	3.63	Stable	3.5	IMPACT-468	Combo	PD	No	No	Yes	1.71	Dead	4.34	IV	Subsequent-line	1	no	no
9891	2018	31 - 35	Female	Gastric	7.13	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Alive	3.88	IV	Subsequent-line	1	no	no
9892	2018	61 - 65	Male	NSCLC	5.29	Stable	15.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.8	Dead	9.1	IV	First-line	1	no	yes
9893	2018	56 - 60	Male	NSCLC	2.64	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.49	Dead	3.12	IV	Subsequent-line	1	no	no
9894	2018	71 - 75	Female	Bladder	3.18	Stable	14	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	5.68	IV	Subsequent-line	0	no	no
9895	2018	66 - 70	Female	Head & Neck	1.79	Indeterminate	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	4.01	IV	Subsequent-line	2	no	no
9896	2018	51 - 55	Female	Hepatobiliary	1.85	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.81	Dead	8.08	IV	Subsequent-line	1	no	no
9898	2018	76 - 80	Female	Bladder	1.21	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.92	Dead	11.66	IV	Subsequent-line	1	no	yes
9899	2018	61 - 65	Female	NSCLC	2		0	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.86	Dead	3.15	IV	Subsequent-line	0	no	no
9900	2018	71 - 75	Female	NSCLC	7.44	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.68	Dead	4.83	IV	Subsequent-line	1	no	no
9901	2018	61 - 65	Male	NSCLC	3.44	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.05	Alive	7.16	IV	Subsequent-line	1	no	no
9902	2018	66 - 70	Female	NSCLC	16.75	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.44	Dead	13.44	IV	First-line	1	no	no
9903	2018	66 - 70	Male	NSCLC	3.06	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.11	Alive	7.49	IV	Subsequent-line	0	no	no
9904	2018	66 - 70	Male	NSCLC	2.04	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	16.85	Alive	18.79	IV	First-line	1	no	no
9906	2018	91 - 95	Male	Bladder	4.78	Stable	18.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2	Dead	5.85	IV	First-line	2	no	yes
9909	2018	61 - 65	Female	NSCLC	9.8	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	9.03	IV	Subsequent-line	1	no	no
9911	2018	56 - 60	Female	NSCLC	6.27	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.1	Dead	8.15	IV	Subsequent-line	1	no	no
9912	2018	56 - 60	Male	Esophageal	3.2	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	1.84	Dead	2.66	IV	Subsequent-line	0	no	no
9913	2018	61 - 65	Male	NSCLC	1.91	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.94	Alive	15.87	IV	Subsequent-line	0	no	no
9914	2018	61 - 65	Female	NSCLC	5.8	Indeterminate	9.7	IMPACT-468	Combo	PD	No	No	Yes	0.56	Dead	6.8	IV	Subsequent-line	1	no	no
9915	2018	81 - 85	Male	Gastric	4.39	Unstable	43	IMPACT-468	Combo	SD	No	No	Yes	2.63	Dead	2.63	IV	First-line	1	other-MMRd	yes
9916	2018	41 - 45	Male	NSCLC	14.1	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	0.95	IV	First-line	0	no	no
9917	2018	71 - 75	Female	NSCLC	4.08	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	3.45	IV	Subsequent-line	1	no	no
9918	2018	61 - 65	Male	NSCLC	4.2	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	12.39	Dead	12.39	IV	Subsequent-line		no	no
9920	2018	61 - 65	Male	NSCLC	6.08	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	12.55	IV	First-line	0	no	no
9921	2018	61 - 65	Female	NSCLC	2.67	Stable	17.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.79	Alive	18.79	IV	First-line	1	no	no
9922	2018	86 - 90	Female	NSCLC	1.96	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.54	Alive	11.99	IV	Subsequent-line		no	no
9923	2018	66 - 70	Female	Endometrial	3	Unstable	26.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	11.04	Alive	12.19	IV	Subsequent-line	0	other-MMRd	yes
9924	2018	71 - 75	Female	Melanoma	3.94	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.25	Alive	4.93	IV	Subsequent-line	1	no	no
9925	2018	56 - 60	Female	Colorectal	7.67	Indeterminate	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	1.41	IV	Subsequent-line	2	no	no
9926	2018	71 - 75	Female	NSCLC	9.63	Stable	9.7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.39	Alive	15.31	IV	Subsequent-line	0	no	no
9927	2018	71 - 75	Female	Colorectal	5	Unstable	102.7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.33	Dead	2.33	IV	Subsequent-line	1	mut-MMRd	yes
9928	2018	61 - 65	Female	NSCLC	3	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	10.12	IV	Subsequent-line	1	no	no
9929	2018	31 - 35	Female	Hepatobiliary	16	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.54	Dead	1.54	IV	Subsequent-line	1	no	yes
9930	2018	41 - 45	Female	Melanoma	1.45	Stable	26.3	IMPACT-468	Combo	PR	Yes	Yes	Yes	3.32	Alive	17.94	IV	First-line	1	no	yes
9931	2018	41 - 45	Male	Esophageal	4.5	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.99	Alive	16.99	IV	First-line	0	no	no
9932	2018	61 - 65	Male	NSCLC	7.75	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.42	Dead	4.9	IV	Subsequent-line	1	no	no
9933	2018	76 - 80	Male	NSCLC	14.82		0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.27	Dead	8.21	IV	Subsequent-line	1	no	no
9934	2018	61 - 65	Female	NSCLC	5	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	19.09	Alive	19.09	IV	First-line		no	no
9935	2018	61 - 65	Male	NSCLC	5.8	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.52	Alive	9.86	IV	Subsequent-line	1	no	no
9936	2018	81 - 85	Male	NSCLC	10	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.76	Dead	2.86	IV	Subsequent-line	1	no	no
9937	2018	56 - 60	Male	Bladder	4.12	Stable	5.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	8.05	Dead	9.53	II	First-line	0	no	no
9939	2018	66 - 70	Female	NSCLC	6	Stable	2.6	IMPACT-468	Combo	PR	Yes	Yes	Yes	11.17	Alive	17.94	IV	Subsequent-line	1	no	no
9940	2018	71 - 75	Female	Endometrial	8.4	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.9	Dead	8.31	IV	Subsequent-line	0	no	no
9941	2018	56 - 60	Male	Sarcoma	3.5	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.32	Dead	16.82	IV	Subsequent-line	0	no	no
9942	2018	51 - 55	Male	NSCLC	32.6	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	2.66	Dead	2.66	IV	First-line		no	no
9943	2018	41 - 45	Female	Melanoma	2.33	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Dead	5.42	IV	First-line	0	no	no
9944	2018	61 - 65	Female	Sarcoma	10.38	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.53	Dead	0.53	IV	Subsequent-line	2	no	no
9946	2018	46 - 50	Male	NSCLC	4	Stable	27.2	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	17.38	Alive	17.61	IV	First-line	1	no	no
9947	2018	66 - 70	Male	NSCLC	7.42	Stable	16.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.69	Alive	16.85	IV	First-line	1	no	no
9949	2018	71 - 75	Male	NSCLC	14.83	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	12.09	Alive	17.25	IV	First-line		no	no
9950	2018	66 - 70	Male	NSCLC	7.92	Stable	31.6	IMPACT-468	Combo	PR	Yes	Yes	No	17.58	Alive	17.58	IV	First-line	1	no	no
9951	2018	76 - 80	Male	Melanoma	3.92	Stable	30.7	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	17.25	Alive	17.41	IV	First-line	0	no	no
9952	2018	51 - 55	Male	Renal	3.1	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.62	Alive	10.09	IV	First-line	0	no	no
9953	2018	46 - 50	Female	NSCLC	5.05	Stable	5.3	IMPACT-468	Combo	PD	No	No	Yes	1.28	Alive	17.64	III	First-line	0	no	no
9954	2018	71 - 75	Female	NSCLC	6	Stable	13.2	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.9	Dead	9.66	III	Subsequent-line	1	no	no
9955	2018	71 - 75	Male	NSCLC	3.83	Stable	7.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.99	Dead	6.01	IV	Subsequent-line	1	no	no
9957	2018	66 - 70	Female	NSCLC	5.14	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.56	Alive	18.4	IV	First-line	0	no	no
9958	2018	61 - 65	Male	NSCLC	13.67	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.45	Dead	5.06	IV	First-line	1	no	no
9959	2018	66 - 70	Male	SCLC	11	Stable	7.9	IMPACT-468	Combo	PR	Yes	Yes	Yes	7.56	Dead	14.59	IV	Subsequent-line	0	no	no
9960	2018	66 - 70	Male	NSCLC	4.71	Stable	7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	3.25	Dead	6.67	IV	Subsequent-line		no	no
9961	2018	61 - 65	Female	NSCLC	2.03	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.91	Alive	17.05	IV	First-line	0	no	no
9962	2018	76 - 80	Male	NSCLC	2.17	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.11	Dead	4.11	IV	Subsequent-line	1	no	no
9963	2018	51 - 55	Male	Bladder	1.77	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.69	Dead	11.96	IV	First-line	0	no	no
9964	2018	61 - 65	Female	NSCLC	5.31	Stable	10.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.03	Alive	17.48	IV	Subsequent-line	1	no	no
9965	2018	46 - 50	Male	Renal	5.3	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.42	Alive	11.79	IV	First-line	0	no	no
9966	2018	66 - 70	Female	NSCLC	4.33	Stable	16.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	1.35	IV	Subsequent-line	1	no	no
9967	2018	66 - 70	Female	Sarcoma	5.86	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	0.76	Dead	6.97	IV	Subsequent-line	1	no	no
9968	2018	61 - 65	Male	Esophageal	1.83	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2	Dead	5.19	IV	Subsequent-line	1	no	no
9969	2018	61 - 65	Female	NSCLC	2.18	Stable	10.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	5.29	IV	Subsequent-line	1	no	no
9970	2018	71 - 75	Female	NSCLC	7	Stable	3.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.7	Alive	16.66	IV	First-line	1	no	no
9972	2018	91 - 95	Male	Melanoma	5.33	Stable	158.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	6.87	Alive	6.87	III	First-line	1	no	no
9974	2018	71 - 75	Female	Endometrial	3.83	Stable	22.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.52	Alive	16.56	IV	Subsequent-line	1	no	yes
9975	2018	56 - 60	Female	Endometrial	2.75	Stable	4.4	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	16.53	Alive	16.56	III	Subsequent-line	0	no	no
9976	2018	71 - 75	Male	Melanoma	3.5	Stable	29.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.47	Alive	15.93	IV	First-line	0	no	yes
9977	2018	66 - 70	Male	Sarcoma	4		7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	15.18	IV	Subsequent-line	1	no	yes
9978	2018	46 - 50	Female	NSCLC	10.29	Stable	11.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.16	Alive	16.16	IV	First-line	0	no	no
9980	2018	61 - 65	Male	NSCLC	4.3	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.22	Dead	9.99	IV	First-line	1	no	no
9981	2018	61 - 65	Male	NSCLC	5.25	Stable	11.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.87	Alive	16.85	IV	First-line	1	no	no
9982	2018	71 - 75	Male	Esophageal	25	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.79	Dead	1.31	IV	Subsequent-line	1	no	no
9983	2018	66 - 70	Male	NSCLC	2.06	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.3	Dead	8.84	IV	Subsequent-line	0	no	no
9984	2018	31 - 35	Female	Endometrial	5.86	Unstable	15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.18	Alive	9.59	IV	Subsequent-line	1	other-MMRd	no
9985	2018	76 - 80	Female	Colorectal	10.71	Unstable	44.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.57	Dead	8.31	IV	Subsequent-line	2	other-MMRd	no
9986	2018	66 - 70	Female	Endometrial	1.78	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.29	Alive	11.27	IV	Subsequent-line	0	no	no
9987	2018	51 - 55	Male	NSCLC	16	Stable	13.2	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.37	Alive	16.79	IV	First-line	1	no	yes
9988	2018	66 - 70	Male	Hepatobiliary	2.75	Stable	7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.93	Dead	6.93	IV	Subsequent-line	1	no	no
9989	2018	21 - 25	Male	Colorectal	10.17	Unstable	65.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	14.03	Alive	14.49	III	Subsequent-line	0	mut-MMRd	yes
9990	2018	51 - 55	Male	NSCLC	5.4	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.87	Alive	15.87	IV	First-line	0	no	no
9991	2018	46 - 50	Female	NSCLC	3.31	Stable	26.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.9	Alive	16.13	IV	First-line		no	no
9992	2018	71 - 75	Female	NSCLC	4	Stable	13.2	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	9.63	Alive	11.66	IV	Subsequent-line		no	no
9993	2018	61 - 65	Male	NSCLC	36	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	1.28	IV	First-line		no	no
9994	2018	61 - 65	Male	NSCLC	4.56	Stable	11.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	10.55	Dead	11.43	IV	First-line		no	yes
9995	2018	81 - 85	Female	NSCLC	8.56	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	6.37	IV	Subsequent-line	2	no	no
9996	2018	51 - 55	Female	NSCLC	3.17	Stable	25.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.24	Alive	15.93	IV	First-line	0	no	no
9997	2018	66 - 70	Male	NSCLC	2.23	Stable	14.9	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	15.41	Alive	15.41	IV	First-line	0	no	no
9998	2018	76 - 80	Female	NSCLC	6.94	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.14	Dead	2.14	IV	Subsequent-line	1	no	no
9999	2018	46 - 50	Female	NSCLC	4.38	Stable	13.2	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	16.56	Alive	16.56	IV	First-line	1	no	no
10000	2018	61 - 65	Male	NSCLC	3.33	Stable	39.5	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.37	Alive	13.14	III	Subsequent-line	0	no	yes
10001	2018	61 - 65	Male	NSCLC	1.56	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	9.33	Alive	16.36	IV	First-line	0	no	no
10002	2018	81 - 85	Male	NSCLC	4.54	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.04	Dead	4.14	II	First-line	1	no	no
10003	2018	66 - 70	Male	NSCLC	9.1	Stable	15.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.58	Dead	2.6	IV	First-line	2	no	no
10004	2018	61 - 65	Male	Melanoma	3.1	Stable	21.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	9.03	Alive	9.03	IV	First-line	0	no	no
10005	2018	71 - 75	Male	NSCLC	5.36	Stable	7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.25	Dead	4.57	IV	First-line	1	no	no
10006	2018	81 - 85	Female	Colorectal	15.92	Unstable	78.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	0.89	IV	Subsequent-line	2	mut-MMRd	no
10008	2018	61 - 65	Female	Pancreatic	3.2	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	2.5	IV	Subsequent-line	1	no	no
10009	2018	71 - 75	Male	Melanoma	3.94	Stable	0.9	IMPACT-468	Combo	PD	No	No	Yes	0.49	Dead	0.49	IV	First-line	0	no	no
10011	2018	61 - 65	Female	NSCLC	2.88	Stable	13.2	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.64	Alive	15.64	IV	First-line	2	no	no
10012	2018	71 - 75	Male	NSCLC	2.24	Stable	10.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.74	Alive	16.1	IV	First-line	1	no	no
10013	2018	66 - 70	Female	NSCLC	4.75	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	14.49	Alive	15.18	IV	First-line	1	no	no
10014	2018	81 - 85	Male	NSCLC	3.88	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	4.21	Dead	5.82	IV	First-line	1	no	no
10015	2018	66 - 70	Female	NSCLC	3.6	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.75	Dead	10.71	IV	Subsequent-line	1	no	no
10016	2018	56 - 60	Male	NSCLC	12.3	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.46	Dead	6.08	IV	First-line	0	no	no
10017	2018	81 - 85	Female	NSCLC	19.88	Unstable	47.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.74	Dead	1.74	IV	First-line	1	mut-MMRd	yes
10019	2018	61 - 65	Female	Endometrial	7	Unstable	38.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.11	Alive	14.62	III	Subsequent-line	1	other-MMRd	yes
10020	2018	61 - 65	Male	Colorectal	9.45	Stable	17.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Dead	3.45	IV	First-line	0	no	no
10021	2018	61 - 65	Male	Gastric	5.92	Stable	3.5	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	Yes	10.91	Alive	13.83	IV	First-line	1	no	no
10023	2018	66 - 70	Male	NSCLC	1.86	Stable	7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	12.45	Alive	15.9	IV	First-line	0	no	no
10025	2018	56 - 60	Male	NSCLC	9.25	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.82	Dead	0.82	IV	First-line	1	no	no
10026	2018	81 - 85	Male	NSCLC	8	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	6.9	Alive	10.97	IV	Subsequent-line		no	no
10027	2018	66 - 70	Male	NSCLC	6.5	Stable	12.3	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	11.7	Alive	12.22	III	Subsequent-line	1	no	no
10028	2018	86 - 90	Male	NSCLC	4.82	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.54	Dead	1.54	IV	First-line	1	no	no
10029	2018	76 - 80	Female	NSCLC	4.77	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	14.69	Alive	15.41	IV	First-line		no	no
10030	2018	56 - 60	Male	NSCLC	4.92	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.08	Alive	14.95	IV	First-line	0	no	no
10032	2018	46 - 50	Male	NSCLC	34.67	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.38	Dead	3.15	IV	Subsequent-line	1	no	no
10033	2018	56 - 60	Female	NSCLC	2.33	Stable	8.8	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	7.03	Alive	11.99	III	Subsequent-line	1	no	no
10034	2018	71 - 75	Female	Bladder	1.79	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	11.93	Alive	12.06	IV	Subsequent-line	0	no	no
10035	2018	76 - 80	Female	NSCLC	6	Stable	14.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	11.96	Alive	12.48	III	Subsequent-line	1	no	no
10036	2018	76 - 80	Female	Endometrial	4.33	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Dead	9.4	IV	Subsequent-line	0	no	no
10037	2018	66 - 70	Female	NSCLC	2.53	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Alive	15.9	IV	First-line	1	no	no
10038	2018	61 - 65	Male	Melanoma	7	Stable	17.6	IMPACT-468	Combo	PR	Yes	Yes	Yes	2.6	Alive	7.85	III	First-line	0	no	yes
10039	2018	61 - 65	Male	Sarcoma	8.33	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Alive	9.43	IV	Subsequent-line	0	no	no
10040	2018	61 - 65	Male	NSCLC	11.83	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.46	Dead	4.67	IV	First-line	1	no	yes
10041	2018	76 - 80	Male	NSCLC	8.86	Stable	9.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	15.41	Alive	15.41	IV	First-line		no	no
10042	2018	66 - 70	Male	Melanoma	7.09	Stable	2.6	IMPACT-468	Combo	PD	No	No	Yes	1.28	Dead	2.79	IV	First-line		no	no
10043	2018	71 - 75	Male	Bladder	2.89	Stable	7	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	13.8	Alive	13.96	IV	First-line	1	no	no
10044	2018	56 - 60	Female	NSCLC	5.38	Stable	14	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	12.55	Alive	14.69	IV	Subsequent-line	0	no	no
10047	2018	61 - 65	Male	NSCLC	9.2	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.77	Dead	5.98	IV	First-line	1	no	no
10049	2018	66 - 70	Male	NSCLC	4.11	Stable	12.3	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	15.41	Alive	15.41	IV	First-line	0	no	no
10050	2018	51 - 55	Female	NSCLC	4.08	Stable	9.7	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.6	Dead	14.29	IV	First-line	1	no	no
10053	2018	51 - 55	Female	NSCLC	3.42	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.2	Alive	14.75	IV	First-line	0	no	no
10054	2018	71 - 75	Female	NSCLC	10.89	Stable	0	IMPACT-468	Combo	PD	No	No	Yes	2.6	Dead	6.64	IV	Subsequent-line		no	no
10055	2018	61 - 65	Female	NSCLC	8.13	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.56	Dead	1.61	IV	First-line	1	no	no
10056	2018	71 - 75	Female	NSCLC	3.7	Stable	13.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.15	Dead	5.06	IV	Subsequent-line	0	no	no
10057	2018	81 - 85	Female	NSCLC	6.29	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	3.45	Dead	3.45	IV	First-line		no	no
10058	2018	76 - 80	Male	Melanoma	2.6	Stable	1.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	11.73	Alive	13.17	IV	First-line	1	no	no
10059	2018	81 - 85	Female	SCLC	5.08	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	4.9	Alive	8.02	IV	Subsequent-line		no	no
10060	2018	66 - 70	Female	Endometrial	3.67	Stable	4.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.61	Alive	12.42	IV	Subsequent-line	0	no	no
10061	2018	51 - 55	Female	NSCLC	2.44	Stable	0.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.36	Alive	13.44	IV	Subsequent-line	1	no	no
10062	2018	66 - 70	Female	Endometrial	3.33	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.41	Dead	1.51	IV	Subsequent-line	1	no	no
10063	2018	61 - 65	Female	NSCLC	23.3	Stable	3.5	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.04	Alive	14.36	IV	First-line	1	no	no
10065	2018	56 - 60	Female	NSCLC	3.26	Stable	2.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.71	Dead	1.71	IV	Subsequent-line	2	no	no
10066	2018	71 - 75	Male	NSCLC	3.41	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	8.11	Dead	8.11	IV	First-line		no	no
10069	2018	66 - 70	Male	NSCLC	0.97	Stable	16.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.13	Dead	0.13	IV	First-line	1	no	no
10070	2018	66 - 70	Female	NSCLC	5.47	Stable	12.3	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.07	Alive	13.57	IV	First-line	1	no	no
10071	2018	51 - 55	Female	NSCLC	3.19	Stable	16.7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	7.39	Alive	13.63	IV	First-line	0	no	yes
10072	2018	61 - 65	Female	SCLC	3.62	Stable	10.5	IMPACT-468	Combo	SD	No	No	Yes	5.52	Alive	9.92	IV	Subsequent-line	0	no	no
10074	2018	26 - 30	Female	NSCLC	1.44	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.76	Dead	10.02	IV	Subsequent-line	0	no	no
10075	2018	71 - 75	Male	NSCLC	4.75	Stable	13.2	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	8.05	Alive	10.15	III	Subsequent-line	1	no	no
10076	2018	71 - 75	Male	NSCLC	12.67	Stable	14.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	13.77	Alive	13.77	IV	First-line	1	no	no
10077	2018	66 - 70	Male	NSCLC	4.92	Stable	8.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.23	Alive	10.28	IV	First-line	1	no	no
10078	2018	71 - 75	Male	NSCLC	1.08	Stable	14.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.3	Dead	10.32	IV	First-line		no	no
10079	2018	71 - 75	Female	NSCLC	13	Stable	0.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.66	Dead	2.66	IV	First-line	1	no	no
10080	2018	56 - 60	Female	Colorectal	6	Stable	6.1	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.45	Dead	1.81	IV	Subsequent-line	1	no	no
10081	2018	61 - 65	Male	NSCLC	2.5	Stable	3.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	13.57	Alive	13.57	IV	First-line	0	no	no
10082	2018	51 - 55	Female	NSCLC	4.56	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	5.29	Alive	12.94	IV	First-line	1	no	no
10083	2018	61 - 65	Female	NSCLC	2.56	Stable	4.4	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	11.73	Alive	11.76	IV	Subsequent-line	0	no	no
10084	2018	61 - 65	Female	Hepatobiliary	4	Stable	0.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	6.05	Alive	8.31	IV	Subsequent-line	1	no	no
10085	2018	61 - 65	Female	NSCLC	3.38	Stable	1.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.53	Dead	7.62	IV	First-line	0	no	no
10086	2018	76 - 80	Male	NSCLC	2.22	Stable	7	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	11.73	Alive	12.42	IV	First-line	0	no	yes
10087	2018	51 - 55	Male	Esophageal	3.32	Stable	6.1	IMPACT-468	PD-1/PD-L1	CR	Yes	Yes	No	11.04	Alive	11.04	IV	First-line	1	no	no
10088	2018	66 - 70	Male	Head & Neck	8	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.68	Alive	9.49	IV	Subsequent-line	1	no	no
10089	2018	76 - 80	Female	Endometrial	2.86	Unstable	149.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	2.14	Dead	7.75	IV	Subsequent-line	0	mut-MMRd	yes
10090	2018	61 - 65	Male	NSCLC	9	Stable	12.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	13.11	Alive	13.11	IV	First-line	1	no	no
10091	2018	81 - 85	Female	NSCLC	9.14	Stable	0	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	12.45	Alive	13.31	IV	First-line		no	no
10092	2018	81 - 85	Female	NSCLC	5.4	Stable	21.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	6.21	IV	First-line		no	no
10093	2018	66 - 70	Male	NSCLC	7.43	Stable	15.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.6	Dead	2.6	IV	First-line	1	no	no
10094	2018	56 - 60	Female	NSCLC	4.4	Stable	7.9	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.31	Alive	13.08	IV	First-line	1	no	no
10095	2018	61 - 65	Male	NSCLC	3.33	Stable	7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	9.26	Alive	10.64	III	Subsequent-line	1	no	no
10097	2018	81 - 85	Male	NSCLC	5.4	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	12.98	Alive	13.11	IV	First-line	1	no	no
10098	2018	66 - 70	Male	NSCLC	1.71	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	10.71	Alive	11.24	IV	Subsequent-line	1	no	no
10099	2018	71 - 75	Female	Endometrial	8.5	Unstable	34.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.84	Alive	12.48	IV	Subsequent-line	0	other-MMRd	yes
10100	2018	61 - 65	Female	Endometrial	9.43	Stable	1.8	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.36	Dead	1.97	IV	Subsequent-line	0	no	no
10101	2018	61 - 65	Male	NSCLC	6.85	Stable	76.4	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.35	Dead	3.65	IV	First-line	1	no	no
10102	2018	66 - 70	Female	Endometrial	2.79	Stable	2.6	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	3.48	Alive	11.3	IV	Subsequent-line	1	no	no
10103	2018	76 - 80	Male	NSCLC	5.5	Stable	10.5	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	11.79	Alive	11.79	IV	First-line	1	no	no
10104	2018	51 - 55	Male	Sarcoma	7.57	Stable	7.9	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	5.59	Alive	11.99	IV	Subsequent-line	0	no	no
10105	2018	76 - 80	Female	NSCLC	5.2	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.64	Alive	11.1	IV	Subsequent-line	1	no	no
10106	2018	66 - 70	Female	NSCLC	4	Stable	9.7	IMPACT-468	PD-1/PD-L1	SD	No	Yes	No	11.04	Alive	11.27	IV	First-line	1	no	no
10107	2018	71 - 75	Male	NSCLC	5.85	Stable	7.9	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	7.66	Alive	11.99	IV	First-line	1	no	no
10109	2018	56 - 60	Female	NSCLC	9.5	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	2.43	Dead	2.43	IV	First-line		no	no
10110	2018	81 - 85	Female	NSCLC	2.33	Stable	8.8	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	10.05	Dead	10.05	IV	First-line		no	no
10111	2018	46 - 50	Male	Pancreatic	8.64	Stable	0	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.89	Alive	9.3	IV	Subsequent-line	1	no	no
10112	2018	71 - 75	Male	NSCLC	5.2	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	7.43	Alive	11.56	IV	First-line	1	no	no
10113	2018	61 - 65	Female	Hepatobiliary	4.08	Stable	6.1	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	1.38	Dead	1.51	III	First-line	1	no	yes
10114	2018	66 - 70	Female	NSCLC	2.29	Stable	8.8	IMPACT-468	PD-1/PD-L1	SD	No	No	Yes	4.7	Alive	11.6	IV	Subsequent-line		no	no
10115	2018	71 - 75	Male	NSCLC	12.4	Stable	20.2	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.23	Alive	9.72	IV	First-line	3	no	yes
10117	2018	61 - 65	Male	Esophageal	3.62	Stable	5.3	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	No	10.25	Alive	10.25	IV	First-line	1	no	yes
10118	2018	61 - 65	Male	NSCLC	21.29	Stable	17.6	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.95	Dead	0.95	IV	First-line	2	no	yes
10119	2018	76 - 80	Male	NSCLC	4.73	Stable	9.7	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	0.66	Dead	0.89	IV	First-line	1	no	no
10122	2018	76 - 80	Male	NSCLC	2.53	Stable	5.3	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	1.28	Dead	2.96	IV	First-line	0	no	no
10123	2018	56 - 60	Male	NSCLC	5.63	Stable	14	IMPACT-468	PD-1/PD-L1	PD	No	No	Yes	5.39	Dead	10.45	IV	First-line	1	no	no
10124	2018	61 - 65	Male	Gastric	1.87	Stable	8.8	IMPACT-468	PD-1/PD-L1	SD	No	Yes	Yes	8.61	Alive	8.77	IV	First-line	0	no	no
10125	2018	81 - 85	Female	NSCLC	11.13	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	No	7.56	Alive	7.66	IV	First-line	0	no	no
10126	2018	51 - 55	Female	NSCLC	4.4	Stable	2.6	IMPACT-468	PD-1/PD-L1	PR	Yes	Yes	Yes	6.77	Alive	10.68	IV	First-line	0	no	no
10127	2018	61 - 65	Male	Gastric	6.82	Stable	4.4	IMPACT-468	PD-1/PD-L1	SD	No	No	No	7.82	Alive	9.2	IV	First-line	1	no	no
